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ABSTRACT 
A DIVERSITY-ORIENTED SYNTHESIS APPROACH TO FUNCTIONALIZED 
AZAHETEROCYCLES USING CYCLIC ALPHA-HALO ENEFORMAMIDES 
by 
Spencer Allen Langevin 
June 2017 
 Functionalized piperidines, azepanes, azamacrocycles, morpholines, and 
thiomorpholines are common structural motifs found in a wide range of pharmaceuticals 
such as carmegliptine, levofloxacin, thioridazine, claviciptic acid, and azithomycin. As a 
result, there is a strong desire to construct highly functionalized nitrogen-bearing ring 
scaffolds in order to construct a wide range of drug possibilities. There are several non-
modular and step-uneconomical synthetic methods used in the construction of these 
aforementioned motifs such as ring closing metathesis, ring expansions, and 
intramolecular reductive amination. In this research, we present a step-economical, cost-
effective, scalable, and diversity-oriented synthesis approach to highly functionalized N-
heterocycles through the intermediacy of α-halo enamines/enamides. The synthetic utility 
of the method is exemplified through the construction of quaternary cyclic propargylic 
and homoallylic amines, polycyclic lactams, as well as chiral dihydro 1,4-oxazines and 
thiazines.  Given the generality of the approach, we are confident that the synthesis and 
medicinal chemistry communities will undoubtedly embrace it, thus, endowing it with a 
practical advantage over existing methodologies.  
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CHAPTER 1  
 
INTRODUCTION 
 
 
1.1 Relevance of Azaheterocycles 
A heterocycle is a ring structure where at least one of the atoms that makes up the 
ring is something other than carbon.  An azaheterocycle is a specific type of heterocycle 
where at least one of the atoms making up the ring is nitrogen.  Synthesis of heterocycles 
is an extremely popular field of study amongst organic chemists for several reasons.  
Heterocycles are found in a wide range of pharmaceuticals, from naturally occurring 
compounds to fully synthetic compounds. Specifically, azaheterocycles are found to 
make up 59% of small molecule pharmaceuticals.1 The remarkable number of 
pharmaceuticals that contain an azaheterocycle is one of the many reasons why the 
medicinal and synthetic communities have shown such great interest in developing drugs 
containing an azaheterocycle backbone. 
Azaheterocycles are found in many pharmaceutical drugs and aren’t limited to 
any one class of drug.  They are found in antidepressants, antibiotics, antihistamines, HIV 
drugs, antineoplastic drugs and many more. Additionally, there are many different types 
of azaheterocycles ranging from 3 membered rings to macrocycles as large as 25-
membered or more.  On top of ring size, azaheterocycles can vary with respect to 
aromaticity, one or more additional heteroatoms, linearly or branchly fused to one or 
more rings. The large variety of azaheterocycles and their range of biological activity has 
led to a huge push to explore these rings structures as well as finding new and improved 
ways of synthesizing fully functionalized azaheterocycles motifs that can be tested for 
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biological activity and provide the foundation for larger more complex molecular 
architectures. 
Specifically, this has led us to explore the more common azaheterocycles.  In this 
research we are interested in exploring heterocycles commonly found in pharmaceuticals, 
including piperidines (the most common heterocycle found in FDA approved drugs), 
thiomorpholines (10th most common heterocycle), and morpholines (17th most common 
heterocycle).1  A full list of the top 25 azaheterocycles found in FDA approved 
pharmaceuticals is shown in Figure 1-1. We also intend to explore azaheterocycles of 
different ring sizes, specifically 7- and 13-membered (macrocycle).  
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Figure 1-1  Top 27 azaheterocycle motifs in U.S. FDA approved drugs1 
1.1.1 Relevance of piperidines 
As mentioned previously, the piperidine motif is the most common 
azaheterocycle amongst FDA-approved drugs.1 Fittingly, their prevalence in 
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pharmaceuticals with diverse biological activities endears them to the synthesis and 
medicinal chemistry communities. Several examples of compounds containing the 
piperidine motif are shown in Figure 1-2.  
S
HN O
OH
OH
N
NH
O
H
H
Nelfinavir
N
MeO
MeO
H
NH2
N
O
F
Carmegliptine
HN
N N
H
H
OCH3
F
O
OH
O
Moxifloxacin
Figure 1-2  Examples of pharmaceuticals bearing a piperidine motif 
 The three examples in Figure 1-2 show the wide range of biological activity of 
drugs bearing a piperidine motif and showing the different ways the piperidine motif is 
arranged within each compound.  Nelfinavir is an antiviral used in the treatment of 
human immunodeficiency virus (HIV). Nelfinavir made $325 million after the first year 
it was released, which at the time was one of the largest profits for a pharmaceutical drug 
in its first year.2 Nelfinavir is a type of protease inhibitor and is used to inhibit HIV-1 and 
HIV-2 proteases.  HIV proteases are responsible for replication of the virus as well as 
releasing mature viruses from the infected cell. As is the case for most HIV treatments, 
nelfinavir is often used in tandem with reverse transcriptase inhibitors in order to provide 
the most effective treatment. The piperidine moiety in nelfinavir is carbo-functionalized 
in three positions and has a large group coming off of nitrogen.  There are three 
stereocenters on the piperidine skeleton.  This stereochemical facet provides a great 
challenge for a synthetic chemist as the piperidine.  Thus, the synthetic chemist will have 
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to append several functional handles on the piperidine skeleton while making sure 
chemoselectivity and stereospecificity are achievable.  
 Carmegliptine is a drug that is still in development but has shown great promise in 
the treatment of type II diabetes.  Carmegliptine is a dipeptidyl peptidase IV (DPP-IV) 
inhibitor.  DPP-IV is an enzyme that deactivates glucagon-like peptide-1 (GLP1) and 
glucose-dependent insulin tropic polypeptide (GIP) following food consumption. If DPP-
IV is inhibited, GLP1 and GIP remain activated longer thus prolonging their anti-
hyperglycemic functions.3 Carmegliptine is a great example as it shows that the nitrogen 
in the piperidine motif is actually a bridge to another ring. This is typically referred to as 
a nitrogen bridge.  This provides a challenge for synthetic chemist as creating bicycles 
already provides a synthetic challenge and constructing a bicycle where nitrogen is the 
bridge provides an even greater challenge, because when synthesizing the molecule 
chemo selectivity must be controlled throughout the synthesis.  
Moxifloxacin (Avelox) is an antibacterial used in the treatment of several Gram-
negative bacterial infections.  It is used for the treatment of sinusitis, bronchitis, 
pneumonia, several types of skin infections, and abdominal infections.  Avelox was 
released in 1999 and reached sales of almost $700 million by 2007. It ranks 140th of the 
200 most common drugs prescribed in the United States.4 Moxifloxacin provides several 
challenges to synthesize as it has three nitrogen-bearing heterocycles, two of which are 
piperidines and one is pyrollidine. Additionally, one of the piperidines has an 
unsaturation and is fused to a benzene ring thus providing even more complexity.  
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1.1.2 Relevance of morpholines 
Morpholines are the 17th most common azaheterocyle found in FDA approved 
pharmaceuticals (Figure 1-1)1.  They are also the ranked 5th for most common 6 
membered non-aromatic azaheterocycle amongst FDA approved drugs (1-3).  
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Figure 1-3  Top five six-membered nonaromatic azaheterocycles1 
Morpholines differ from piperidines as they have two heteroatoms in the six 
membered ring, where the other heteroatom is oxygen in the 4 position.  Having two 
heteroatoms increases complexity as now the positions adjacent to oxygen are more 
acidic than that of the positions adjacent to nitrogen. Morpholines also have a wide 
variety of biological activity and are wildly popular in synthetic research. Morpholine 
motifs are commonly found in many drug types, including antidepressants, appetite 
suppressants, antitumor agents, antioxidants, and antibiotics5. Morpholines are also found 
in many industrial agents that are commonly used as corrosion inhibitors, optical 
bleaching agents, textile dying agents, and fruit preservation agents1. Several examples of 
compounds containing morpholines are shown in Figure 1-4. 
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Figure 1-4  Examples of pharmaceuticals bearing a morpholine motif 
 Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor used to treat 
several types of breast, lung, and other cancers. EGFR is a transmembrane protein that is 
activated by binding to epidermal grown factor (EGF) and transforming growth factor α 
(TGFα). Mutations in EGFR have been known to cause cancer, thus inhibiting this 
protein once mutations have occurred  has been shown to reduce or minimize the growth 
of cancer.6 Gefitinib has two heterocycles in the molecule, morpholine and quinazoline. 
Structurally, the addition of the morpholine would be the less problematic addition to this 
molecule, but the morpholine does play a major role in its biological activity.    
 Aprepitant (Emend) is used to reduce chemotherapy-induced nausea and vomiting 
(CINV). Aprepitant is known as an NK1 antagonist. NK1 antagonists block signals 
coming from NK1 receptors. NK1 receptors are what cause the impulse to vomit and thus 
blocking these receptors reduces nausea and vomiting.7 Aprepitant has a morpholine 
motif where substituents are coming off of carbons 2 and 3. The substituent coming off of 
the carbon adjacent to oxygen is a trifluoromethylated phenyl and the substituent coming 
off the carbon adjacent to the nitrogen is fluorophenyl group. The substituent coming of 
nitrogen is triazolinone. It also has three chiral centers all within close proximity. 
Another big part of synthetic chemistry is fluorine chemistry as the addition of fluorine 
increases the bioavailability of a molecule.  
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 Levofloxacin (Levaquin) is an antibiotic used to treat such bacterial infections as: 
sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and gastroenteritis. 
Levofloxacin is used to treat both Gram-positive and Gram-negative bacteria. It works by 
inhibiting DNA gyrase and topoisomerase IV.  DNA gyrase is used by bacteria to 
supercoil DNA so that it will fit in the cell and topoisomerase IV is used to separate DNA 
after it has been replicated.8  If either mechanism is inhibited, the result is the death of the 
bacteria. One of the challenges here is the presence of a nitrogen bridge and three fused 
rings. However, the more important aspect to consider is the stereochemistry.  This is 
because the other stereoisomer has no effect on the treatment of bacterial infections. 
Thus, maintaining stereochemistry is of the utmost importance. 
1.1.3 Relevance of thiomorpholines 
Thiomorpholines are six-membered saturated heterocycles with two heteroatoms, 
oxygen and sulfur. The oxygen and sulfur are on opposite (para) sides of the ring. 
Thiomorpholines are ranked 10th amongst FDA approved pharmaceuticals (Figure 1-1).1 
They are also the third most common six-membered saturated heterocycle (Figure 1-3). 
They are commonly found in several pharmaceuticals as well as frequently used as 
ligands for catalyst, or thiomorpholine derivatives themselves can be used as catalyst.  
Because of the wide range of uses for thiomorpholines and because of the struggle to 
synthesize fully functionalized thiomorpholines, they are a very popular research topic 
amongst organic chemists. Several compounds containing thiomorpholines are shown in 
Figure 1-5.  
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Figure 1-5  Examples of pharmaceuticals bearing a thiomorpholine motif  
 Thioridazine (Mellaril) is an antipsychotic drug used to treat schizophrenia. 
Mellaril was withdrawn in 2005 because it was causing severe cardiac arrhythmias. It is 
being further studied for its use as an antibiotic.  Thioridazine works by inhibiting two 
different cytochrome p450 enzymes, CYP1A2 and CYP3A29.  The drug did prove 
effective toward the treatment of schizophrenia however due to the side effects it has 
been removed from the market.  However, due to the success against schizophrenia, 
several derivatives have been made and are being tested to see if they can successfully 
treat schizophrenia without the unwanted side effects. Thioridazine does contain a 
thiolmorpholine, but more specifically when fused with two benzene rings on either side, 
it is referred to as a phenothiazine.  
 Perphenazine (Trilafon) is also an antipsychotic and has been used for many 
years. It is used to treat schizophrenia and bipolar disorder. Perphenazine is about five 
times as potent as chlorpromazine, making it a medium potency antipsychotic. 
Perphenazine can be taken both orally or by intramuscular injection. Perphenazine is 
often used in combination with fluoxetine, a type of serotonin reuptake inhibitor 
(SSRI).10 Perphenazine also has a phenothiazine backbone, but it also has a piperazine 
motif.  Piperazine in another azaheterocycle, specifically it is a six-membered ring with 
two nitrogens para from one another. This makes it even more interesting to synthetic 
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chemists and it consists of multiple azaheterocycles and piperazines are ranked third on 
the FDA-approved pharmaceutical lists (Figure 1-1) and second amongst six-membered 
saturated azaheterocycles (Figure 1-3).1 
1.1.4 Relevance of azepanes and nitrogen bearing macrocycles 
Azepanes are seven-membered saturated rings containing one nitrogen 
heteroatom.  Azepanes are rarer than its five- and six-membered counterparts; however, 
they still make up more than 40 % of azaheterocycle pharmaceuticals with rings greater 
than six membered.  Azepanes are ranked third for approved seven-membered 
azaheterocycles FDA drugs (Figure 1-6).1  
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Figure 1-6  Top five seven-membered azaheterocycles FDA-approved drugs1 
Azepanes and their derivatives have several pharmaceutical and biological 
applications. Additionally, recent research has shown they can be used as ligands for 
Diels-Alder and aza-cope rearrangements.11 Azepane motifs are found in antibiotics, 
antipsychotics, anti-histamines, anticonvulsants, and many more. Azepanes have also 
been extracted from a wide variety of natural resources, ranging from sea sponges to 
fungi.  Two examples of azapanes in pharmaceuticals are shown in Figure 1-7. 
 Nitrogen-bearing macrocycles are even rarer than the six- and seven-membered 
ring counterparts; however, they have been found in several pharmaceuticals as well as 
extracted from natural products. Although, research into macrocycles is still a popular 
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field amongst synthetic chemists because of the difficulty in making such large rings and 
the relatively untapped potential they may have. Depending on the source, the definition 
of a macrocycle is not consistent. Thus, we will consider them to be any ring greater than 
10 atoms in size; however, some would argue anything 8 or more would be considered a 
macrocycle. Two examples of nitrogen-bearing macrocycles are shown in Figure 1-7. 
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Figure 1-7  Examples of pharmaceuticals containing a azepane motif or nitrogen-bearing 
macrocycle 
 Azelastine is an antihistamine used to treat the symptoms of nasal allergies. 
Azelastine has many trade names and is available as a nasal spray and eye drops. 
Azelastine has three major effects: anti-histamine, mast-cell stabilizing,and anti-
inflammatory.12 Azelastine has two heterocycles: a phthalazinone motif (a 6-membered 
cyclic lactam featuring two adjacent nitrogen atoms fused to a benzene ring) and a 
methylated azepane coming off the lactam nitrogen.  
 Claviciptic acid was first synthesized in 2007 by Ku’s group.13 A more efficient 
synthesis was devolved by Tahara’s group in 2015.14 The overall synthesis took 10 steps. 
The key steps in the synthesis included asymmetric phase-transfer catalytic alkylation, 
and diastereoselective Pd(II)-catalyzed intramolecular aminocyclization. Claviciptic acid 
was isolated from ClaViceps fusiformis, which is a plant pathogen typically found on 
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pearl millet in Africa and India. Claviciptic acid has a very unique fused tricycle 
consisting of 5-, 6-, and 7-membered rings. When first isolated the compound was found 
as a racemic mixture. Groups such as Bartoccini15 have synthesized both stereoisomers. 
Currently, studies are being done to determine any biological activity as antibiotics, 
antifungal, and antineoplastics. 
 Plerixafor (Mozobil) is an immunostimulant used to mobilize hematopoietic stem 
cells into the bloodstream.  It is used to treat cancers such as lymphoma and multiple 
myeloma. It is used in combination with granulocyte colony-stimulating factor (G-CSF). 
G-CSF is used to move peripheral blood stem cells, which is used to generate 
hematopoietic stems cells used for transplantation. Unfortunately, G-CSF is not effective 
in 15 to 20 percent of patients, thus is used in combination with plerixafor. When used in 
combination with plerixafor, more stem cells are generated and can be used for 
transplantation.16 Plerixafor has two 14 membered rings bearing four nitrogen atoms 
each. This introduces even more complexity as the compound consists of two 
macrocycles and has multiple heteroatoms in each.  
 Azithromycin is an antibiotic used to treat several types of bacterial infections 
such as: middle ear infections, strep throat, pneumonia, and several types of intestinal 
infections. It can be administered orally or intravenously. It is listed as one of the safest 
medicines by the World Health Organization (WHO).  Azithomycin has a very broad 
usage and inhibits many types of Gram-positive and Gram-negative bacteria.17 
Azithomycin has a 15-membered macrocycle bearing both a nitrogen and an oxygen. It 
has several stereocenters, thus synthesizing this molecule can be difficult as maintaining 
stereochemistry as well as having a very unstable 15-membered ring proves problematic.  
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1.2 Diversity-oriented synthesis (DOS) 
One of many challenges for an organic chemist is to construct a scheme to 
develop several compounds that are all structurally unique and vary in more ways than 
one.  A true diversity oriented synthesis approach produces compounds that are different 
in the structural building block, stereochemistry, functional groups, and molecular 
framework. The simplest definition of DOS can then be explained as the thoughtful, 
immediate and efficient synthesis of several compounds in a specific approach to solve a 
complex problem.15 The purpose behind DOS is that compounds that look structurally 
similar typically have similar biological activity.  In a diversity oriented synthesis 
approach, the molecules are different enough that the biological activity of each 
compound can differ exponentially.  
1.2.1 Merits of diversity-oriented synthesis (DOS) 
As was said in the simplest definition of DOS, the end goal is to solve complex 
problems. Ultimately, this is driven by having a problem that has no hypothesis, meaning 
that we are trying to find a molecule that is biologically active but don’t know where to 
start.  In many cases there is enough known about the problem that a hypothesis can be 
formed and one can design a target molecule that can then be synthesized. Therein lies 
the difference between the hypothesis driven approach and a DOS approach. A diversity 
oriented approach develops a large library of structurally diverse compounds that can 
then be tested toward a specific problem. Once a molecule shows promise then a more 
detailed hypothesis-driven approach can be utilized.  This is why neither a hypothesis-
driven approach nor diversity oriented approach is better than the other. In most cases 
one drives the other. 
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 Target-oriented synthesis (TOS) and DOS both involve complexity-generating 
reactions, however TOS is convergent, meaning they develop several fragments of 
compounds and couple them together to form one target molecule.  A DOS uses 
multicomponent-coupling reactions and branched pathways with a forward synthetic 
approach to develop multiple structurally unique compounds.15 This is best illustrated in 
Figure 1-8. 
 
Figure 1-8  Differences between target-oriented synthesis (TOS) and diversity oriented 
synthesis (DOS)15 
 One of the many advantages of DOS is in drug discovery.  Between the years of 
1989-2002 two-thirds of FDA approved drugs were slightly modified compounds of 
already existing drugs.15 Over the last several years the number of new-molecular entities 
(NME) has decreased. This only further illustrates the need for DOS.  As previously 
stated, TOS is synonymous with the hypothesis-driven approach. Thus a target, or 
hypothesis, of a potential compound must be made then sought after.  Such an approach 
creates a large influx in the amount of drugs that are structurally similar to drugs already 
on the market.  In order to find new and structurally unique drugs, a DOS approach 
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would be desired. The use of more DOS approaches and the increasing popularity of 
DOS should lead to an increase in NME that hit the market.  
 There are two major approaches to drug discovery. The first approach looks for 
small molecules that produce a desired outcome.  Such as developing small molecules 
that are toxic to bacteria. This approach has been wildly successful, and has generated 
such drugs as vancomycin, penicillin, streptomycin, tetracycline, erythromycin, 
sulfonamides, and many more. The second approach looks for a target enzyme or protein 
that a drug could modulate, attenuate, or inhibit its function. Both of these approaches 
require a large library of structurally diverse compounds in order to achieve the desired 
effect.  DOS is perfect as it has the potential of developing a large library of compounds 
efficiently. Additionally, DOS provides a large variety of compounds that will allow for 
structure activity relationships (SAR) studies, which can aid in determining enzyme 
binding sites as the site in a molecule that has the largest effect on target enzymes.  
 The power behind a DOS approach is in very few steps a single substrate can be 
converted into many structurally-complex and structurally-diverse compounds. The 
crucial step to creating structurally-complex molecules is to use complex-generating 
reactions. The crucial step to generating structurally-diverse compounds is to use diverse 
starting materials with several branching points.   
1.2.2 Challenges with diversity-oriented synthesis (DOS) 
In some ways a DOS can prove to be more demanding than a TOS. In DOS,  
methodology has to be designed that will tolerate several different solvents, substrates, 
and functional groups.  Another problem to avoid with the DOS approach is to maintain a 
systematic approach and avoid a shotgun-type approach to science, meaning aimlessly 
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developing several compounds and just wildly testing each one for everything.  This 
would require a large amount of man power and would not be a cost-effective strategy. 
There have to be some boundaries to what compounds are developed and what each one 
is tested for.  Thus, the systematic part of a DOS needs to be a major part of the overall 
scheme.  
 The main challenge associated with a DOS is planning a systematic pathway that 
generates a large variety of structurally unique compounds.  This requires the use of 
several different starting scaffolds that can then be branched in several different ways 
using complex reactions. This isn’t as trivial as it may seem because not all starting 
substrates will act in a similar way.  That said, trivial reactions won’t provide a diverse 
enough library, thus complex reactions are needed.  This introduces an even bigger 
challenge as in many cases with complex reactions, the complex reactions haven’t been 
tested to their full potential.  However, that’s part of the power of a DOS, as in addition 
to a large library of compounds, new methodology can be discovered and then used in a 
TOS; an example of one approach feeding another.  Ultimately both approaches have 
their pros and cons and DOS is becoming more and more popular through the years, but 
there will always be a place for TOS. 
1.2.3 Commonly employed DOS approaches to N-heterocycles 
 One of the common ways DOS is used is to create multiple compounds that are 
structurally similar, however they are able to create compounds with varying ring sizes.  
An example of this DOS approach is by the Springs group, who constructed a pathway 
that used a wide range of substituted acyclic precursors 1 and was able to construct 
biaryl-containing medium rings efficiently and atropdiastereoselectively 2.16 They were 
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able to generate multiple ring sizes of 9-, 10-, and 11-membered heterocycles bearing 
both nitrogen and oxygen (Figure 1-9). This is just one example of such a synthetic 
pathway. Developing DOS to construct complex molecules with varying ring sizes is an 
extremely challenging process that is becoming very popular amongst synthetic chemists. 
Although it seems trivial that a change in a ring by one atom wouldn’t make much of a 
difference it has been shown that as ring sizes change, the biological activity of those 
molecules can change significantly. 
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1 2  
Figure 1-9  Example of DOS to vary ring size in a complex medium-sized oxygen- and 
nitrogen-bearing heterocycle16 
 Another way that DOS is used is to determine structure to activity relationships. 
Figure 1-10 shows how the Dandapani group was able to use DOS to construct a 
molecule that showed biological activity toward the treatment of parasite Trypanosoma 
cruzi, the etiological agent of Chagas disease. Because they used DOS, they were able to 
determine structure to activity relationships.  Shown in Figure 1-10 they were able to 
modify the substituent coming off nitrogen.  Figure 1-10 only shows a few of the many 
compounds they were able to generate and test against Trypanosoma cruzi. They were 
also able to change the substituent on the other nitrogen to an isopropyl group.  This gave 
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them over 100 compounds in total.  The idea being to show how subtle changes in 
substituents can have a huge effect on biological activity.  By changing the amine 
substituent from phenyl to pyridine they saw a 2500 times drop in potency.  Such a 
simple change in structure caused a huge drop.  However, this shows the importance of 
this substituent as well as what kind of substituents are necessary for the compound to 
have an effect on Trypanosoma cruzi. This further illustrates the importance of DOS and 
how it can be used in SAR related studies. 
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Figure 1-10  Example of how DOS can be used to determine structure-activity-
relationships (SAR) 
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1.3 Enamides and Enecarbamates 
First, we must discuss the differences between enamides and enecarbamates 
before we go into their importance.  The difference is in the electron withdrawing group 
(EWG) coming off of nitrogen (Figure 1-11).  
N
EWG
Enamides, EWG = COR
Enecarbamates, EWG = COOR
(C2)
(C3)


 
Figure 1-11  Shows the difference between an enamide and enecarbamates 
In the last several years, enamides and enecarbamates have become heavily 
studied and have been used in a variety of ways to introduce new synthetic 
transformations for the synthesis of both natural products and biologically active 
compounds.17 Due to the electron donating nature of nitrogen, enamides are more 
electron-rich than an alkene alone. Thus, this activates the C=C double bond, giving 
enamides and enecarbamates nucleophilic and electrophilic properties. This causes the α-
carbon to be electrophilic and the β-carbon to be nucleophilic and subject to electrophilic 
attacks. The electrophilic nature of both the α-carbon and β-carbon can be controlled by 
the group attached to nitrogen. Common groups that have been explored are amides, 
carbamates, and sulfonamides.18-20 Enamides and enecarbamates provide an important 
building block to many more complex larger nitrogen-bearing compounds. Therefore, the 
challenge to the synthetic community is to selectively and directly functionalize enamides 
and enecarbamates and to demonstrate their utility. One of the many ways that enamides 
and enecarbamates have been utilized is via direct metal-catalyzed functionalization of C-
H bonds.21-26 This is an effective method at directing chemical synthesis, since it avoids 
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the need to pre-activate substrates, which can prove to be quite costly and inefficient as it 
can add several synthetic steps. Over the last fifteen years, a lot of progress has been 
made with the use of alkenes, alkynes, arenes, and heterocycles with a large range of 
coupling partners. The popularity of C-H activation continues to grow and is being 
recognized for its large synthetic potential in the construction of new methodologies and 
synthetic application toward total synthesis.  
1.3.1 Synthetic utility of enamides and enecarbamates- direct C2 
intramolecular functionalization 
In recent years, several groups have demonstrated that using intramolecular Heck 
coupling reactions on acyclic enamides and enecarbamates have been a means of 
producing azaheterocycles. Some of the important early work was done by Griggs and his 
group utilizing Heck coupling reactions to create a large library of azaheterocycle 
substrates.27 An example of such a reaction is illustrated in Figure 1-12 where Zhang28 
and his group used an intramolecular Heck coupling reaction on N-acyl-2,3-dihydro-4-
pyridinoneto 3 to form a tricycle with a nitrogen bridge 4. This is just one of many 
examples that utilize a cyclic enamide to generate fused heterocycles. 
N O
R
R'
N O
R
R'
Pd(OAc)2 (10 mol %)
PPh3 (20 mol %)
1.1 equiv Ce2CO3
DMF, 120 oC, 3 d
R = hex, CH2Ar
R' = H, OMe
9 examples
60-83 %
3 4  
Figure 1-12  Example of a Heck coupling reaction with an enamide to form a tricycle 
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1.3.2 Synthetic utility of enamides and enecarbamates- direct C2 and C3 
intermolecular functionalization 
One of the major challenges with the work of enamides and enecarbamates is to  
control regioselectivity, in particular controlling whether the desired addition takes place 
at C2 or C3.  This has generated a large amount of interest as many have not only tried to 
control which carbon the addition takes place, but also maintain stereochemistry.  As 
discussed, one of the challenges of a DOS is to create a library of structurally unique 
substrates while maintaining complexity.  In this case the complexity is associated with 
maintaining both stereo- and regio-selectivity.  
Shown in Figure 1-13 is work by Gillaizeau’s group,29 Pd-catalyzed 
regioselective decarboxylative arylation. One of the limitations of this reaction is the 
need to use electron rich ortho-methoxy-substituted benzoic acids 6. Additionally, only 
C2 activation occurred when the protecting group on nitrogen was electron withdrawing 
and only a single coupling event occurred (see 7).  When there was electron rich or 
neutral groups on nitrogen a double coupling event occurred.  The reaction is also 
plagued by challenges associated with double bond isomerization (see 8). This happens to 
be a common limitation with these cyclic enamide compounds, and finding ways to avoid 
the migration is being explored in many different ways. 
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Figure 1-13  Example showing the challenges of an addition to an enamide 
regioselectively at carbon C2 
 Another challenge with enamides is to achieve C3 regioselective functionalization 
when the C2 position is unsubstituted.  This is made all the more difficult by the fact that 
the C2 position is vinylic and α-amino, thus, inherently more reactive than its C3 
counterpart (Figure 1-14).  
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Figure 1-14  Examples of the challenges of double bond isomerization and control of 
regioselectivity with enamides/ enecarbamates 
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One method of accomplishing this task has been the use of diaryliodonium salts in 
tandem with a copper catalyst, as eloquently demonstrated by Gillaizeau30 (Figure 1-15). 
The reactions worked well and mostly displayed regioselectivity toward the C3 position 
10. The reaction also tolerated a large variety of functional groups 9. Unfortunately, in 
some cases when the diaryliodonium salt was in huge excess, (e.g., 5 equiv), 
regioselectivity was compromised and coupling at both the C2 and C3 positions was 
observed. Other drawbacks of this methodology are the need for a high catalyst loading 
and the use of expensive reagents, thus, rendering it cost ineffective. 
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Figure 1-15  Regioselective C3 arylation of enamides 
1.3.3 Challenges associated with vinyl triflates, stannanes, and phosphates 
Primarily due to the aforementioned regioselectivity issues, several groups rely on 
the use of preactivated enamides and enecarbamates. Along these lines, enamides bearing 
a pendant leaving group at C2 such as a triflate, phosphate, stannane, iodide, boronate 
have been exploited with notoriety.  
 Vinyl triflates are used in a variety of coupling reactions including Stille, Heck, 
cuprate additions, and Nozaki-Hiyama couplings. A triflate is a powerful leaving group 
and has been utilized in many ways. Figure 1-16 shows Speckamp’s synthesis of a vinyl 
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triflate 13 from an ethoxy lactam 11.  This is one of the many challenges with vinyl 
triflates.  It takes a total of four steps to generate the vinyl triflate.  Additionally, triflate 
reagents aren’t cheap and the scheme includes harsh reaction conditions such as the use 
of butyl lithium.  Another challenge that must be mentioned is the protecting group of 
nitrogen is limited in the following step (see 12).  This limits how modular the reaction 
scheme can be. 
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1) BuLi (1.2 equiv)
THF, -20 oC, 30 min
2) TsCl (1.2 equiv)
-20 oC, rt 3h
1) KHMDS (1.1 equiv)
THF, -78 oC, 1h
2) Tf2O (1.1 equiv)
-78 oC to rt
75 % 60 %
11 12 13
Figure 1-16  Preparation of vinyl triflates from an ethoxy lactam 
There are many challenges associated with constructing cyclic enamides and 
enecarbamates with the use of vinyl phosphates (Figure 1-17).  One of those challenges 
with vinyl phosphates is that they are not bench stable and are extremely difficult to 
isolate, thus once they are generated they need to be moved to the next step in the 
reaction.  Another challenge associated with the use of vinyl phosphates is cost.  The 
reaction scheme requires the use of expensive catalyst and lithium reagents. Additionally, 
once the lactam is protected with COOPh or a Boc group (see 14), it takes three 
additional steps to achieve the final desired product 14-16. 31 
N O
COOPh
N
COOPh
O
P
OPh
O
OPh
N
COOPh
1) LDA (1.2 equiv)
TMEDA (1.2 equiv)
2) ClP(O)(OPh)2
    THF, -78 oC
        (82%)
HCOOH (2 equiv)
Et3N (3 equiv)
Pd(OAc)2 (4 mol %)
PPh3 (8 mol %)
DME reflux, 40 min
          (79 %)
14 15 16  
Figure 1-17  Preparation cyclic enecarbamate utilizing vinyl phosphates 
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 Stannanes offer another functional handle similar to that of vinyl triflates and 
phosphates. However, like vinyl phosphates and triflates, the use of expensive reagents as 
well as an expensive catalyst is necessary.  Additionally, the starting alkyne 18 is not 
something that can be store bought, thus the reagents necessary to generate the alkyne 
further increases the cost and provides even more steps. Shown in Figure 1-18 
Kazmaier32 and his group generated stannanes 18 using their previously constructed 
catalyst.  This provides additional complication, because in order to achieve good yields 
specific catalysts are required.  Another point of interest is they do an additional reaction 
to replace the stanine with an iodo group (see 19).  Mostly, because iodide is a great 
leaving group in its own right but can be used under more reaction conditions than its 
stannane precursor.  
R
N
EWG R'
R
SnBu3N
EWG
R'
R
IN
EWG
R'
Bu3SnH (2 equiv)
MoBI3 (2 mol %)
THF, CO, 55 oC, 16 hr
I2 (1.5 equiv)
DCM, 0 oC, 3 h
R = n-Hex, c-Pr, ph
R' = Me, Bn
EWG = Ts, Boc
17 18 19  
Figure 1-18  Preparation of stannanes from substituted alkynes 
 Triflates, phosphates, and stannanes are all useful functional handles and have all 
been used in several cross-coupling reactions that generate functionalized 
azaheterocycles. However, we would like to find a more step-economic, cost-effective, 
and bench stable approach to generating an enamide bearing traceless functionality at C2. 
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1.3.4 Cyclic α-halo eneformamides as an alternative to triflates, phosphates, 
boronates and stannanes 
 One of the main goals of our group was to develop a substrate like that of 
enecarbamates and enamides but in a more step-economical, and cost effective manner.  
This led us to the preparation of α-halo eneformamides (Figure 1-19).  
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n = 1, 2, 8 X = Cl, Br, I
POX3 (3 equiv)
DMF (6 equiv)
DCM, reflux, 2-24 h
20 21  
Figure 1-19  Preparation of  cyclic α-halo eneformamide from lactam 
Unlike that of the previous work shown with triflates, stannanes, and phosphates 
we were able to demonstrate the construction of the α-haloeneformamide 21 in one step 
through the use of a Vilsmeier-Haack reaction.  Through the Vilsmeier-Haack reaction 
we were able to make an enamide - more specifically an eneformamide. This reaction 
also provides a halogen as a good leaving group coming off the C2 position.  Another 
benefit is we have shown that this reaction can be done on several different lactam sizes, 
a six-, seven-, and thirteen-membered lactam (see 20). Additionally, the halogen can be 
modified depending on the type of phosphoryl reagent used. This provides a method for 
increasing the reactivity of the functional handle coming off the C2 position.  As shown 
previously with the work on stannanes, it took a series of five steps to achieve what we 
have in one.  Another benefit of this transformation is that the reaction is scalable. We 
have shown that this reaction can be increased to up to 100 mmol in scale. Also, this 
reaction does not require any use of a metal based catalyst, thus this reaction is very cost 
effective and the reagents used are relatively inexpensive compared to the reagents used 
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with triflates, stannanes, and phosphates.  Another cause for excitement is that the 
compound is bench stable.  Meaning, the compound can be held on to for long periods of 
time without falling apart and since the reaction is also scalable large amounts can be 
made and used over a long period of time. This is extremely beneficial, both from a cost 
effective standpoint and from a time conservation standpoint.   
 From a functional point of view this already functionalized precursor can be even 
further functionalized.  The halogen connected to C2 can be used for several types of 
coupling reactions, such as Heck, Susuki, and Sonagashira cross-couplings to name a 
few. The C3 position is vinylic, and the C4 position is allylic thus, both positions can be 
accessed for further functionalization. Additionally, the other α-carbon can be 
functionalized as it is α-amino and therefore the hydrogens in that position are acidic and 
begging to be functionalized. Furthermore, we intend to show the extremely vast utility 
of this synthetic intermediate as well as show the synthetic utility of the products that are 
constructed from it.  
1.4 Our Prior Work on Cyclic α-halo Eneformamides 
1.4.1 Expedient access to α, β-difunctionalized azepenes using cyclic α-halo 
eneformamides 
 Some of the first work we did using the cyclic α-halo eneformamide was on the 
seven-membered variant.  Having already demonstrated work showing we could 
effectively perform several types of coupling reactions on C2 position, we wanted to 
show approaches to functionalization of both the C2 and C3 positions.  The first approach 
is to functionalize the C2 position to give 24 and then the C3 position to afford 23 and the 
second approach is to functionalize the C3 position to give 25 followed by 
 27 
functionalizing the C2 position to afford 23.  This is illustrated in Figure 1-20.  Although 
it seems more likely that the bottom-up approach would be preferred because of the 
halogen on C2 acting as a functional handle, if the correct reaction conditions are found 
then direct C3 functionalization can take place followed by using coupling reactions 
using the halogen functional handle to functionalize C2.  
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Figure 1-20  Two vicinal functionalization strategies using a cyclic α-halo eneformamide 
 As shown in Figure 1-21 we were able to directly and regioselectively arylate the 
C3 position 27 using palladium catalyzed conditions used by Gunda.33 Consistent with 
what Gunda reported, the reaction depends highly on the aryl-iodo coupling partner.  It 
was recognized that if the aryl-iodo coupling partner was electron withdrawing in nature 
the reaction was slow and produced low yields.  Additionally, if the iodide coupling 
partner was ortho-substituted the reaction was slow and produced low yields.  However, 
these conditions did allow for direct and regioselective arylation of the C3 position and 
didn’t react with the functional handle on C2.  
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Figure 1-21  Palladium catalyzed C3 arylation of cyclic α-halo eneformamide 
 To illustrate the top-bottom approach after we directly functionalized the C3 
position 28 we then wanted to illustrate that the subsequent functionalization of the C2 
position was possible using the chloro group as a functional handle.  To illustrate this we 
used Susuki cross-couplings with aryl boronic acids to afford the doubly substituted 
azepenes (see 29 and 30).34  To further illustrate the substituted precursor’s utility, 
Sonagashira cross-couplings with trimethylsilylacetylene were conducted in a catalytic 
amount of CuI (see 33 and 34). This shows two possible examples of how we were able 
to successfully use the top-down approach on our cyclic α-chloro eneformamides (Figure 
1-22). 
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Figure 1-22  Palladium-catalyzed α-arylation and alkynylation of C2-functionalized 
cyclic α-chloro eneformamides 
 In a previous publication we showed that cyclic α-chloro eneformamides could be 
vinylated, alkynlated and arylated through the use of Heck, Suzuki, and Sonagashira 
cross-couplings.35 We then took select examples of the α-alkenyl eneformamides 35 and 
used these to explore the bottom-up approach to vicinally difunctionalyzed azepenes.  We 
took our library of newly formed dienes and explored the use of Diels-Alder / 
benzannulation type reaction. We took our dienes and reacted them with several 
asymmetrical and symmetrical dienophiles to create benzannulated azepenes (see 36 and 
37) (Figure 1-23).  
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Figure 1-23  Preparation of 2-benzazepanes using α-alkenyl eneformamides 
1.4.2 One-shot access to α, β-difunctionalized azepenes and 
dehydropiperidines by reductive cross-coupling of α-selenonyl-β-selenyl 
enamides with organic bromide 
 One of the goals in the use of our cyclic α-chloro eneformamides is to find new 
ways to access differentially-substituted azaheterocycles.  We envisioned a route where 
we could take our cyclic α-chloro eneformamides and replace the bromo group with a 
selenonyl group A. This approach would then allow us to explore Denmark-motivated36 
cross-couplings and the electron withdrawing nature of the selenonyl group would afford 
us the opportunity to explore Comins37 directed lithiation / trapping with electrophiles 
B,C (Figure 1-24). 
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Figure 1-24  Preparation of α-selenonyl eneformamides followed by directed 
lithiation/trapping 
 Once the selenonyl group was added, Denmark-motivated cross-coupling 
conditions were utilized. The resulting carbofunctionalized products shown in Figure 1-
25 were obtained in satisfactory yields. To show the versatility of these reaction 
conditions aryl, heteroaryl, alkenyl, and allyl Grignard reagents were used. 
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Figure 1-25  Select examples of the Denmark-motivated cross-coupling 
 After utilizing Comins-directing lithiation/trapping we were able to utilize the 
new α-selenonyl and β-selenyl functional handles to add aryl groups in a selective 
manner to both the C2 and C3 positions (Figure 1-26). In order to add two different 
substituents this undoubtedly takes advantage of the reactivity difference between the α-
selenonyl and β-selenyl requisite groups.  Additionally, for the C3 functionalization to 
occur the reaction mixture needed to be heated to 40 °C. This strategy allowed for a wide 
range of aryl, allyl, alkenyl compounds to be added and allowed for quick and efficient 
access to bis-functionalization of the C2 and C3 positions.38 
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Figure 1- 26  Select examples of bis-functionalization utilizing α-selenonyl and β-selenyl 
requisite groups 
1.5 Statement of Purpose 
• Extension of the scope of reactivity of cyclic α-halo eneformamides to other ring 
sizes, especially macrocycles.  
• Demonstration of the synthetic utility of α-substituted eneformamides through the 
preparation of quaternary propargylic and homallylic cyclic amines 
• Synthesis of dihydro-1,4-oxazines, thiazines and their synthetic applications 
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CHAPTER 2 
 
EXTENDING THE SCOPE OF REACTIVITY OF CYCLIC ALPHA-HALO 
ENEFORMAMIDES TO OTHER RING SIZES, ESPECIALLY MACROCYCLES 
2.1 Introduction 
As previously discussed, azaheterocycles make up the backbone of many FDA 
approved pharmaceuticals.  Specifically, functionalized piperidines, azepanes, and aza-
cyclotridecanes are found to make up the backbone of a large number of those 
pharmaceuticals and have been found to have a significant variety of biological activity. 
Shown in Figure 2-1 are select examples of pharmaceuticals or biologically active 
compounds containing these important structural backbones, including morphine (a well-
known opiate containing a piperidine backbone), securinine (a therapeutic for primarily 
neurological-related diseases containing an azepane backbone), and manazamine A (a 13-
membered aza-macrococyclic compound derived from sea sponges being tested for anti-
cancer and anthelmintic properties). 
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Figure 2-1  Representative piperidine, azepane, and azamacrocycle alkaloids 
 Commonly employed strategies to access these highly functionalized piperidines 
and azepanes found in these pharmaceuticals is through the use of enamides or 
enecarbamates. These enamide and enecarbamate precursors provide many advantages to 
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accessing a variety of functionalized azaheterocycles.39-44 Specifically, the double bond 
corresponding to the enamide or enecarbamate on pyrollidines and piperidines has been 
utilized for oxidation and reduction reactions43, 45 and has been used in carbon-carbon 
bond formations. The double bond has also been used in several cross-coupling reactions 
utilizing a functional handle at the C2 position such as vinyl triflates,46, 47 vinyl 
phosphates,31 or stannanes.32 It has also been shown that access to C3 functionalization 
can be achieved through the use of Lewis acids or by the use of palladium,29, 42 iridium,48 
or iron44 cross-coupling strategies. 
 With this in mind, we recognized that these cross-coupling strategies provide the 
best way to access highly functionalized azaheterocycles, particularly when attempting to 
functionalize the C2 and C3 positons.  Synthetic strategies to functionalize the C2 and C3 
positions are highly sought after as they offer access to several substitution patterns found 
in many pharmaceuticals such as compounds in Figure 2-1. We also wanted to seek a 
synthetic route that could be utilized in different ring systems. As we stated, there has 
been a variety of work done on 5-, 6-, and 7-membered ring systems. As a complement to 
the previously reported tactics, we wanted to find a synthetic strategy that could be used 
for a large variety of ring systems including N-macrocycles. We however recognize that 
increasing ring size can be a challenging and frustrating task given that increasing the 
ring size increases reactivity yet decreases stability and imposes conformational 
constraints.  
 Prior to our work, it has been shown by Occhiato, Coudert, and Sulikowski that 
cross-couplings can be done using vinyl triflates,46 vinyl phosphates,31 and α-iodo 
enecarbamates49 as functional handles with the use of metalated coupling reagents 
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(Figure 2-2 top). However, the authors noted that these enecarbamates were not stable 
and thus required the use of highly reactive metalated coupling reagents.46, 49 Since the 
compounds are so unstable, the reaction conditions must be chosen carefully because 
under many cross-coupling conditions these enecarbamate derivatives are prone to ring-
opening.46 This led us to find a more efficient bench stable methodology. Although 
enecarbamates and enamides are highly useful precursors for more functionalized 
azaheterocycles, their lack of stability and proneness to ring opening makes them less 
practical and less appealing as synthetic intermediates. 
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Figure 2-2  Comparison of previous C2 functionalization strategies to our work 
 The need for a more cost-effective, bench-stable, and modular precursor has led 
us to our highly coveted cyclic α-halo eneformamides.  The cyclic α-halo eneformamide 
allows easy access to C2 and C3 functionalization to afford highly functionalized 
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piperidines, azepanes, and aza-macrocycles. The use of cyclic α-halo eneformamides 
stands above other methodologies in many ways.  The cyclic α-halo eneformamides 
provide several advantages over the competition as they can be coupled with 
nonmetalated alkenes which eliminates the need to use toxic reagents such as stannanes, 
and eliminates the need for vinyl boronic acids/esters which are costly and unstable.   
Another added advantage to the use of cyclic α-halo eneformamides is their cost-
effectiveness and ability to be generated in one step from a simple lactam precursor as 
opposed to the several steps required by the previously employed tactics31, 46 shown in 
Figure 2-2. This allows for quick access to cyclic α-halo eneformamides where the 
functional handle at the C2 position and the ring size are modular. This has allowed us to 
access cyclic α-halo eneformamides with ring sizes of 6, 7, and 13, synthesized from 
valerolactam, caprolactam, and laurolactam, respectively. The unique balance of stability 
and reactivity has allowed us to employ a wide range of coupling strategies, such as 
Heck, Suzuki, and Sonagashira cross-couplings in a cost-effective, scalable, and highly 
modular diversity-oriented approach. 
2.2 Results and Discussion 
2.2.1 Synthesis of 6-, 7-, and 13-membered cyclic α-halo eneformamides 
 Having previously demonstrated that a Vilsmeier-Haack reaction could be used to 
make a 7-membered cyclic α-halo eneformamide from caprolactam35 we decided to 
expand this reaction to the 6- and 13-membered rings.  The 6- and 13-membered cyclic 
α-halo eneformamides were synthesized using the same conditions as the ones used to 
make the 7-membered cyclic α-halo eneformamide only using valerolactam and 
laurolactam respectively (Figure 2-3). We recognize the reactivity trends between these 
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ring systems are very unpredictable and it turned out that extending the Vilsmeier-Haack 
reaction to different ring systems was a daunting task.  At first glance we expected that as 
we increased ring size, reactivity would increase and thus reaction time would in theory 
decrease. However, this was not the case. Our studies have revealed that when increasing 
the ring size from 6 to 7, reaction times do decrease (see 2b vs 2d). However, when going 
from the 7- to the 13-membered ring system the reaction time goes from 3 hours to 3 
days (see 2e).  This is probably a reflection of the conformational differences and 
entropic costs associated with the ring systems.  The 13-membered ring is so large that 
the reaction probably takes more time due to steric hindrance and the need to orient itself 
in the proper conformation.  All that said, we were able to extend the Vilsmeier-Haack 
reaction to both the 6- and 13-membered ring systems as well as change the functional 
handle at C2 to either chlorine or bromine (see 2a-d).  It is also worth mentioning that 
this chemistry can be further extended to attach an iodo group instead of chlorine or 
bromine by simply using phosphorus oxyiodide instead of its chlorine or bromine 
variants. This is important as it allows us to increase the reactivity of the functional 
handle as going from chlorine, to bromine, to iodide increases the leaving ability of the 
functional handle, therefore allowing for coupling with less reactive partners. The 
reaction is highly scalable as exemplified by the fact that we can seamlessly prepare 2e in 
>100 mmol scale. Since Vilsmeier-Haack reactions with lactams of type 1 are notoriously 
promiscuous, from the standpoint of regioselectivity (i.e. N- vs. C-formylation),50 it is 
quite impressive that 2a-e are obtained in high efficiency and site selectivity. Both 
efficiency and selectivity are maximized when the Vilsmeier-Haack reagent is generated 
under refluxing conditions prior to slow introduction of 1. In the case of laurolactam, we 
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have found that the reaction can be arrested at the stage where novel chloro 
eneformamidinium ion A predominates. This is noteworthy given that A is an acyclic 
diamino carbene (ADC) surrogate.  
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Figure 2-3  Synthesis of 6-, 7-, and 13-membered cyclic α-halo eneformamides 
Transition metal-catalyzed cross-coupling reactions, especially those employing 
traceless activation groups (e.g., cuprates) have revolutionized almost all areas of 
chemical synthesis.51, 52 However, efforts toward improving cost, versatility, and 
operational simplicity of these methods continually necessitate the development of simple 
protocols that rely on feedstock organic, native functionality such as chlorides as 
requisite handles for uniting complex fragments.53-58 Of greater appeal to the synthesis 
community is the prospect of utilizing these cheap and readily available organic chlorides 
together with unactivated nucleophiles, given that this beneficially obviates the need for 
preactivation. 
As part of a systematic scaffolding approach aimed at exploiting the versatility of 
cyclic α-halo eneformamides such as 2 (Fig. 2-3) in synthesis,59-61 and seeking to achieve 
C-2 and C-3 functionalization of N-containing macrocycles, it was surmised that cross-
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coupling reactions featuring cyclic chloro eneformamide 2e offered a resplendent 
platform. Using the small, electronegative formyl group as a directing/protecting group 
and the chlorine atom at C-2 as a functional handle, we envisioned that 2e would be 
amenable to conventional cross-coupling manifolds (e.g., Sonogashira,62 Heck,63-65 and 
Suzuki66-70). Having collaboratively achieved partial success on the azepene59 and 
dehydropiperidine60 scaffolds, and in lieu of unsuccessful attempts to functionalize the 
azetidine and pyrrolidine homologues of 2e, it became even more obvious to us that 
extending reactivity trends from one N-heterocycle to another can be quite daunting and 
at times foolhardy. Nevertheless, we stoically embraced the challenge of exploring the 
amenability of potentially fragile macrocyclic chloro eneformamide 2e to C-2/C-3 
functionalization protocols. Primarily due to the substantial enthalpic and entropic costs 
associated with the formation of large rings,71, 72 efficient construction and 
functionalization of nitrogen-containing macrocycles such as azacyclotridecanes73 have 
unsurprisingly posed a greater challenge to the synthesis community than have the 
corresponding medium ring congeners such as the azepane-,59, 74 piperidine-,75-86 and 
pyrrolidine- motifs.87-91 Nevertheless, the architectural complexity of these functionalized 
large ring N-heterocycles and their prevalence in natural products, pharmaceuticals, 
materials, fragrances, ligands, and catalysts continue to inspire the development of 
increasingly more efficient strategies for their construction and functionalization. 
We further recognized that successful implementation of our ideals would not 
only provide expedient access to differentially functionalized azacyclotridecanes, but 
increase the 3D-chemical space for the discovery of new N-macrocycles with medicinal 
value. Furthermore, these eneformamide precursors and products represent excellent 
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synthetic intermediates for a diverse range of transformations since they bear latent 
functionality at the α and β positions. For example, they may be engaged in 
hydrogenation,92 cyclopropanation,93 halogenation,94 amination,95 aminoxylation,96 
alkylboration,97 hydroarylation,98 hydroallylation,99 oxo-amination,100 
trifluoromethylation,101 hexannelations,102 or allylic functionalization protocols.103 
2.2.2 α-alkenylation of 13-membered cyclic α-chloro eneformamides 
Vinylated piperidines, azepanes, and azamacrocycles are highly desired 
compounds because they offer the ability to be used in the construction of highly sought-
after pharmaceuticals.  Specifically, these vinylated precursors can be used as dienes in 
hexannelations en-route to creating fused polycyclic compounds such as those in Figure 
2-1. It has been previously reported that alkenylation of enamides at C2 can be done by 
using palladium-catalyzed Heck type conditions and alkenylations at C3 were possible 
under Fujiwara−Moritani104, 105 type conditions. This led Sarpong and one of us35 to 
optimize these conditions for the use of the 7-membered cyclic α-halo eneformamides.  
Using similar conditions, we have now expanded this chemistry to the 13-membered ring 
system (Figure 2-4). Using these reported optimized conditions we decided to explore the 
limitations of the coupling partner with the 13-membered cyclic α-halo eneformamide.  
We began to explore the alkene coupling partners with our cyclic α-halo 
eneformamide 2e to create the diene 3a. We explored several types of coupling partners 
that included electronically diverse monosubstituted acyclic alkenes. We discovered 
similar limitations to those experienced by Sarpong35 and others with Heck type coupling 
reactions.  The reaction occurs faster with better yield when the alkene coupling partner 
is electron rich (see 3a1-5) compared to that of its electron poor counterpart such as 3a6. 
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This is likely due to the electron withdrawing alkene affecting the oxidative-addition step 
in the catalytic cycle. 
When allyl bromide is employed as the alkene coupling partner, the reaction 
proceeds with double-bond isomerization and concomitant expulsion of the bromide, 
thus, affording allylated eneformamide 3a7. Other leaving group bearing allyl coupling 
partners such as allyl acetate fail to furnish 3a7, thus emphasizing the importance of the 
bromide in generating π-allyl complexes. 
To further investigate the reactivity trends from the 6- to 7- to 13-membered 
eneformamide we decided to see if we could couple the eneformamides together.  In the 
case of the 6 and 7-membered rings they were both able to couple together creating a 
mixture of reduced and oxidized compounds (see 3a10/11 and 3b10/11). This is due to 
the elimination of chlorine generating one double bond and the 1,4-elimination of 
palladium causing one of the eneformamides to have two double bonds (see 3a12-14). 
The mixture can be converged through chemoselective hydrogenation (using H2/Pd) for 
the isolated double bond in the presence of the eneformamide double bond. This 
facilitated characterization of the homo-coupled product of the six membered 
eneformamide (Sarpong59 group had already shown the case of the 7-membered variant). 
Once we established that the 6 and 7 membered rings were able to successfully homo-
couple and the 13-membered did not, we wanted to provide further evidence of their 
reactivity.  To do this, we placed the 13-membered and 6-membered together and the 13-
membered and 7-membered eneformamides together under the same coupling conditions 
and only saw homo-coupling of the 6- and 7-membered ring systems (see 3a8/9). We 
then placed the 6 and 7-membered eneformamides together and saw primarly homo-
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coupling of the 7-membered over the 6.  This further established that the reactivity trend 
of the 7-membered is faster than the 6, which is faster than the 13. 
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Figure 2-4  Alkenylation of macrocyclic α-chloro eneformamide 2e 
2.2.3 α-Arylation of 13 membered cyclic α-chloro eneformamides 
After amply demonstrating that congruent with its azepane congener, 2e 
undergoes productive Heck alkenylation,  it was of interest to evaluate its performance in 
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Suzuki cross-coupling under conditions analogous to those popularized by Sarpong.35 
Using similar conditions, we surveyed several aryl coupling partners (Figure 2-5).  We 
investigated electron-rich, electron-poor, sterically demanding, and heteroaryl π-
excessive and π-deficient substituents to test the limitations of the reaction conditions and 
the 13-membered cyclic α-halo eneformamide as opposed to its 7-membered counterpart.  
 Similar to the vinylation cross-couplings, we see a trend matching that of the 7-
membered cyclic α-halo eneformamide.  However, as was the case with the vinylations, 
the reaction times with the 13-membered cyclic α-halo eneformamide are significantly 
slower than the reaction times for the 7-membered cyclic α-halo eneformamide. The 
reaction proceeds much faster and more efficiently if the coupling partner is electron rich 
(3b3) as opposed to if the coupling partner is electron neutral 3b1 or electron poor 3b4.  
We also tested to see if sterics would play a role by using a sterically demanding naphthyl 
group (3b2) and got relatively good yields in comparison to a smaller phenyl group 3b6.  
We also compared heteroaryl π-deficient and π-excessive groups 3b5 vs. 3b6 and saw 
that π-excessive groups 3b5 react more efficiently and much faster than π-deficient 
groups 3b6.  
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Figure 2-5  Arylation of 13-membered cyclic α-halo eneformamide 2e 
2.2.4 α-alkynylation of 6-, 7-, and 13-membered cyclic α-halo eneformamides 
To further investigate the utility of our cyclic α-halo eneformamide, we 
investigated the possibility of synthesizing α-alkynyl azacyclotridecenes under 
Sonagashira cross-coupling conditions106 (Figure 2-6).  In the event, all three cyclic α-
chloro eneformamides were coupled with a variety of terminal alkyne coupling partners.  
Several different alkynes were used, ranging from electron rich to electron poor.  To no 
surprise 2e coupled slower than the 6- or 7-membered counterpart.  In many cases, the 6- 
and 7-membered rings could undergo alkynylation at room temperature, whereas 2e 
required temperatures as high as 60 °C.  Electron withdrawing groups 3c21-26 were also 
slow to react for all ring systems and required heat of up to 40 °C.  Conversely electron 
neutral 3c7-9, 3a13-20 and electron rich groups 3c10-12 proceeded much faster with 
better yields. This comes as no surprise, as with the use of palladium-catalysts, electron-
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poor coupling partners have shown low reactivity and low yields for all three types of 
coupling reactions investigated, which corresponds to the results found by Sarpong’s35 
group when they investigated the 7-membered cyclic α-halo eneformamides. Silyl-
bearing acetylenes are well tolerated (see 3a4-6 and 3c1-3). This is noteworthy since they 
are easily removable, thus allowing for late-stage diversification.  Additionally, in the 
case of the tethered alkynes 3a21-26, only the 4-, 5-, and 6-membered tethers can be 
purchased commercially so the use of the TMS or TIPS leaving groups afford the 
opportunity to attach longer tethers which can then be used to create aza-polycyclic 
enynes.  
PdCl2(PPh3)2 (5 mol%)
CuI (1 mol%), DMF: Et3N (5:1)
23 to 60 oC
R H (1.2 equiv)
N
CHO
n
Cl N
CHO
n
R
3c2a, n = 1; 2c, n = 2; 2e, n = 8
N
CHO
n
PMP
3c4; n = 1, 92%
3c5; n = 2, 96*
3c6; n = 8, 91%
3c1; n = 1, 88%
3c2; n = 2, 91%
3c3; n = 8, 85%
N
CHO
N
CHO
n
N
CHO
n
TMS
N
CHO
n
TIPS
3c7; n = 1, 91%
3c8; n = 2, 94%*
3c9; n = 8, 89%
N
CHO
n
3c18; n = 1, 89%
3c19; n = 2, 91%
3c20; n = 8, 86%
3c16; n = 1, 90%
3c17; n = 2, 94%*
N
CHO
n
Cl
3c21; n = 1, 95%
3c22; n = 2, 90%*
3c23; n = 8, 91%
3c10; n = 1, 93%
3c11; n = 2, 97%
3c12; n = 8, 94%
N
CHO
n
3c13; n = 1, 90%
3c14; n = 2, 92%
3c15; n = 8, 91%
N
CHO
n
3c24; n = 1, 87%
3c25; n = 2, 92%
3c26; n = 8, 93%
Me
( ) ( )
( ) ( ) ( )
Cl
( ) ( ) ( )
( ) ( )
n
( )
* indicates result is from Sarpong group38  
Figure 2-6  Alkynylations of 6-, 7-, and 13-membered cyclic α-chloro eneformamides 
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2.2.5 Oxo-halogenation of α-chloro eneformamides 
The ability to achieve vicinal heterodifunctionalization of alkenes is an important  
yet challenging transformation that has gained an extensive amount of attention from the 
organic synthetic community, as it provides considerable access to a wide range of 
natural products and pharmaceuticals.  Surprisingly, there is very little literature on 
methods to achieve vicinal heterodifunctionalization of vinyl chlorides. Thus, we decided 
to build on the lone example reported by Sarpong and one of us. Pleasingly, 2e 
successfully undergoes N-halo succinimide-mediated oxo-iodination, oxo-bromination, 
and oxo-chlorination to give the vicinally heterodifunctionalized N-protected α-
halogenated lactams depicted in .Fig. 2-7 This is noteworthy as it only takes two steps to 
undergo this transformation, the Vilsmeier-Haack reaction followed by oxo-halogenation 
versus many conventional approaches to α-halo lactams take considerably more steps and 
are rather inefficient.107 Important to note, reaction times go considerably faster when 
using N-iodo succinimide compared to N-bromo succinimide compared to N-chloro 
succinimide.  This is expected as the reactivity of the halogen increases from chloro to 
bromo to iodo leaving groups.  
3d1; X = I, 93% (after 10 min)
3d2; X = Br, 90% (after 30 min)
3d3; X = Cl, 86% (after 4 h)
N
CHO
ON Cl
X
NXS (1. 1 equiv)
THF:H2O (5:1), rt
CHO
1e
 
Figure 2-7. Oxo-halogenation of α-chloro eneformamide 1e 
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2.3 Conclusion 
In conclusion, palladium-catalyzed Heck, Suzuki, and Sonogashira cross-coupling 
conditions have been employed to alkenylate, arylate, and alkynylate the α-position of the 
lactam-derived 6, 7, and 13 membered cyclic α-halo eneformamides. Similar trends were 
noticed with electron poor and electron rich coupling partners for each type of coupling 
on each ring system.  Additionally, we were able to achieve vicinal 
heterodifunctionalization using N-halo succinimide-mediated oxo-halogenation with 
chloride, bromide, and iodide as the halogens to construct N-protected α-halogenated 
lactams. The 13-membered cyclic α-halo eneformamides reacted slower than the 6 which 
was slower than the 7 showing that reactivity trends with different size ring systems can 
be difficult to predict. The stage has now been set for the synthesis of complex N-
heterocycles using the current strategy, as described in the subsequent chapter. 
2.4 Methods 
All experiments involving palladium precatalysts were carried out under an inert 
atmosphere of argon or nitrogen. Et3N, MeOH, THF, benzene, toluene, Et2O, and 
acetonitrile were distilled using the Grubbs solvent system. Anhydrous DMF and 1,4-
dioxane were used as purchased. Dichloromethane was distilled from MgSO4. NaTFA, 
K2CO3, CuI, NaBH3CN, and the boronic acids were used as purchased. The concentration 
of commercial n-BuLi (solution in hexanes) was determined prior to use by No-D NMR 
spectroscopy.108 All alkenes and alkynes were newly purchased and used without further 
purification. Column chromatography was performed on silica gel (230-400 mesh). Thin-
layer chromatography (TLC) was performed on silica plates. Visualization of the TLC 
plates was aided by UV irradiation at 254 nm or by staining with CAM, p-anisaldehyde, 
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or KMnO4. Unless otherwise indicated, 
1H, 13C, DEPT-135 NMR spectra were acquired 
using C6D6 or CDCl3 as solvent at room temperature. Chemical shifts are quoted in parts 
per million (ppm). 34, 38, 59, 109-112 
2.4.1 General procedure A: synthesis of 2-halo enamides 
The corresponding phosphorus oxyhalide (30 mmol, 3 equiv) dissolved in CH2Cl2 
(18 mL) was added dropwise to a solution of DMF (60 mmol, 6 equiv) in CH2Cl2 (50 
mL) at 0 °C. The resulting mixture (pale yellow in the case of the chloride or milky white 
in the case of the bromide) was refluxed for 20 min. A solution of caprolactam (10 mmol, 
1 equiv) in CH2Cl2 (50 mL) was added slowly under reflux. After complete addition of 
the lactam, the mixture was stirred under reflux for the indicated time period (TLC and 
LC-MS monitoring was used to followed the extent of the reaction). Upon completion, 
the mixture was allowed to warm to room temperature and then poured into a large flask 
containing crushed ice. After stirring at rt for 30 min, the layers were separated. 
Powdered K2CO3 was added slowly to the mixture and the flask was swirled after each 
addition (Caution: it bubbles vigorously). The addition/swirling was continued until 
persistent cloudiness was observed. The neutralized/slightly basic mixture was extracted 
three times with CH2Cl2. The combined organic layer was concentrated to ~100 mL and 
was dried over Na2SO4 for 30 min. The mixture was filtered and concentrated under 
reduced pressure to give the desired product as an oil. Purification: Flash chromatography 
on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Caution: The 2-
haloenamides are bench stable at room temperature for days but should be stored in the 
refrigerator either neat or as a solution in benzene.34, 38, 59, 109-112 
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2.4.2 General procedure B: Heck coupling of 2-halo enamides with 
unactivated alkenes 
The 2-halo enamide (1 mmol, 1.0 equiv) in DMF (2 mL, 0.50 M), Pd(OAc)2 (5 
mol%), additive (1 to 2.0 equiv), alkene (2 to 6 equiv) was added to an oven-dried, 
septum-capped vial equipped with a stir bar under a nitrogen atmosphere. The mixture 
was then stirred at 80 oC for the desired length of time (as indicated by TLC and LC-MS, 
usually 1 h). Upon completion, the mixture was quenched with water and extracted with 
CH2Cl2. The combined organic layers were concentrated to ~10 mL and dried for ~30 
min with Na2SO4. It was filtered and evaporated to give the crude product. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc. Note: 1 equiv NaTFA or 2 
equiv of K2CO3 were employed. With dioxane as the solvent, longer reaction times 
(monitoring by TLC and LC-MS, usually 2 h) are required. 34, 38, 59, 109-112 
To a solution of cyclic enol ether (1 equiv), palladium diacetate (0.1equiv) and 
silver acetate (2.5 equiv) in DMF and DMSO (10:1) at 80 °C, under open air condition 
was added the cycloalkene (1.5 equiv) drop wise. The mixture was allowed to stir at 80 
°C for 24 h. Then the mixture was diluted with ethyl acetate (2 mL), filtered, washed with 
water (5 mL) and brine (5 mL). The organic layer was evaporated and the residue was 
purified by flash column chromatography (Hexane/EtOAc) (6:1) to afford the product as 
an oil. 34, 38, 59, 109-112 
2.4.3 General procedure C: Suzuki coupling of 2-halo enamides with boronic 
acids 
The 2-halo enamide (1 mmol, 1.0 equiv) in DMF (5 mL) was added to an oven-
dried, septum-capped 2-neck-round bottom flask equipped with a stir bar under nitrogen 
atmosphere. The desired boronic acid (1.2 equiv) was added followed by addition of Et3N 
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(0.7 mL, 5 mmol, 5 equiv). After completely degassing the flask, PdCl2(PPh3)2 (35 mg, 5 
mol%) was added rapidly. The mixture was then stirred at the desired temperature for the 
desired length of time (as indicated by TLC and LC-MS). Upon completion, the mixture 
was quenched with water and extracted with CH2Cl2. The combined organic layers were 
concentrated to ~20 mL and and dried with for ~30 min with Na2SO4. It was filtered and 
evaporated to give the crude product. Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc. 
34, 38, 59, 109-112 
2.4.4 General procedure D: Sonogashira coupling of 2-halo enamides with 
terminal alkynes 
The 2-halo enamide (1 mmol, 1.0 equiv) in DMF (5 mL) was added to an oven-
dried, septum-capped 2-neck-round bottom flask equipped with a stir bar under nitrogen 
atmosphere. The desired alkyne (1.2 equiv) was added followed by addition of Et3N (0.7 
mL, 5 mmol, 5 equiv). After completely degassing the flask, PdCl2(PPh3)2 (35 mg, 5 
mol%) and CuI (2 mg, 1 mol%) were added rapidly and concurrently. The mixture was 
then stirred at the desired temperature for the desired length of time (as indicated by TLC 
and LC-MS). Upon completion, the mixture was quenched with water and extracted with 
CH2Cl2. The combined organic layers were concentrated to ~20 mL and dried with for 
~30 min with Na2SO4. It was filtered and evaporated to give the crude product. 
Purification: Flash chromatography on silica eluting with hexane/EtOAc. Note: The 
coupling can be performed in the absence of CuI but longer reaction times (monitoring by 
TLC and LC-MS) are required. 34, 38, 59, 109-112 
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2.5 Peak Assignments 
2.5.1 Peak assignment of 2a 
N
CHO
Cl
DMF (6 equiv), POX3 (3 equiv)
CH2Cl2, rt, 18 h
N
H
O
2a, 89%-valerolactam (I)  
Prepared using General Procedure A. Valerolactam (991.3 mg, 10 mmol), 
POCl3 (4.6 g, 2.8 mL, 30 mmol), DMF (4.63 mL, 60 mmol), Temp = 40 
oC, time = 4 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 1310 mg, 89%. Spectroscopic data as previously reported 
by us. 109 
2.5.2 Peak assignment of 2b 
N
CHO
Br
DMF (6 equiv), POBr3 (3 equiv)
CH2Cl2, rt, 18 h
N
H
O
2b, 91%-valerolactam (I)  
Prepared using General Procedure A. Valerolactam (991.3 mg, 10 mmol), 
POBr3 (8.6 g, 30 mmol), DMF (4.63 mL, 60 mmol), Temp = 40 
oC, time = 2 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 1730 mg, 91%. Spectroscopic data as previously reported 
by us. 109 
2.5.3 Peak assignment of 2c 
N
CHO
ClN
H
O
DMF (6 equiv), POCl3 (3 equiv)
CH2Cl2, reflux, 3 h
2c, 88%II  
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Prepared using General Procedure A. Caprolactam (1131.6 mg, 10 mmol), 
POCl3 (4.6 g, 2.8 mL, 30 mmol), DMF (4.63 mL, 60 mmol), Temp = 40 
oC, time = 3 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 1408 mg, 88%. Spectroscopic data as previously reported 
by us.109  
2.5.4 Peak assignment of 2d 
N
CHO
BrN
H
O
DMF (6 equiv), POBr3 (3 equiv)
CH2Cl2, reflux, 0.5 h
2d, 92%II  
Prepared using General Procedure A. Caprolactam (991.3 mg, 10 mmol), POCl3 
(4.6 g, 2.8 mL, 30 mmol), DMF (4.63 mL, 60 mmol), Temp = 40 oC, time = 0.5 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 1877 mg, 92%. Spectroscopic data as previously reported 
by us.109  
 
2.5.5 Peak assignment of 2e 
DMF (6 equiv)
POCl3 (3 equiv)
CH2Cl2, reflux, 72 h N
CHO
ClN
H
O
100 mmol
2e, 91% (from III)
inverse addition
III
 
Prepared using General Procedure A; Laurolactam III (11.3 g, 100 mmol), 
POCl3 (46 g, 28 mL, 300 mmol), DMF (46.3 mL, 600 mmol), Temp = 40 
oC, time = 72 h; 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
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hexane/EtOAc (80:20).Yield = 22100 mg, 91%. 1H NMR (400 MHz, C6D6, mixture of 
rotamers) δ 8.13 (s, 1H). 5.10 to 4.99 (t, 1H), 3.64 to 3.57 (t, 2H), 2.09 to 1.04 (m, 18H). 
13C NMR (101 MHz, C6D6) δ 161.3, 130.9, 128.0, 128.0, 127.7, 127.5, 40.1, 28.1, 27.5, 
26.6, 26.6, 26.5, 25.5, 25.0, 24.8, 24.2, 23.3. HRMS-EI+ (m/z): calc’d for C13H22ClNO 
243.1390; found 243.1395. 
2.5.6 Peak assignment of 3a1 
N
CHO
3a1  
Prepared using General Procedure B. 2e (1.0 mmol), Pd(OAc)2, (11.5 mg, 5 
mol%), and styrene (0.46 mL, 4 mmol, 4 equiv), (1.5 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 100 oC, time = 1 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 243 mg, 
78%. 1H NMR (400 MHz, CDCl3) δ 8.13 & 8.02 (1H, ss, major & minor rotamers)), 7.52 
to 7.22 (5H, m), 6.98 to 6.94 (1H, d, major rotamer), 6.69 to 6.65 (1H, d, minor rotamer), 
6.51 to 6.35 (1H, both rotamers), 5.65 to 5.61 (1H, t, both rotamers), 3.65 to 3.51 (2H, t, 
both rotamers), 2.42 to 2.25 (2H, t, both rotamers), 1.78 to 1.22 (16H, m, both rotamers). 
13C NMR (101 MHz, CDCl3) δ 163.8, 163.3, 138.4, 138.2, 137.0, 136.4, 136.3, 135.6, 
134.8, 133.7, 131.3, 130.1, 129.2, 129.1, 128.8, 128.8, 128.7, 128.6, 128.3, 128.0, 127.9, 
127.6, 127.0, 126.9, 126.8, 126.5, 126.5, 126.4, 120.7, 119.6, 44.4, 42.7, 26.5, 26.3, 26.1, 
26.6, 26.0, 25.8, 25.8, 25.7, 25.7, 25.4, 25.1, 25.0, 24.9, 24.7, 24.2, 23.9, 23.7, 23.4. 
HRMS calc for C21H29NO 311.2249, found 311.2255. 
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2.5.7 Peak assignment of 3a2 
N
CHO
3a2
OMe
 
Prepared using General Procedure B. 2e (159.6 mg, 1.0 mmol) Pd(OAc)2, (11.5 
mg, 5 mol%),  and 4-methoxystyrene (1.5 equiv), (1.5 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 90 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (27:75). Yield = 297 mg, 
87%. 1H NMR (400 MHz, CDCl3) δ 8.17 (1H, s,s, minor & major), 7.33 to 7.31 (2H, 
d,d), 6.87 to 6.85 (2H, d), 6.56 to 6.46 (1H, d), 6.30 to 6.23 (1H, d), 5.62 to 5.58 (1H, t), 
3.79 to 3. 58 (5H, m), 2.38 to 2.24 (2H, m), 1.63 to 1.25 (16H, m). 13C NMR (101 MHz, 
CDCl3) δ 163.8, 159.8, 139.3, 138.5, 137.2, 136.2, 135.1, 134.6, 133.2, 132.5, 130.8, 
130.8, 129.8, 128.1, 127.9, 127.8, 127.7, 127.3, 127.7, 127.2, 126.9, 124.9, 123.3, 119.6, 
115.5, 114.2, 55.4, 55.3, 43.1, 42.7, 30.6, 29.7, 29.5, 29.4, 28.7, 28.3, 28.5, 27.4, 27.1, 
26.9, 26.8, 26.7, 26.6, 26.5, 26.5, 26.3, 26.1, 26.0, 25.8, 24.6, 23.3, 23.8, 23.7, 23.2. 
HRMS calc for C22H31NO2 341.2355, found 341.2351. 
2.5.8 Peak assignment of 3a3 
N
CHO
3a3
OtBu
 
Prepared using General Procedure B. 2e (159.6 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), and 4-tert-butoxystyrene (1.5 equiv), K2CO3 (138 mg, 1 mmol, 1 equiv), 
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DMF (5 mL), Temp = 100 oC, time = 3 h. Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 314.1 mg, 82%. 
1H NMR (400 MHz, CDCl3) δ 8.17 (1H, s,s, minor & major), 8.21 to 7.28 (s, 1H), 7.42 
to 7.28 (d, 2H), 6.82 to 6.22 (m, 1H), 3.68 to 3.37 (T, 2H), 2.61 to 2.02 (m, 2H), 2.00 to 
1.02 (m, 16H). 13C NMR (101 MHz, CDCl3) δ 162.8, 158.2, 138.2, 132.5, 131.4, 130.5, 
129.4, 128.9, 127.4, 126.2, 124.2, 123.1, 44.2, 42.1, 40.5, 30.6,  29.2, 28.7, 27.9, 27.4, 
27.1, 26.9, 26.8, 26.7, 26.1, 25.6, 24.9, 24.7, 24.6, 24.6, 24.2, 23.9, 23.6, 23.4, 23.4. 
HRMS calc for C25H37NO2 383.2824, found 383.2827. 
2.5.9 Peak assignment of 3a4 
N
CHO
3a4
Me
 
Prepared using General Procedure B. 2e (159.6 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), 4-methylstyrene (0.346 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 161.7 mg, 
80%. 1H NMR (400 MHz, CDCl3) δ 8.28, to 8.00 (s, 1H), 7.34 to 7.10 (m, 4H), 6.96 to 
6.79 (d, 1H), 6.64 to  6.30 (d, 1H), 5.69 to  5.09 (t, 1H), 3.70 to  3.36 (m, 2H), 2.62 to 
1.23 (m, 18H). 13C NMR (101 MHz, CDCl3) δ 163.3, 161.9, 138.4, 138.4, 137.9, 137.1, 
135.9, 133.7, 133.0, 131.2, 129.5, 129.2, 128.7, 127.1, 126.7, 124.6, 123.9, 119.7, 48.1, 
44.3, 43.1, 42.8, 39.9, 39.3, 36.1, 29.7, 28.3, 27.9, 26.9, 26.8, 26.7, 25.0, 24.8, 23.9, 21.3, 
21.3, 21.1. HRMS calc for C22H31NO 325.2416, found 325.4915. 
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2.5.10 Peak assignment of 3a5 
N
CHO
3a5
tBu
 
Prepared using General Procedure B. 2e (159.6 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), 4-tert-butylstyrene (0.346 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 
1 equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 278.9 mg, 
76%. 1H NMR (400 MHz, CDCl3) δ 8.28 to 8.01 (s, 1H), 7.38 to 7.26 (m, 4H), 6.95 to 
6.91 (m, 1H), 6.79 to 6.34 (m, 1H), 5.69 to  5.59 (t, 1H), 3.59 to  3.02 (m, 2H), 2.59 to 
1.17 (m, 27H). 13C NMR (101 MHz, CDCl3) δ 163.3, 151.7, 138.4, 137.1, 135.1, 133.7, 
131.1, 129.1, 127.8, 125.7, 124.79, 120.5, 48.1, 44.3, 43.1, 42.7, 39.4, 34.7, 31.4, 31.3. 
29.7, 28.4, 27.6, 26.8, 25.8, 24.8, 24.8, 24.7, 24.7, 24.5, 24.2, 23.9, 23.7, 23.7, 23.5. 
HRMS calc for C25H37NO 367.1216, found 367.1215. 
2.5.11 Peak Assignment of 3a6 
N
CHO
3a6
F
 
Prepared using General Procedure B. 1a (159.6 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), 4-fluorostyrene (0.346 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 230.3 mg, 
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70%. 1H NMR (400 MHz, CDCl3) δ 8.28 to  7.98 (s, 1H), 7.39 to 6.79 (m, 4H), 6.62 to  
6.51 (d, 1H), 6.44 to  6.22 (d, 1H), 5.85 to 5.28 (t, 1H), 3.77 to 3.43 (m, 2H), 3.28 to 0.83 
(m, 18H). 13C NMR (101 MHz, CDCl3) δ 163.9, 138.2, 136.8, 135.8, 134.9, 133.7, 132.1, 
131.5, 130.9, 129.4, 128.0, 127.9, 126.8, 125.4, 120.5, 115.9, 48.1, 44.3, 42.7, 40.9, 39.9, 
36.9, 31.5, 29.7, 28.3, 27.8, 26.9, 25.8, 25.8, 24.9, 23.9, 23.6, 23.6, 23.4. HRMS calc for 
C15H16FNO 329.2216, found 329.4515. 
2.5.12 Peak assignment of 3a7 
N
CHO
3a7, 72% (using allyl bromide)
       0% conv with allyl acetate  
Prepared using General Procedure B. 2e (159.6 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), allyl bromide (0.300 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 179.3 mg, 
75%. 1H NMR (400 MHz, CDCl3) δ 8.07 to  7.82 (s, 1H), 7.26 to 6.74 (m, 2H),  6.29 to 
6.25 (m, 1H), 6.04 to 4.92 (t, 1H), 4.63 to  4.54 (m, 2H), 4.19 to 1.17 (m, 18H). 13C NMR 
(101 MHz, CDCl3) δ 163.7, 136.6, 132.9, 124.1, 117.5, 110.7, 76.7, 64.8, 43.1, 41.3, 
39.9, 37.9, 36.1, 31.8, 28.2, 27.1, 26.1, 25.9, 25.3, 25.0, 24.0, 23.8, 23.7, 23.2, 23.0. 
HRMS calc for C1H27NO 249.21, found 249.3915. 
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2.5.13 Peak assignment of 3a10/3a10b 
N
CHO
N
CHO
n
N
CHO
N
CHO
3a10b
n
n+
3a10, n = 0, 70%
( )
( )
( )
 
Prepared using General Procedure B. 2a (99.3 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), allyl bromide (0.300 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 155.7 mg, 
70%. As reported by us.109 
2.5.14 Peak assignment of 3a11/3a11b 
N
CHO
N
CHO
n
n
N
CHO
N
CHO
3a11b
n
n+
3a11, n = 1, 79%
( )
( )
( )
 
Prepared using General Procedure B. 2a (113.2 mg, 1.0 mmol), Pd(OAc)2, (11.5 
mg, 5 mol%), allyl bromide (0.300 mL, 3 mmol, 3 equiv), K2CO3 (138 mg, 1 mmol, 1 
equiv), DMF (5 mL), Temp = 80 oC, time = 3 h. Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 194.7 mg, 
79%. As reported by us.109 
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2.5.15 Peak assignment of 3b1 
N
CHO
Ph
3b1, 82%  
Prepared using General Procedure C. From 2e (160 mg, 1.0 mmol), phenyl 
boronic acid (146 mg, 1.2 mmol), temp = 24 oC, time = 18 h. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (70:30). 
Yield = 157 mg, 78%. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.39 & 8.10 
(1H, s), 7.53 to 7.22 (5H, m), 5.65 to 5.60 & 5.32 to 5.28 (1H, t, t), 3.55 to 3.23 (2H, m), 
2.25 to 2.09 (2H, m), 1.70 to 1.27 (16H, m). 13C NMR (101 MHz, CDCl3) δ 162.9, 137.5, 
134.3, 129.5, 128.7, 128.5, 41.3, 28.3, 27.6, 27.5, 27.3, 27.1, 26.7, 26.4, 26.3, 26.1, 25.9, 
25.7, 25.0, 24.7, 23.9, 22.9. HRMS calc for C19H27NO 285.1154, found 285.1156. 
2.5.16 Peak assignment of 3b2 
N
CHO
3b2  
Prepared using General Procedure C. 2e (160 mg, 1.0 mmol), 2-naphthyl 
boronic acid (206 mg, 1.2 mmol) Temp = 100 oC, time = 6 h. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (70:30). 
Yield = 257.9 mg, 77%. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.53 & 8.29 
(1H, s), 8.16 to 7.24 (7H, m), 5.76 to 5.67 (1H, t), 3.77 to 3.24 (2H, t), 2.25 to 2.04 (2H, 
m), 1.91 to 1.23 (16H, m). 13C NMR (101 MHz, CDCl3) δ 164.2, 163.5, 162.9, 139.8, 
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137.6, 134.5, 133.3, 133.3, 133.1, 133.1, 131.7, 129.8, 129.4, 129.1, 128.6, 128.5, 128.5, 
128.2, 128.1, 128.1, 127.9, 127.7, 127.7, 127.4, 126.7, 126.6, 126.6, 126.5, 126.4, 126.1, 
126.0, 125.8, 125.8, 124.5, 122.9, 77.5, 77.2, 76.9, 44.9, 43.5, 41.5, 28.3, 28.1, 27.9, 27.8, 
27.4, 27.4, 27.2, 27.0, 26.5, 26.5, 26.4, 26.0, 25.9, 25.8, 25.6, 25.2, 25.1, 24.8, 24.5, 24.4, 
23.9, 23.7, 23.0, 14.3. HRMS calc for C23H39NO 335.2210, found 335.4815. 
2.5.17 Peak assignment of 3b3 
N
CHO
3b3
OMe
 
Prepared using General Procedure C. 2e (160 mg, 1.0 mmol), 4-methoxyphenyl 
boronic acid (183 mg, 1.2 mmol) Temp = 24 oC, time = 18 h. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). 
Yield = 203.5 mg, 88%. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.28 & 8.17 
(1H, s,s), 7.26 to 7.14 (2H, dd), 6.92 to 6.79 (2H, dd), 5.51 to 5.45 (1H, t), 3.76 (3H, s), 
3.43 to 3.29 (2H, m), 2.29 to 2.06 (2H, m), 1.63 to 1.20 (16H, m). 13C NMR (101 MHz, 
CDCl3) δ 164.0, 139.4, 137.2, 132.2, 130.3, 129.0, 128.7, 126.5, 116.5, 114.0, 113.8, 
55.3, 47.7, 44.8, 43.2, 41.2, 40.5, 29.5, 28.3, 27.9, 26.9, 25.8, 25.8, 25.0, 24.9, 23.9, 23.6, 
23.3, 22.8, 22.7. HRMS calc for C20H29NO2 315.2256, found 315.2255. 
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2.5.18 Peak assignment of 3b4 
N
CHO
3b4
Cl
 
Prepared using General Procedure C. 2e (160 mg, 1.0 mmol), 4-chlorophenyl 
boronic acid (188 mg, 1.2 mmol) Temp = 24 oC, time = 18 h. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). 
Yield = 165 mg, 70%. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.30 & 8.23 
(1H, s,s), 7.44 to 7.11 (4H, m), 5.64 to 5.59 (1H, t), 3.54 to 3.51 (1H, m), 3.43 to 3.24 
(1H, m), 2.42 to 2.05 (2H, m), 1.76 to 1.20 (16H, m). 13C NMR (101 MHz, CDCl3) δ 
162.6, 136.5, 134.8, 133.5, 132.8, 131.5, 130.9, 129.8, 128.9, 128.1, 116.8, 47.5, 46.3, 
44.6, 43.3, 41.3, 40.6, 34.6, 29.7, 28.3, 27.8, 27.0, 26.4, 25.0, 24.9, 24.2, 23.9, 22.8, 22.8. 
HRMS calc for C19H26NOCl 319.1759, found 319.2661. 
2.5.19 Peak assignment of 3b5 
N
CHO
3b5
S
 
Prepared using General Procedure C. 2e (160 mg, 1.0 mmol), 2-thienylboronic 
acid (307.2 mg, 1.2 mmol) Temp = 24 oC, time = 18 h. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). 
Yield = 165 mg, 88%. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.33 & 8.15 
(1H, s,s), 7.42 to 6.87 (3H, m), 5.87 to 5.65 (1H, t), 3.57 to 3.37 (2H, m), 2.68 to 2.03 
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(2H, m), 1.89 to 1.24 (16H, m). 13C NMR (101 MHz, CDCl3) δ 162.7, 161.6, 141.5, 
137.5, 134.1, 133.9, 132.2, 131.8, 131.6, 131.5, 128.4, 127.9, 127.5, 127.5, 127.3, 127.2, 
126.5, 125.3, 124.9, 124.7, 124.3, 77.4, 77.1, 76.8, 48.0, 45.4, 43.9, 42.2, 28.6, 28.3, 28.3, 
28.1, 27.6, 27.6, 27.5, 27.4, 27.3, 27.2, 26.7, 26.7, 26.5, 26.5, 26.4, 26.4, 26.2, 26.2, 26.1, 
26.0, 25.8, 25.6, 25.5, 25.4, 25.3, 25.2, 24.9, 24.5, 24.3, 24.3, 24.1, 24.0, 23.7, 23.1. 
HRMS calc for C1H25NOS 291.1759, found 291.4561. 
2.5.20 Peak assignment of 3c1 
N
CHO TIPS
3c1, 96%  
Prepared using General Procedure D. 2a (1.00 mmol) and triisopropyl-
silylacetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 279 mg, 96%. 
1H NMR (400 
MHz, Chloroform-d) δ 8.99 (s, 1H), 5.54 (t, J = 4.4 Hz, 1H), 3.66 – 3.58 (m, 2H), 2.17 
(td, J = 6.3, 4.1 Hz, 2H), 1.78 (m, 4H), 1.05 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 
161.0, 120.8, 119.2, 98.8, 95.6, 38.9, 23.2, 20.5, 18.6, 11.4, 11.1, 10.8. HRMS-EI+ (m/z): 
calc’d for C17H29NOSi 291.2018; found 291.2022. 
2.5.21 Peak assignment of 3c2 
N
CHO
TIPS3c2, 91 %  
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Prepared using General Procedure D. 2c (1.00 mmol) and triisopropyl-
silylacetylene (2 mmol, 2 equiv), Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 279 mg, 96%.
1H NMR (400 
MHz, Chloroform-d) δ 8.59 (s, 1H), 5.84 (t, J = 6.1 Hz, 1H), 3.62 (t, J = 5.9 Hz, 2H), 
2.19 (q, J = 5.9 Hz, 2H), 1.72 (p, J = 6.1 Hz, 2H), 1.58 (q, J = 6.1 Hz, 2H), 0.99 (s, 21H). 
13C NMR (101 MHz, CDCl3) δ 162.25, 129.90, 125.42, 102.79, 91.85, 44.10, 27.67, 
27.50, 24.08, 18.59, 10.87. HRMS calc for C18H31NOSi 305.1759, found 305.4561. 
2.5.22 Peak assignment of 3c3. 
N
CHO
3c3
TIPS
 
Prepared from General Procedure D. 2e (1.00 mmol) and triisopropyl-silylacetylene (2 
mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 1% Et3N) 
eluting with hexane/EtOAc (90:10). Yield = 279 mg, 96%.1H NMR (400 MHz, 
Chloroform-d) δ 8.59 (s, 1H), 5.84 (t, J = 6.1 Hz, 1H), 3.62 (t, J = 5.9 Hz, 2H), 2.19 (q, J 
= 5.9 Hz, 2H), 1.72 (p, J = 6.1 Hz, 2H), 1.58 (q, J = 6.1 Hz, 2H), 0.99 (s, 21H). 13C NMR 
(101 MHz, CDCl3) δ 162.25, 129.90, 125.42, 102.79, 91.85, 44.10, 43.9, 42.2, 28.6, 28.3, 
28.3, 28.1, 27.6, 27. 27.2, 26.7, 26.7, 26.5, 26.5, 26.4, 26.4, 26.2, 26.2, 26.1, 26.0, 25. 
24.5, 24.3, 24.3, 24.1, 24.0, 23.7, 23.1. 27.67, 27.50, 24.08, 18.59, 10.27. HRMS calc for 
C24H43NOSi 389.3759, found 389.6561. 
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2.5.23 Peak assignment of 3c4 
N
CHO SiMe3
3c4, 92%  
Prepared using General Procedure D. 2a (1.00 mmol) and 
trimethylsilylacetylene (2 mmol, 2 equiv), Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 190 mg, 92%. 
1H 
NMR (400 MHz, C6D6) δ 9.32 (s, 1H), 5.24 to 5.22 (t, 1H), 3.39 to 3.36 (t, 2H), 1.54 to 
1.47 (m, 2H), 1.15 to 1.09 (m, 2H), 0.09 (s, 9H). 13C NMR (101 MHz, C6D6) δ 160.4, 
121.6, 118.6, 98.9, 98.4, 39.2, 23.4, 20.8, 0.1. HRMS-EI+ (m/z): calc’d for C11H17NOSi 
207.1079; found 207.1083. 
2.5.24 Peak assignment of 3c5 
3c5, 96%
N
CHO SiMe3
 
Prepared using General Procedure D. 2c (1.0 mmol) and trimethylsilylacetylene 
(2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 1% 
Et3N) eluting with hexane/EtOAc (90:10). Yield = 212 mg, 96%. Data as previously 
reported by us.59  
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2.5.25 Peak assignment of 3c6 
 
Prepared using General Procedure D. 2e (1.0 mmol) and trimethylsilyl acetylene 
(2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 1% 
Et3N) eluting with hexane/EtOAc (90:10). Yield = 278 mg, 91%. 
1H NMR (400 MHz, 
C6D6, mixture of rotamers) δ 8.22 & 8.00 (1H, s, s), 5.78 5.57 (1H, t), 3.67 to 3.53 (2H, 
t), 2.24 to 2.19 (2H, m), 1.66 to 1.02 16H, m), 0.28 (9H, s). 13C NMR (101 MHz, C6D6, 
mixture of rotamers) δ 162.0, 161.9,, 135.9, 135.5, 135.0, 134.2, 134.1, 129.2, 128.4, 
128.1, 128.0, 128.0, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.5, 127.5, 123.4, 123.3, 
118.6, 101.7, 101.3, 100.8, 98.8, 93.6, 92.3, 77.0, 46.8, 42.3, 42.2, 40.7, 29.0, 28.5, 28.4, 
28.3, 28.2, 28.0, 27.7, 27.7, 27.6, 27.5, 27.0, 26.8, 26.7, 26.7, 26.6, 26.5, 25.8, 25.7, 25.7, 
25.3, 25.1, 24.7, 24.7, 24.5, 23.7, 23.6, 23.3, -0.4, -0.6. HRMS-EI+ (m/z): calc’d for 
C18H31NOSi 305.2175; found 305.2179. 
2.5.26 Peak assignment of 3c7 
N
CHO Ph
3c7  
Prepared using General Procedure D. 2a (99.3 mg, 1.0 mmol) and 
phenylacetylene. Purification: Flash chromatography on silica (pretreated with 1% Et3N) 
eluting with hexane/EtOAc (70:30). Yield = 192 mg, 91%. 1H NMR (400 MHz, C6D6) δ 
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9.35 (1H), 7.28 to 7.21 (2H), 7.00 to 6.93 (3H), 5.28 to 5.25 (1H), 3.46 to 3.43 (2H), 1.60 
to 1.52 (2H), 1.20 to 1.14 (2H). 13C NMR (101 MHz, C6D6) δ 160.5, 132.0, 129.3, 129.0, 
122.7, 121.5, 118.0, 93.39, 83.0, 39.3, 23.5, 20.8. HRMS-EI+ (m/z): calc’d for C14H13NO 
211.0997; found 211.0993. 
2.5.27 Peak assignment of 3c8 
N
CHO Ph
3c8, 94%  
Prepared using General Procedure D. 2c (113.2 mg, 1.0 mmol) Purification: 
Flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc 
(70:30). Yield = 212 mg, 94%. Data as previously reported by us.59 
2.5.28 Peak assignment of 3c9 
3c9, 89%
N
CHO
 
Prepared using General Procedure D. 2e (1.0 mmol) and phenylacetylene (2 
mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 1% Et3N) 
eluting with hexane/EtOAc (90:10). Yield = 275 mg, 89%. 1H NMR (400 MHz, CDCl3, 
mixture of rotamers) δ 8.29 & 8.15 (1H, s,s), 7.72 to 7.12 (5H, m), 5.88 to 5.72 (1H, m), 
3.76 to 3.65 (2H, t), 2.60 to 2.14 (2H, m), 1.73 to1.04 (16H, m). 13C NMR (101 MHz, 
CDCl3) δ 163.1, 162.5, 136.9, 135.68, 135.6, 135.3, 135.2, 135.2, 134.0, 133.1, 132.5, 
132.2, 132.1, 132.0, 131.9, 131.7, 131.6, 131.59, 130.3, 129.6, 129.1, 128.8, 128.6, 128.5, 
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128.4, 128.3, 128.1, 127.9, 127.7, 122.3, 121.8, 95.3, 88.9, 85.4, 85.2, 42.8, 41.3, 36.5, 
34.6, 31.4, 29.7, 29.2, 28.6, 28.5, 28.4, 28.2, 28.1, 28.0, 27.9, 27.6, 26.9, 26.8, 26.7, 26.5, 
26.4, 26.2, 26.0, 25.9, 25.8, 25.6, 25.5, 25.5, 25.3, 25.0, 24.9, 24.8, 24.7, 24.5, 23.7, 23.6, 
23.6, 23.4. HRMS-EI+ (m/z): calc’d for C21H27NO 309.2093; found 309.2096. 
2.5.29 Peak assignment of 3c10 
3c10, 93%
N
CHO
OMe  
Prepared using General Procedure D. 2a (1.0 mmol) and p-methoxy-
phenylacetylene (2 mmol, 2 equiv). Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 224 mg, 93%. 
1H 
NMR (400 MHz, Chloroform-d) δ 9.06 (1H, s), 7.32 (2H, d), 6.75 (2H, d), 5.59 to 5.57 
(1H, t), 3.71 to 3.52 (5H, m), 2.27 to 2.18 (2H, m), 1.88 to 1.73 (2H, m). 13C NMR (101 
MHz, Chloroform-d) δ 161.3, 160.2, 134.1, 133.1, 128.5, 121.0, 118.0, 114.2, 113.9, 
93.0, 80.5, 55.4, 39.1, 23.4, 20.7. HRMS-EI+ (m/z): calc’d for C15H15NO2 241.1103; 
found 241.1107. 
2.5.30 Peak assignment of 3c11 
N
CHO
3c11, 97%
OMe  
Prepared from using General Procedure D. 2c (1.0 mmol) and p-
methoxyphenylacetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica 
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(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 247 mg, 97%. 
1H 
NMR (400 MHz, Benzene-d6) δ 8.94 to 8.37 (1H, s), 7.46 to 7.00 (2H, m), 6.67 to 6.58 
(2H, m), 6.06 to 5.72 (1H, t), 3.58 to 3.55 (3H, s), 1.87 to 1.83 (2H, m), 1.51 to 1.38 (2H, 
m), 1.30 to 1.07 (2H, m). 13C NMR (101 MHz, Benzene-d6) δ 161.4, 160.2, 135.4, 128.8, 
125.9, 114.4, 89.9, 85.3, 54.6, 43.9, 28.0, 27.4, 24.1. HRMS-EI+ (m/z): calc’d for 
C16H17NO2 255.1259; found 255.1263. 
2.5.31 Peak assignment of 3c12 
N
CHO
OMe3c12, 94%  
Prepared using General Procedure D. 2e (1.0 mmol) and p-methoxyphenyl-
acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 
1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 319 mg, 94%. 
1H NMR (400 
MHz, CDCl3, mixture of rotamers) δ 8.31 & 8.13 (1H, s,s), 7.48 to 7.26 (2H, dd), 6.97 to 
6.82 (2H, dd), 5.89 to 5.73 (1H, t), 3.86 to 3.66 (5H, m), 2.30 to 2.14 (2H, m), 1.73 to1.22 
(16H, m). 13C NMR (101 MHz, CDCl3) δ 163.2, 162.1, 160.9, 160.2, 160.1, 159.9, 139.7, 
134.9, 134.8, 134.0, 133.2, 133.1, 133.1, 133.0, 132.9, 123.3, 123.3, 119.6, 114.2, 114.2, 
114.1, 114.1, 114.0, 113.9, 113.8, 113.2, 95.3, 88.9, 87.9, 83.9, 81.3, 81.2, 77.5, 77.1, 
76.8, 73.0, 60.4, 55.4, 55.3, 47.7, 42.7, 41.2, 29.2, 28.5, 28.5, 28.4, 28.3, 28.2, 28.1, 27.9, 
27.6, 26.8, 26.8, 26.7, 26.5, 26.2, 26.0, 25.7, 25.6, 25.5, 25.2, 24.9, 24.8, 24.4, 23.7, 23.6, 
23.5, 23.3, 21.1. HRMS-EI+ (m/z): calc’d for C22H29NO2 339.2198; found 339.2193. 
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2.5.32 Peak assignment of 3c13 
3c13, 90%
N
CHO
Me  
Prepared using General Procedure D. 2a (1.0 mmol) and p-methylphenyl-
acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 
1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 203 mg, 90%. 
1H NMR (400 
MHz, Chloroform-d) δ 9.06 (1H, s), 7.32 (2H, d), 7.26 (2H, d), 5.59 to 5.57 (1H, t), 3.71 
to 3.52 (2H, t), 2.34 to 2.18 (5H, m), 1.81 to 1.76 (2H, m). 13C NMR (101 MHz, 
Chloroform-d) δ 161.2, 139.6, 133.1, 132.2, 128.6, 120.9, 118.8, 93.1, 81.1, 39.1, 23.4, 
21.6, 20.7. HRMS-EI+ (m/z): calc’d for C15H15NO 225.1154; found 225.1159. 
2.5.33 Peak assignment of 3c14 
N
CHO
3c14, 92%
Me  
Prepared using General Procedure D. 2c (1.0 mmol) and p-methylphenyl-
acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 
1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 220 mg, 92%. 
1H NMR (400 
MHz, Benzene-d6) δ 8.98 (1H, s), 7.89 to 7.21 (2H, d) 6.86 to 6.04 (2H, d), 5.73 to 5.70 
(1H, s), 3.58 to 3.55 (2H, t), 2.03 to 1.99 (3H, s), 1.81 to 1.62 (2H, m), 1.49 to 1.37 (2H, 
t), 1.26 to 1.03 (2H, t). 13C NMR (101 MHz, Benzene-d6) δ 161.4, 138.8, 133.9, 129.3, 
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126.9, 119.5, 90.0, 86.0, 43.8, 27.9, 27.4, 24.1, 21.1. HRMS-EI+ (m/z): calc’d for 
C16H17NO 239.1310; found 239.1314. 
2.5.34 Peak assignment of 3c15 
N
CHO
Me
3c15, 91%
 
Prepared from using General Procedure D. 2e (1.0 mmol) and p-methylphenyl-
acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica (pretreated with 
1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 294 mg, 91%. 
1H NMR (400 
MHz, CDCl3, mixture of rotamers) δ 8.29 & 8.05, 7.74 to 7.26 (4H, m), 5.84 to 5.76 (1H, 
m), 3.84 to 3.66 (2H, m), 2.47 to 2.15 (5H, m), 1.73 to 1.17 (16H, m). 13C NMR (101 
MHz, CDCl3, mixture of rotamers) δ 163.2, 162.6, 162.1, 160.9, 140.0, 139.5, 139.3, 
139.0, 138.7, 135.3, 135.2, 135.2, 134.9, 134.9, 132.4, 132.2, 132.1, 131.9, 131.8, 131.5, 
131.5, 131.5, 130.5, 130.3, 129.6, 129.3, 129.3, 129.2, 129.1, 128.9, 128.6, 128.5, 128.2, 
128.2, 128.0, 127.7, 127.7, 127.6, 123.2, 119.1, 119.1, 118.8, 114.2, 95.4, 89.1, 88.2, 
84.7, 84.6, 81.9, 81.6, 77.5, 77.2, 76.8, 73.5, 55.3, 47.8, 43.3, 42.8, 41.2, 29.8, 29.2, 28.6, 
28.5, 28.5, 28.4, 28.3, 28.1, 27.9, 27.7, 26.9, 26.8, 26.7, 26.5, 26.2, 26.0, 25.8, 25.6, 25.5, 
25.2, 24.9, 24.8, 24.6, 24.4, 23.7, 23.6, 23.5, 23.3, 21.7, 21.6, 21.6, 21.6. HRMS-EI+ 
(m/z): calc’d for C22H29NO 323.2249; found 323.2252. 
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2.5.35 Peak assignment of 3c16 
3c16, 90%
N
CHO
 
Prepared using General Procedure D. 2a (145 mg, 1.0 mmol) and 1-
ethynylcyclohexene (0.24 mL, 2 mmol, 2 equiv). Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 193 mg, 
90%. 1H NMR (400 MHz, C6D6) δ 9.39 (1H, s), 6.01 to 5.96 (1H, t), 5.22 to 5.20 (1H, t), 
3.46 to 3.43 (2H, t), 1.99 to 1.94 (2H, m), 1.78 to 1.73 (2H, m), 1.57 to 1.46 (2H, q), 1.35 
to 1.22 (4H, m), 1.17 to 1.11 (2H, m). 13C NMR (101 MHz, C6D6) δ 160.6, 136.6, 121.9, 
120.6, 116.8, 95.3, 80.6, 39.3, 29.3, 26.2, 23.5, 22.7, 21.9, 20.9. HRMS-EI+ (m/z): calc’d 
for C14H17NO 215.1310; found 215.1313. 
2.5.36 Peak assignment of 3c17 
3c17, 94%
N
CHO
 
Prepared from using General Procedure D. 2c (160 mg, 1.0 mmol) and 1-
ethynylcyclohexene (0.24 mL, 2 mmol, 2 equiv). Purification: Flash chromatography on 
silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 215.4 mg, 
94%. Data as previously reported by us.59 
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2.5.37 Peak assignment of 3c18 
3c18, 89%
N
CHO
 
Prepared using General Procedure D. 2a (145 mg, 1.0 mmol) and 1-
ethynylcyclopropane (2 mmol, 2 equiv). Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 156 mg, 89%. 1H 
NMR (400 MHz, Benzene-d6) δ 9.45 to 9.12 (1H, s), 5.42 to 5.03 (1H, t), 3.64 to 3. 43 
(2H, t), 1. 77 to 1.52 (2H, m), 1. 48 to 0.22 (7H, m). 13C NMR (101 MHz, Chloroform-
d) δ 161.6, 121.2, 117.6, 97.8, 68.7, 39.4, 23.5, 21.1, 9.1, 0.3. HRMS-EI+ (m/z): calc’d 
for C11H13NO 175.0997; found 175.0993. 
2.5.38 Peak assignment of 3c19 
3c19, 91%
N
CHO
 
Prepared using General Procedure D. 2c (160 mg, 1.0 mmol) and 1-
ethynylcyclopropane (2 mmol, 2 equiv). Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 172 mg, 91%. 1H 
NMR (400 MHz, Benzene-d6) δ 8.90 to 8.85 (1H, s), 5.60 to 5.37 (1H, t), 3.54 to 3.29 
(2H, t), 2.13 to 1.92 (2H, m), 1.77 to 1.41 (2H, m), 1.24 to 1.18 (2H, m), 1.08 to 1.01 
(2H, m), 0.85 to 0.26 (4H, m). 13C NMR (101 MHz, Benzene-d6) δ 161.69, 93.78, 73.06, 
43.73, 27.87, 27.13, 23.50, 8.43. HRMS-EI+ (m/z): calc’d for C12H15NO 189.1154; found 
189.1151. 
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2.5.39 Peak assignment of 3c20 
3c20, 86%
N
CHO
 
Prepared using General Procedure D. 2e (243 mg, 1.0 mmol) and 1-
ethynylcyclopropane (2 mmol, 2 equiv). Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 235 mg, 86%. 
1H 
NMR (400 MHz, CDCl3, mixture of rotamers) δ 8.16 & 7.96 (1H, s,s), 5.80 to 5.57 (1H, 
t), 3.66 to 3.41 (2H, t), 2.36 to 2.02 (2H, m), 1.73 to 0.98 (17H, m), 0.93 to 0.68 (4H, m). 
13C NMR (101 MHz, CDCl3) δ 163.1, 162.0, 138.8, 134.0, 123.2, 123.1, 99.9, 93.0, 77.4, 
77.1, 76.8, 71.7, 68.9, 47.5, 43.1, 42.5, 40.9, 28.8, 28.5, 28.4, 28.4, 28.2, 28.0, 28.0, 27.9, 
27.7, 27.6, 27.5, 26.8, 26.6, 26.6, 26.4, 26.1, 26.0, 25.9, 25.8, 25.7, 25.6, 25.4, 25.1, 24.9, 
24.8, 24.6, 24.4, 23.7, 23.6, 23.5, 23.3, 9.8, 9.6, 9.3, 9.0, 8.7, 8.6, 8.5. HRMS-EI+ (m/z): 
calc’d for C18H27NO 273.2093; found 273.2090. 
2.5.40 Peak assignment of 3c21 
3c21, 95%
N
CHO
Cl
 
Prepared using General Procedure D. 2a (145 mg, 1.0 mmol) and 5-chloro-1-
pentyne (0.21 mL, 2.0 mmol). Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (70:30). Yield = 200 mg, 95%. 
1H NMR (400 
MHz, C6D6) δ 9.25 (1H, s), 5.14 to 5.11 (1H, t), 3.45 to 3.42 (2H, t), 3.08 to 3.05 (2H, t), 
2.02 to 1.98 (2H, t), 1.57 to 1.33 (4H, m), 1.18 to 1.12 (2H, m). 13C NMR (101 MHz, 
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C6D6) δ 160.5, 121.5, 116.9, 92.5, 75.2, 44.0, 39.3, 31.4, 23.4, 21.0, 16.9. HRMS-EI+ 
(m/z): calc’d for C11H14ClNO 211.0764; found 211.0769. 
2.5.41 Peak assignment of 3c22 
3c22, 90%
N
CHO Cl
 
Prepared using General Procedure D. 1b (160 mg, 1.0 mmol) and 5-chloro-1-
pentyne (0.21 mL, 2.0 mmol). Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 203 mg, 90%. Data as 
previously reported by us.59 
2.5.42 Peak assignment of 3c23 
N
CHO
Cl
3c23, 91%  
Prepared using General Procedure D. 2e (243 mg, 1.0 mmol) and 5-chloro-1-
pentyne (0.21 mL, 2.0 mmol). Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 281 mg, 91%. 
1H NMR (400 
MHz, CDCl3) δ 8.18 & 7.96 (1H, s,s), 5.85 to 5.77 (1H, t), 3.77 to 3.55 (4H, m), 2.68 to 
1.18 (22H, m). 13C NMR (101 MHz, CDCl3) δ 163.1, 162.0, 160.8, 139.2, 135.2, 122.9, 
122.6, 94.4, 87.8, 86.8, 77.5, 77.5, 77.4, 77.1, 76.8, 75.0, 47.6, 43.6, 43.6, 43.4, 42.5, 
41.0, 31.2, 31.1, 31.0, 28.9, 28.5, 28.4, 28.4, 28.2, 28.1, 28.0, 27.8, 27.6, 27.5, 26.8, 26.7, 
26.6, 26.4, 26.3, 26.0, 25.9, 25.7, 25.5, 25.4, 25.2, 24.8, 24.8, 24.6, 24.4, 23.7, 23.6, 23.5, 
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23.3, 16.8, 16.6, 16.6. HRMS-EI+ (m/z): calc’d for C18H28ClNO 309.1859; found 
309.1862. 
2.5.43 Peak assignment of 3c24 
 
Prepared from 1a (145 mg, 1.0 mmol) and 6-chloro-1-hexyne (2.0 mmol, 2 equiv) 
using General Procedure D. Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 196 mg, 87%. 
1H NMR (400 
MHz, Benzene-d6) δ 9.30 to 8.91 (1H, s), 5.22 to 4.71 (1H, t), 3.50 to 3.37 (2H, t), 3.09 
to 3.06 (2H, t), 2.01 to 1.88 (2H, m), 1.70 to 1.61 (2H, m), 1.51 to 1.42 (2H, m), 1.32 to 
1.20 (2H, m), 1.12 to 0.94 (4H, m). 13C NMR (101 MHz, Benzene-d6) δ 160.1, 121.1, 
116.0, 108.3, 93.1, 74.4, 44.0, 38.8, 31.5, 25.4, 23.4, 20.8, 18.2. HRMS-EI+ (m/z): calc’d 
for C12H16ClNO 225.0920; found 225.0923. 
2.5.44 Peak assignment of 3c25 
 
Prepared from 1b (160 mg, 1.0 mmol) and 6-chloro-1-hexyne (2.0 mmol, 2 equiv) 
using General Procedure D. Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 220 mg, 92%. 
1H NMR (400 
MHz, Chloroform-d) δ 8.56 to 8.07 (1H, s), 5.80 to 5.77 (1H, t), 3.80 to 3.41 (2H, t), 2.68 
to 2.19 (4H, m), 1.93 to 1.50 (10H, m). 13C NMR (101 MHz, Chloroform-d) δ 162.5, 
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128.8, 125.4, 89.9, 8.1, 44.5, 31.6, 28.7, 27.8, 25.6, 23.6, 18.6. HRMS-EI+ (m/z): calc’d 
for C13H18ClNO 239.1077; found 239.1074. 
2.5.45 Peak assignment of 3c26 
 
Prepared from 1c (243 mg, 1.0 mmol) and 6-chloro-1-hexyne (2.0 mmol, 2 equiv) 
using General Procedure D. Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (90:10). Yield = 300 mg, 93%. 
1H NMR (400 
MHz, Benzene-d6) δ 8.30 to 7.87 (1H, s), 5.53 to 5.15 (1H, t), 3.88 to 3.74 (2H, t), 3.24 
to 3.06 (2H, m), 2.29 to 0.97 (24H, m). 13C NMR (101 MHz, Benzene-d6) δ 162.2, 
161.1, 138.6, 138.2, 133.4, 123.5, 123.3, 95.3, 88.7, 77.7, 75.2, 44.1, 44.0, 42.3, 31.6, 
28.5, 27.7, 26.7, 25.8, 25.6, 24.8, 24.5, 23.7, 23.6, 23.4, 18.4. HRMS-EI+ (m/z): calc’d 
for C19H30ClNO 323.2016; found 323.2020. 
2.5.46 Peak assignment of 3d1 
N O
I
CHO
3d1  
To 2e (160 mg, 1 mmol, 1.0 equiv) dissolved in THF (5 mL) and H2O (5 mL), 
was added NIS (270 mg, 1.2 mmol, 1.2 equiv) at room temperature. After complete 
consumption of the eneformamide (as indicated by TLC and LCMS-monitoring; <10 
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min), the mixture was diluted with EtOAc (20 mL) and poured into a separating funnel. It 
was washed with sat. Na2S2O3(aq) and then with brine. The organic layer was dried over 
Na2SO4 and concentrated under reduced pressure to give the product as an oil. Yield = 
326.4 mg, 93%.  1H NMR (400 MHz, CDCl3) δ 9.33 (1H, s), 4.67 to 4.64 (1H, m), 4.07 
to 4.00 (1H, m), 3.47 to 3.42 (1H, m), 2.45 to 2.37 (1H, m), 2.25 to 2.00 (1H, m), 1.73 to 
1.17 (16H, m). 13C NMR (101 MHz, CDCl3) δ 173.0, 162.9, 77.4, 77.1, 76.8, 40.4, 36.4, 
26.6, 26.6, 25.7, 25.7, 24.4, 24.2, 23.3, 18.9.  
Peak assignment 3d2 
N O
Br
CHO
3d2  
 To 2e (160 mg, 1 mmol, 1.0 equiv) dissolved in THF (5 mL) and H2O (5 mL), 
was added NBS (214 mg, 1.2 mmol, 1.2 equiv) at room temperature. After complete 
consumption of the eneformamide (as indicated by TLC and LCMS-monitoring; <10 
min), the mixture was diluted with EtOAc (20 mL) and poured into a separating funnel. It 
was washed with sat. Na2S2O3(aq) and then with brine. The organic layer was dried over 
Na2SO4 and concentrated under reduced pressure to give the product as an oil. Yield = 
272.7 mg, 90%.  1H NMR (400 MHz, CDCl3) δ 9.32 (s, 1H), 4.74 (m, 1H), 4.20 to 3.93 
(m, 1H), 3.68 to 3.42 (m, 1H), 2.31 to 2.22 (m, 1H), 2.06 to  1.98 (m, 1H), 1.69 to 0.81 
(m, 16H). 13C NMR (101 MHz, CDCl3) δ 171.1, 162.5, 54.0, 45.2, 40.6, 40.4, 38.7, 34.3, 
31.7, 31.5, 30.4, 30.2, 29.7, 29.2, 28.9, 28.3, 28.2, 28.1, 27.5, 27.2, 26.6, 26.4, 26.1, 25.9, 
25.9, 25.8, 25.6, 25.4, 25.2, 24.9, 24.7, 24.4, 24.2, 23.7, 23.7, 23.5, 23.4, 23.0. 
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2.5.47 Peak assignment 3d3 
 
To 2e (160 mg, 1 mmol, 1.0 equiv) dissolved in THF (5 mL) and H2O (5 mL), 
was added NCS (160 mg, 1.2 mmol, 1.2 equiv) at room temperature. After complete 
consumption of the eneformamide (as indicated by TLC and LCMS-monitoring; <10 
min), the mixture was diluted with EtOAc (20 mL) and poured into a separating funnel. It 
was washed with sat. Na2S2O3(aq) and then with brine. The organic layer was dried over 
Na2SO4 and concentrated under reduced pressure to give the product as an oil. Yield = 
272.7 mg, 90%.  1H NMR (400 MHz, CDCl3) δ 6.80 to  6.68 (s, 1H), 4.46 to 4.44 (m, 
1H), 3.80 to  3.73 (m, 1H), 3.39 to 3.35 (m, 1H), 2.92 to  2.86 (m, 1H), 2.54 to  2.51 (m, 
1H), 2.16 to  1.22 (m, 16H). 13C NMR (101 MHz, CDCl3) δ 169.0, 61.0, 39.7, 39.3, 34.8, 
27.6, 27.2, 26.7, 26.5, 26.4, 26.3, 26.1, 25.7, 25.6, 25.5, 24.8, 24.8, 24.5, 23.9, 23.5, 22.3. 
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CHAPTER 3 
 
SYNTHETIC UTILITY OF ALPHA-SUBSTITUTED ENEFORMAMIDES: 
PREPARATION OF QUATERNARY PROPARGYLIC AND HOMOALLYLIC 
CYCLIC AMINES 
3.1 Introduction 
After constructing such a large library of alkynylated and alkenylated 
eneformamides, we wanted to demonstrate their synthetic utility. The utility of N-acyl 
imino dienes and enamidynes has been previously explored by the likes of Toste113 and 
Occhiato114 in Conia-ene and carboauration-type reactions. We therefore sought to 
further examine the dynamic range of utility that such complex alkenyl and alkynyl α-
eneformamides have to offer.  
 One of the many goals of a synthetic organic chemist is to form new carbon-
carbon bonds. Generating new carbon-carbon bonds is an important synthetic process as 
it paves new ways to make structurally unique and biologically active molecules or 
pharmacophores commonly found in a large variety of pharmaceuticals. This led us to 
investigate nucleophilic addition to a cyclic imine with an organometallic reagent.80, 115-
124 This process generates new carbon-carbon bonds and creates a saturated125 cyclic 
amine, which, as we discussed, saturated piperidines and azepanes are commonly found 
in a vast majority of nitrogen bearing FDA approved pharmaceuticals.  
 In our case, the addition of an organometallic reagent to our cyclic enamidyne 
would generate a cyclic α-amino propargylic quaternary stereocenter126, 127.  Specifically, 
the use of an allylic organometallic nucleophile would generate a structurally complex 3-
azaheterocyclic 1,5-enyne.  Thus, from our large library of previously generated 
enamidynes, we can construct a diverse library of α-quaternary homoallylic and 
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propargylic 1,5-enynes (Figure 3-1). These structurally unique quaternary homoallylic 
and propargylic amines offer an outstanding starting point for even more complex 
diversity-oriented synthesis. 
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Figure 3-1  Figure demonstrating cyclic α-quaternary homoallylic and propargylic 1, 5-
enynes 
 We also wanted to demonstrate the utility of our newly made α-alkynyl and α-
alkenyl eneformamides to construct bicycles and tricycles. As discussed in chapter one, 
fused heterocycles play a major role in pharmaceuticals and thus finding new and 
efficient ways to construct these commonly found polycyclic motifs are highly sought 
after amongst the organic synthetic communities.  
 We envisioned that our α-alkynyl eneformamides could be used to construct 
vinylogous lactams by wrapping the alkynyl substituent around onto an acyl group via a 
Knoevenagel type reaction.  Vinylogous lactams are amazing substrates that are great for 
Diels-Alder reactions or Deslongchamps-type annulations and thus can be used to further 
functionalize the vinylogous lactam to afford bicyclic and tricyclic functional motifs.  
 We also wanted to demonstrate the utility of our α-alkenyl eneformamides as they 
make great dienes for Diels-Alder reactions. We envisioned the use of a cyclic diene, as 
that would afford us a tricycle in one step from the use of our α-alkenyl eneformamides.  
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This methodology opens the door to construct highly functionalized polycyclic structures 
with a high degree of modularity.  
3.1.1 Synthetic potential of 3-azaheterocyclic-1,5-enynes 
These α-quartenary homoallylic and propargylic 1, 5-enynes have a huge amount  
of potential synthetic utility (Figure 3-2). We envisioned several transition metal-
catalyzed processes that proceed in a regio- and stereocontrolled way such as 
bromoallylation128 (see 2a/b) or arylcyanation129-132 (see 3a/b).  Additionally we 
envisioned many stereo controlled metal-catalyzed processes that form polycylic systems 
such as: benzannulative cycloisomerization133 (see 4) intramolecular hydroamination134-
141 (see 5), and hydroaminoalkylation142-146 (see 6a/b).  
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Figure 3-2  Synthetic potential of 3-azaheterocyclic-1,5-enynes of type 1 
 These 3-azaheterocyclic-1,5-enynes are optically active α-quaternary propargylic 
and homoallylic amines and have a large amount of synthetic potential and can be used as 
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the precursors to a vast array of pharmaceuticals and biologically active compounds with 
enormous medicinal value. It has been demonstrated by many groups that these 
structurally unique quaternary propargylic amines can be generated from cyclic and 
acyclic precursors, however the α-substituents are limited to methyl and aryl groups and 
have been primarily on 5- and 6-membered ring systems.127, 147, 148  Here, we demonstrate 
that we can generate cyclic quaternary propargylic and homoallylic amines in a cost-
effective, bench stable, and modular manner  
3.1.2 Possible synthetic routes to 3-azaheterocyclic-1,5-enynes 
 We envisioned two synthetic routes that would afford 3-azaheterocyclic 1,5-
enynes such as 1 in an efficient and modular fashion (Figure 3-3). The first approach 
involves taking the cyclic α-alkynyl eneformamides 8 and removing the formyl group. 
Following deformylation, an organometallic allyl reagent would be used to attack the 
cyclic alkynyl imine 7 that comes from the tautomer of the alkynyl ketimine to form 1. 
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Figure 3-3  Potential synthetic routes to achieve 3-azaheterocyclic-1,5-enyne 1 
 There are many potential challenges associated with the first synthetic route 
(Figure 3-4).  First is the reactivity of the cyclic ketimine.  It is well known that cyclic 
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ketimines such as 7 are far less reactive then carbonyls149 and this only adds to the 
challenge as the ketimine is enolizable and sterically hindered 13. It is also recognized 
that ketimines are susceptible to oligomerization150, meaning the ketimine will add to 
itself rather than react with another reactive nucleophile (see 12).  Another challenge 
presented that of chemoselectivity. It is well precedented that cyclic 1, 3-azadienes tend 
to undergo 1, 4 conjugate addition when reacted with allylmagnesium bromide instead of 
1, 2 addition,34 making it very challenging to predict the site selectivity of the reaction.  
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Figure 3-4  Challenges associated with first synthetic route  
 The second approach (Figure 3-3) to 1 involves deformylating a skip diene 10  to 
make 1,4-azadiene 9 followed by  subsequent addition of the alkyne using Zhang-style 
alkynylation151 to make the desired 3-azaheterocyclic-1,5-enynes 1.  The main challenge 
with this approach has been the allylations of the cyclic α-chloro eneformamide don’t 
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tend to proceed chemoselectively from one ring size to another. In some cases, the 
allylation goes to the β-position instead of the α-position.  
3.2 Results and Discussion 
3.2.1 Synthesis of 3-azaheterocyclic-1,5-enynes 
Having already generated a large library of eneformamidynes we wanted to find  
conditions that would work for the first approach (Figure 3-3). We also sought after the 
first approach as we were able to efficiently alkynylate all 3 ring sizes of the α-halo 
eneformamide. Thus, we decided to move forward with our eneformamidynes and use 
base-mediated conditions to remove the formyl group. This created the desired cyclic 
ketiminyne intermediate and subsequent allylation conditions were explored. With 
organometallic additions to cyclic imines in mind, we sought to find efficient conditions 
and a reactive partner to go from the cyclic ketiminyne intermediate 8 to the 3-
azaheterocyclic-1,5-enynes 1. To our excitement, nucleophilic addition of 
allylmagnesium bromide to the cyclic ketiminyne intermediate proceeds efficiently 
without formation of any of the aforementioned undesired oligomerization, enolizable, or 
1,4-conjugate addition products (Figure 3-4).  With these conditions in hand, we 
deformylated a majority of our previously made eneformamidynes and took the 
subsequent crude cyclic ketiminyne intermediates forward with the nucleophilic addition 
of allylmagnesium bromide to form the desired 3-azaheterocyclic-1,5-enynes 1a-n.  
Importantly, methyl-, aryl-, vinyl-, and alkynyl- Grignard reagents didn’t undergo the 
desired transformation, which demonstrates the heightened nucleophilicity of 
allymagnesium bromide compared to the other possible Grignard reagents mentioned.  
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Figure 3-5  Using the first approach to synthesize 3-azaheterocyclic-1,5-enynes 
 Having demonstrated the efficiency of the first approach, we next desired to 
explore the second complementary approach. Using the allylation conditions described 
below, skip dienes 10a/b were prepared.  Unfortunately, the six membered cyclic α-halo 
eneformamide 15a allylates at the β-position instead of the desired α-position to produce 
16.  This further demonstrates that predicting the chemistry from one size heterocycle to 
another can be a very challenging task and should not be treated lightly. In any event, we 
went ahead with the skip dienes 10a/b and deformylated with the same basic mediated 
conditions and alkynylated the resulting cyclic imine with zinc/BINOL-catalyzed 
alkynylation conditions to construct the sought after 3-azaheterocyclic-1,5-enynes 1b/c. 
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Figure 3-6  Using the second approach to synthesize 3-azaheterocyclic-1,5-enynes 
3.2.2 Synthesis of aza-polycycles from α-alkynyl eneformamides 
In addition to creating the highly functionalize 3-azaheterocyclic-1,5-enynes, we  
desired to further utilize our α-alkynyl eneformamides to construct polycyclic motifs.  A 
quick glance at our cyclic eneformamidynes reveals that these functionalized substrates 
are begging to be transformed into polycyclic structures. With this in mind, we explored 
the idea using the TMS-bearing enamidyne.  The first step was the reduction of the 
eneformamide double bond in the presence of an alkyne using N-formyl iminium 
reduction.59 This was followed by desilylation (removal of the TMS group),152 
hydroboration-oxidation (conversion of the alkyne to an aldehyde),153 deformylation 
(removal of protecting group on nitrogen), N-acylation (attaching a cyano bearing acyl 
group to the unveiled  nitrogen), and lastly an acid-mediated Knoevenagel 
condensation154 to construct the cyano-bearing α,β-unsaturated lactam 18 with relatively 
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high yield (Figure 3-7). The most challenging part of this transformation was finding the 
optimum reaction conditions for the Knoevenagel reaction.  We attempted several acid-
mediated conditions such as: TiCl4-Et3N, ZnCl2, Sc(OTf)3, Yb(OTf)3, Yb(tmhd)3, MgBr2, 
and 1 N HCl. Unfortunately, none were successful in providing the desired product 18.  It 
was only when we used exceptionally mild conditions of extremely dilute HCl in 
dichloromethane (20 mM) that we were able to achieve the desired cyano-bearing α,β-
unsaturated lactam 18. 
 
N
CHO
1. NaBH3CN, TFA, CH2Cl2, rt
2. TBAF, THF
3. BH3·Me2S, CH2Cl2, –78 
oC to rt 
   NaOH (aq), then 30% H2O2, rt
4.  6% HCl in MeOH, rt
5. NCCH2COCl, Et3N, CH2Cl2,
    0 oC, 2 h, then rt, 3 h
 6. 20 mM HCl in CH2Cl2,, rt
TMS
N
O
CN
18, 67%17
 
Figure 3-7  Synthesis of vinylogous lactam 18 
 
Once we successfully constructed cyano-bearing α,β-unsaturated lactam 18, we 
evaluated its performance in a Diels-Alder reaction. Our studies have revealed that acid-
labile siloxy diene 19 is a competent reactive partner for 18, leading to the construction of 
highly functionalized tricycle 20.  Unfortunately, we are not able to unambiguously 
determine the relative configuration of the functionalized tricycle 20 at this point and 
further analysis is being done to ascertain the compound’s relative configuration with 
high unambiguity.  
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Figure 3-8  [4 + 2] cycloaddition of diene 19 and dienophile 18 
3.2.3 Synthesis of aza-polycycles from α-alkenyl eneformamides 
Having now demonstrated the synthetic utility of our α-alkynyl eneformamides, 
we next sought to showcase how the α-alkenyl eneformamides could be used to construct 
polycyclic structures. These N-formyl amino dienes are suitable dienes that can be used 
in Diels-Alder reactions. With this is mind, we were able to take α-alkenyl eneformamide 
21 and react it with ester quinone 22, in benzene, at room temperature for several hours 
(Figure 3-9).  Excitingly, a cycloaddition reaction proceeded stereo- and chemo-
selectively to furnish a single isomer of the now fused tricycle 23 in impeccable 
efficiency. Additionally, we were able to acquire X-ray crystal structure of the 
cycloadduct, which provided unambiguous support of the relative configuration (Figure 
3-9). Although Diels-Alder reactions are known to be highly stereospecific, the trans-
relative configuration at the ring fusion position (i.e., ester and H groups) can be 
rationalized by invoking epimerization of the initially formed cis-product to the 
thermodynamically more favorable trans-adduct. One of the more amazing features of 
this compound is that it has four contiguous stereocenters. Pleasingly, one of the 
stereocenters is quartenary and another is β-amino further demonstrating the complexity 
of compound 23. Additionally, the compound has both an enamide and enedione motif 
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which is of importance as it has been shown that there are many synthetic applications of 
both of these motifs, some of which we have demonstrated exhaustively. 
N
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Figure 3-9  Hexannulation of N-formyl amino diene 21 with quinone 22 
 
3.3 Conclusion 
In conclusion, we were able to demonstrate the synthetic utility of cyclic 
eneformamidynes to create novel cyclic α-quartenary homoallylic and propargylic 1,5-
enynes using two different approaches. This work stands alone over existing 
methodologies as we were able to install quaternary centers bearing an allyl group and we 
were easily able to expand our methodology to three highly functionalize ring systems 
including a 13-membered macrocycle. We were also able to further demonstrate the 
utility of α-alkynyl and α-alkenyl eneformamides to construct highly functionalized 
tricycles featuring Knoevenagel and Diels-Alder reactions. The ability to construct fused 
polycyclic structures endears the current strategy to the organic synthetic communities as 
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polycyclic structures are found in a wide range of naturally occurring compounds and 
biologically active pharmaceuticals. 
3.4 Methods 
All experiments involving air- and moisture-sensitive reagents were carried out 
under an inert atmosphere of nitrogen and using freshly distilled solvents. All alkynes, 
secondary amines, and electrophiles such as allyltrimethylsilane were newly purchased 
and used without further purification. Column chromatography was performed on silica 
gel (230-400 mesh). Thin-layer chromatography (TLC) was performed using Silicycle 
SiliaplateTM glass backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) and 
visualized using UV (254 nm) or CAM, p-anisaldehyde, or KMnO4 stain. All reported 
temperatures were internal to the reaction vessel. Unless otherwise indicated, 1H, 13C, and 
DEPT-135 spectra were acquired using C6D6 or CDCl3 as solvent at room temperature. 
Chemical shifts are quoted in parts per million (ppm). HRMS-EI+ data were obtained 
using either electron spray ionization (ESI) or electron impact (EI) techniques. High-
resolution ESI was obtained on an LTQ-FT (ion trap; analyzed using Excalibur). High 
resolution EI was obtained on an Autospec (magnetic sector; analyzed using MassLynx). 
34, 38, 59, 109-112 
3.4.1 General procedure A: deformylation 
A stock solution of n-BuLi (0.15 mL, 0.30 mmol, 2.0 M in hexanes, 1.2 equiv) 
was added to the crude quaternary N-formyl amine 12 (0.25 mmol, 1.0 equiv) dissolved 
in freshly distilled THF (5 mL) at –78 °C. After complete deprotection of the amine (~15 
min, as indicated by TLC and GC-MS monitoring), the mixture was quenched with H2O 
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and diluted with EtOAc. It was washed with sat. NaHCO3 and then with brine. The 
organic layer was dried over Na2SO4, concentrated under reduced pressure, and subjected 
to flash chromatography on silica. 34, 38, 59, 109-112 
3.4.2 General procedure B: Grignard addition 
Allyl magnesium bromide (4.0 mL, 1.0 M solution in THF, 4 equiv) was added 
slowly to the crude α-alkynyl imine (1.0 mmol) dissolved in freshly distilled THF (5 
mL), under nitrogen at ‒78 °C. The mixture was warmed slowly to room temperature. 
After complete consumption of the ester (as indicated by TLC and GC-MS), the mixture 
was cooled to 0 °C, diluted with Et2O and quenched by slow addition of sat. aq NH4Cl. 
The layers were separated and the aqueous layer was extracted twice with EtOAc. The 
combined organic layers were dried over Na2SO4 for 30 min, filtered, and concentrated 
under reduced pressure to give the desired product. Purification: Flash chromatography 
on silica (pretreated with 1% Et3N) eluting with Hexane/EtOAc (1:2). 
34, 38, 59, 109-112 
3.4.3 General procedure C: Heck coupling of 2-halo enamides with 
unactivated alkenes 
The 2-halo enamide (1 mmol, 1.0 equiv) in DMF (2 mL, 0.50 M), Pd(OAc)2 (5 
mol%), additive (1 to 2.0 equiv), alkene (2 to 6 equiv) was added to an oven-dried, 
septum-capped vial equipped with a stir bar, under a nitrogen atmosphere. The mixture 
was then stirred at 80 oC for the desired length of time (as indicated by TLC and LC-MS, 
usually 1 h). Upon completion, the mixture was quenched with water and extracted with 
CH2Cl2. The combined organic layers were concentrated to ~10 mL and dried for ~30 
min with Na2SO4. It was filtered and evaporated to give the crude product. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc. Note: 1 equiv NaTFA or 2 
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equiv of K2CO3 were employed. With dioxane as the solvent, longer reaction times 
(monitoring by TLC and LC-MS, usually 2 h) are required. 34, 38, 59, 109-112 
To a solution of cyclic enol ether (1equiv), at 80 °C, under open air condition was 
added to the cycloalkene (1.5equiv) drop wise. The mixture was allowed to stir at 80 °C 
for 24 h. Then the mixture was diluted with ethyl acetate (2 mL), filtered, washed with 
water (5 mL) and brine (5 mL). The organic layer was evaporated and the residue was 
purified by flash column chromatography (Hexane/EtOAc) (6:1) to afford the product as 
an oil. 34, 38, 59, 109-112 
3.4.4 General procedure D: N-acyl iminium reduction 
To the N-formyl-substrate (1.0 equiv) dissolved in freshly distilled CH2Cl2, was 
added NaBH3CN (5 equiv) slowly under nitrogen at 0 °C. TFA (10 equiv) was added 
slowly and the mixture was stirred for 10 min at 0 °C, then for ~12 h at room temperature 
(monitoring by LCMS and TLC; the reduced compound is significantly more polar). 
Upon completion, the reaction was quenched with sat. NaHCO3. The layers were 
separated and the aqueous layer was extracted with CH2Cl2. The combined organic layers 
were dried over Na2SO4, filtered and evaporated to obtain the crude product, which were 
purified by flash chromatography on silica eluting with hexane/EtOAc. 34, 38, 59, 109-112 
3.5 Peak Assignments 
3.5.1 Peak assignment of 1a 
N
H
TIPS
1a, 88%  
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Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (80:20 to 50:50). Yield = 67 
mg, 88%. 1H NMR (400 MHz, Chloroform-d) δ 6.02 – 5.84 (m, 1H), 5.20 – 4.98 (m, 
2H), 3.02 (td, J = 12.0, 2.8 Hz, 1H), 2.86 – 2.69 (m, 1H), 2.35 (dd, J = 13.3, 6.0 Hz, 1H), 
2.17 (dt, J = 13.2, 9.5 Hz, 1H), 1.82 – 1.31 (m, 7H), 1.03 (m, 21H). 13C NMR (101 MHz, 
CDCl3) δ 133.5, 118.8, 84.6, 73.2, 53.9, 48.0, 42.9, 37.4, 25.6, 21.6, 18.6, 18.6, 18.5, 
11.5, 11.2, 11.1. HRMS-EI+ (m/z): calc’d for C19H35NSi 305.2539; found 305.2544. 
3.5.2 Peak assignment of 1b 
N
H
Ph
1b, 87%  
Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 49 
mg, 87%. 1H NMR (400 MHz, Chloroform-d) δ 7.66 to 6.98 (5H, m), 6.22 to 5.72 (1H, 
m), 5.51 to 4.88 (2H, m), 3.45 to 2.73 (2H, m), 2.51 to 0.81 (9H, m). 13C NMR (101 
MHz, Chloroform-d) δ 133.6, 131.9, 128.3, 127.9, 125.6, 119.1, 92.0, 85.4, 53.9, 48.0, 
43.1, 37.4, 25.7, 21.8. HRMS-EI+ (m/z): calc’d for C16H19N 225.1517; found 225.1521. 
3.5.3 Peak assignment of 1c 
1c, 66%
N
H
 
Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
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39.5 mg, 66%. 1H NMR (400 MHz, Chloroform-d) δ 7.88 to 6.98 (5H, m), 6.10 to 5.72 
(1H, t), 5.26 to 4.95 (2H, m), 3.33 to 2.66 (2H,m), 2.48 to 0.74 (11H, m). 13C NMR (101 
MHz, Chloroform-d) δ 134.4, 131.9, 128.4, 128.1, 123.6, 119.9, 93.6, 84.0, 57.0, 47.9, 
44.8, 42.2, 30.4, 28.0, 22.9. HRMS-EI+ (m/z): calc’d for C17H21N 239.1674; found 
239.1678. 
3.5.4 Peak assignment of 1d 
1d, 74%
N
H
Ph
 
Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
39.5 mg, 74%. 1H NMR (400 MHz, Chloroform-d) δ 7.59 to 7.10 (5H, m), 6.08 to 5.76 
(1H, m), 5.41 to 4.95 (2H, m), 2.82 to 2.54 (2H, m), 2.40 to 2.14 (2H, m), 2.04 to 0.91 
(21H, m). 13C NMR (101 MHz, Chloroform-d) δ 135.4, 132.1, 128.6, 128.2, 123.7, 
118.4, 93.5, 84.2, 56.2, 44.7, 41.6, 37.5, 29.8, 29.2, 27.5, 27.2, 26.7, 25.8, 25.5, 24.9, 
20.6. HRMS-EI+ (m/z): calc’d for C23H33N 323.2613; found 323.2610. 
3.5.5 Peak assignment of 1e 
N
H
1e, 83%
Me  
Prepared from 7 (0.5 mmol) using General Procedures A & B. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 99 mg, 
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83%. 1H NMR (400 MHz, Chloroform-d) δ 7.75 to 7.43 (2H, d), 7.32 to 7.07 (2H, d), 
6.08 to 5.98 (1H, d), 5.22 to 4.98 (2H, m), 3.40 to 2.78 (2H, m), 2.52 to 2.01(6H, m), 1.93 
to 1.74 (2H, m), 1.67 to 1.60 (2H, m), 1.51 to 1.42 (2H, m), 1.25 to 0.69 (2H, m). 13C 
NMR (101 MHz, Chloroform-d) δ 138.0, 133.5, 131.6, 128.5, 120.3, 119.1, 90.7, 85.8, 
54.2, 47.8, 44.0, 37.2, 25.5, 21.5. HRMS-EI+ (m/z): calc’d for C17H21N 239.1674; found 
239.1678. 
3.5.6 Peak assignment of 1f 
1f, 69%
N
H
Me  
Prepared from 7 (0.5 mmol) using General Procedures A & B. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 87 mg, 
69%. 1H NMR (400 MHz, Chloroform-d) δ 7.68 to 7.26 (2H, d), 7.18 to 7.09 (2H, d), 
6.10 to 5.76 (2H, m), 5.26 to 5.01 (2H, m), 4.10 to , 3.29 (2H m), 3.22 to 2.66 (2H, m), 
2.48 to 2.43 (3H, s), 2.34 to 1.12 (8H, m). 13C NMR (101 MHz, Chloroform-d) δ 137.9, 
134.6, 131.8, 129.1, 120.5, 118.3, 92.8, 84.1, 57.4, 47.9, 44.8, 42.3, 29.8, 26.1, 24.0, 22.8. 
HRMS-EI+ (m/z): calc’d for C18H23N 253.1830; found 253.1834. 
3.5.7 Peak assignment of 1g 
1g, 79%
N
H
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Prepared from 7 (0.50 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
90.5 mg, 79%. 1H NMR (400 MHz, Chloroform-d) δ 6.03 to 5.66 (2H, m), 5.38 to 4.91 
(2H, m), 3.81 to 2.70 (2H, m), 2.49 to 0.64 (17H, m). 13C NMR (101 MHz, Chloroform-
d) δ 134.9, 134.0, 121.3, 119.6, 88.7, 87.3, 53.8, 48.0, 44.0, 38.2, 29.7, 29.5, 23.4, 23.0. 
HRMS-EI+ (m/z): calc’d for C16H23N 229.1830; found 229.1830. 
3.5.8 Peak assignment of 1h 
1h, 61%
N
H
 
Prepared from 7 (0.5 mmol) using General Procedures A & B. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 74 mg, 
61%. 1H NMR (400 MHz, Chloroform-d) δ 6.23 to 5.80 (2H,m), 5.28 to 4.92 (2H, m), 
3.03 to 2.77 (2H, m), 2.39 to 2.25 (1H, m), 2.24 to1.82 (2H, m), 1.72 to 0.82 (16H, m). 
13C NMR (101 MHz, Chloroform-d) δ 138.2, 135.8,120.8, 118.6, 90.5, 85.9, 56.8, 47.9, 
44.9, 42.1, 30.4, 30.0, 29.8, 29.5, 27.5, 25.9, 22.9, 22.4, 22.3. HRMS-EI+ (m/z): calc’d 
for C17H25N 243.1987; found 243.1984. 
3.5.9 Peak assignment of 1i 
1i, 72%
N
H
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Prepared from 7 (0.50 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 73 
mg, 72%. 1H NMR (400 MHz, Chloroform-d) δ 5.94 to 5.70 (1H, m), 5.14 to 4.86 (2H, 
m), 2.82 to 2.74 (2H, m), 2.72 to 2.59 (2H, m), 2.29 to 2.22 (2H, m), 2.17 to 0.57 (11H, 
m). 13C NMR (101 MHz, Chloroform-d) δ 134.7, 118.4, 87.0, 79.0, 56.3, 48.0, 44.9, 
42.3, 30.3, 27.6, 22.8, 8.7. HRMS-EI+ (m/z): calc’d for C14H21N 203.1674; found 
203.1677. 
3.5.10 Peak assignment of 1j 
1j, 65%
N
H
Cl
 
Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 39 
mg, 65%. 1H NMR (400 MHz, Benzene-d6) δ 6.25 to 5.99 (1H, m), 5.20 to 5.10 (2H, m), 
3.52 to 3.19 (2H, t), 3.13 to 2.75 (2H, m), 2.74 to 2.46 (2H, m), 2.24 to 2.02 (2 H, t), 1.94 
to 0.31 (11H, m). 13C NMR (101 MHz, Benzene-d6) δ 139.1, 119.5, 83.7, 83.0, 57.9, 
46.9, 43.6, 43.2, 40.0, 31.6, 30.0, 27.3, 22.7, 17.6. HRMS-EI+ (m/z): calc’d for 
C14H22ClN 239.1441; found 239.1445. 
3.5.11 Peak assignment of 1k 
1k, 71%
N
H Cl
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Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
57.3 mg, 71%. 1H NMR (400 MHz, Benzene-d6) δ 6.14 to 5.81 (1H, m), 5.15 to 4.95 
(2H, m), 3.37 to 3.20 (2H, t), 2.84 to 0.26 (29H, m). 13C NMR (101 MHz, Benzene-d6) δ 
136.5, 117.8, 87.0, 85.2, 81.6, 79.3, 55.6, 44.9, 43.0, 41.6, 38.9, 31.8, 28.8, 28.0, 26.6, 
26.0, 24.8, 23.7, 21.2, 20.8, 16.1, 9.1. HRMS-EI+ (m/z): calc’d for C20H34ClN 323.2380; 
found 323.2384. 
3.5.12 Peak assignment of 1l 
N
H
1l, 77%
Cl
 
Prepared from 7 (0.50 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 92 
mg, 77%. 1H NMR (400 MHz, Chloroform-d) δ 5.99 to 5.75 (1H, m), 5.20 to 4.99 (2H, 
m), 3.77 to 3.45 (2H, m), 3.33, to 2.52 (2H, m), 2.39 to 0.82 (15H, m). 13C NMR (101 
MHz, Chloroform-d) δ 133.6, 118.9, 84.6, 82.6, 53.6, 48.0, 44.7, 42.8, 37.3, 31.6, 26.2, 
25.5, 21.6, 18.1. HRMS-EI+ (m/z): calc’d for C14H22ClN 239.1441; found 239.1445. 
3.5.13 Peak assignment of 1m 
1m, 69%
N
H
Cl  
Prepared from 7 (0.50 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 92 
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mg, 69%. 1H NMR (400 MHz, Chloroform-d) δ 5.81 (dt, J = 15.4, 8.1 Hz, 1H), 4.98 to 
4.87 (m , 2H), 3.44 (t, J = 6.7 Hz, 2H), 2.83 (dd, J = 13.7, 6.8 Hz, 1H), 2.70 – 2.62 (m, 
1H), 2.15 to 0.77 (m, 17H). 13C NMR (101 MHz, CDCl3) δ 134.5, 119.3, 84.4, 82.7, 56.3, 
47.7, 44.5, 43.1, 42.1, 31.5, 29.6, 27.5, 25.4, 22.7, 18.4. HRMS-EI+ (m/z): calc’d for 
C15H24ClN 253.1597; found 253.1593. 
3.5.14 Peak assignment of 1n 
1n, 74%
N
H
Cl
 
Prepared from 7 (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
62.3 mg, 74%. 1H NMR (400 MHz, Chloroform-d) δ 5.98 to 5.67 (1H, m), 5.12 to 4.98 
(2H, m), 3.71 to 3.23 (2H, t), 2.68 to 0.59 (29H, m). 13C NMR (101 MHz, Chloroform-d) 
δ 134.9, 118.0, 87.1, 85.0, 81.7, 79.0, 55.7, 44.9, 43.9, 41.4, 37.7, 34.9, 31.9, 30.4, 29.2, 
27.5, 26.8, 25.6, 24.5, 23.7, 20.6, 16.7, 8.5. HRMS-EI+ (m/z): calc’d for C21H36ClN 
337.2536; found 337.2540. 
3.5.15 Peak assignment of 10a 
N
CHO
10a; n = 2, 77%
n
( )
 
Prepared from 15b (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
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29.1 mg, 77%. HRMS-EI+ (m/z): calc’d for C9H13NO 151.0997; found 152.2056. As 
reported by us.59 
 
3.5.16 Peak assignment of 10b 
N
CHO
10b; n = 8, 72%
n
( )
 
Prepared from 15c (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
47.3 mg, 77%. 1H NMR (400 MHz, CDCl3) δ 8.07 to  7.82 (s, 2H), 6.74 (m, 1H), 6.29 to 
4.92 (m, 2H), 4.63 to 4.08 (t, 1H), 3.75 to 3.28 (m, 2H), 3.05 to 1.17 (m, 16H). 13C NMR 
(101 MHz, CDCl3) δ 163.7, 136.6, 134.1, 132.9, 129.9, 126.8, 124.1, 117.6, 117.5, 110.7, 
64.8, 43.1, 41.3, 39.9, 37.9, 36.1, 31.8, 28.2, 27.9, 27.1, 26.9, 25.6, 25.5, 24.0, 24.0, 23.8, 
23.7, 23.2, 23.0. 
3.5.17 Peak assignment of 16 
N
CHO
Cl
16, 69%  
Prepared from 15a (0.25 mmol) using General Procedures A & B. Purification: 
Flash chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 
47.3 mg, 69%. As reported by us.109  
  
 102 
 
3.5.18 Peak assignment of 18 
 
N
O
CN
18, 67%  
N-formyl reduction: Compound 17 (1 mmol) was reduced using General 
Procedure D. 
Desilylation: To all of reduced 17 in THF (10.0 mL) were added CF3CO2H (310 
mg, 2.7 mmol) and a 1.0 M solution of TBAF (4.0 mL, 4.0 mmol) in THF successively at 
0 °C. The resulting reaction mixture was stirred at 0 °C for 3 h. The reaction was 
quenched with water, and the aqueous layer was extracted with diethyl ether. The 
combined organic layers were washed with water and brine, dried over anhydrous 
magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica gel to give corresponding desilylated products. 
Hydroboration-oxidation: To a solution of the crude alkynyl piperidine (1.0 
equiv) in freshly distilled CH2Cl2 (4 mL) at –78 °C was added dropwise a 2 M solution of 
BH3∙SMe2 in THF (500 µL, 1 equiv). After a few minutes, the mixture was warmed to 
room temperature and stirring was continued for 6 h. It was then cooled to 0 °C and a few 
drops of 10% NaOH (aq) were added slowly followed by 0.5 mL of 30% H2O2. The 
mixture was returned to room temperature and stirred for 3 h. Water was added and the 
mixture was extracted with CH2Cl2. The combined organic layers were washed with 
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brine, dried over MgSO4, filtered and concentrated under reduced pressure to afford 
crude aldehyde as an oil.  
Deformylation: 6% HCl (1.5 mL) was added to the solution of N-formylated 
aldehyde (50 mg, 0.18 mmol) in MeOH (10 mL) and the resulting mixture was stirred at 
room temperature for 18 h. After completion of reaction (monitored by TLC), H2O was 
added and the whole mixture was neutralized with aqueous NaHCO3 and extracted with 
CH2Cl2. The combined organic phase was washed with brine, dried over Na2SO4 and 
evaporated under reduce pressure to give the free piperidinal as an oil. 
Acylation: The piperidinal was dissolved in dichloromethane (5 mL) and 
triethylamine (1.0 mL, 7.10 mmol) was added drop-wise at 0 °C, followed by the drop-
wise addition of cyanoacetylchloride (727 mg, 7.10 mmol) as a solution in 
dichloromethane (2 mL). The resulting red solution was stirred at the same temperature 
for 2 h and then warmed to room temperature for 3 h, at which time saturated aqueous 
NaHCO3 (10 mL) was added and volatiles removed in vacuo. The resulting aqueous 
solution was extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts 
were dried over MgSO4, filtered, and concentrated in vacuo. The resulting acylated 
piperidinal was obtained as a red oil. 
Knoevenagel condensation:To the acylated piperidinal was added a 20 mM 
solution of HCl/CH2Cl2 (prepared from AcCl/MeOH) and stirring was continued for 12 h 
at room temperature (TLC monitoring). The solution was diluted with DCM and 
transferred to a separatory funnel. Sat. aqueous NH4Cl was added and the layers were 
separated. The aqueous layer was extracted with DCM and the combined layers were 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to obtain the 
bicycle as an oil. 1H NMR (400 MHz, C6D6) δ 6.57 to 6.54 (t, 1H), 4.42 to 4.38 (m, 1H), 
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2.76 to 2.67 (m, 1H), 2.28 to 2.18 (m, 2H), 1.88,  to 1.80 (m, 2H), 1.55 to 0.78 (m, 5H). 
13C NMR (101 MHz, C6D6) δ 159.15, 152.19, 115.27, 112.15, 53.31, 43.11, 32.60, 
30.68, 24.22, 23.22. HRMS-EI+ (m/z): calc’d for C10H12N2O 176.0950; found 176.0955. 
3.5.19 Peak assignment of 20 
20, 79%
N
O
NC
H
MeO
OTBS
H
 
A 10 mL microwave vial was flame-dried, evacuated and flushed with nitrogen. A 
solution of dienophile 18 (176 mg, 1.0 mmol) in toluene (2 mL) was added to the vial 
under a nitrogen atmosphere followed by a solution of diene 19109 (456 mg, 2 mmol) in 
toluene (2 mL). The mixture was heated to 150 oC under microwave irradiation for 2 h. It 
was then cooled to room temperature and the toluene was azeotroped off. Purification by 
flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc 
(80:20) afforded tricycle 20 in 79% yield and >95:5 dr. Note: It is critical to have 
absolutely pure starting materials as any minor impurities simply lead to decomposition 
of the diene.1H NMR (400 MHz, Benzene-d6) δ 5.66 (ddd, J = 10.4, 4.3, 2.9 Hz, 1H), 
5.37 (ddt, J = 10.4, 2.0, 1.0 Hz, 1H), 4.89 (dp, J = 13.1, 1.9 Hz, 1H), 4.12 (ddt, J = 4.1, 
1.9, 0.9 Hz, 1H), 3.45 (dd, J = 9.9, 6.3 Hz, 1H), 3.31 (t, J = 9.8 Hz, 1H), 3.09 – 2.84 (m, 
5H), 2.78 – 2.62 (m, 1H), 2.29 – 2.04 (m, 3H), 1.45 – 0.87 (m, 24H), 0.02 (s,s, 6H). 13C 
NMR (101 MHz, C6D6) δ 161.9, 127.4, 123.7, 118.9, 76.7, 62.9, 59.1, 55.3, 49.1, 43.9, 
38.0, 33.05, 31.0, 25.6, 25.3, 24.9, 23.3, 17.9, -5.7. HRMS-EI+ (m/z): calc’d for 
C22H36N2O3Si 404.2495; found 404.2491.  
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CHAPTER 4 
 
SYNTHESIS OF DIHYDRO-1,4-OXAZINES, THIAZINES AND THEIR SYNTHETIC 
APPLICATIONS 
4.1 Introduction 
As part of a diversity-oriented synthesis approach to functionalized N,O- and N,S-
heterocycles, it was of interest to explore the possibility of converting thiomorpholinones 
and morpholinones prepared  using methodology developed by a fellow graduate student 
in our laboratories. Specifically we desired access functionalized 1, 4-oxazines and 1, 4-
thiazines because they make up the backbone of a variety of pharmaceuticals making 
them highly sought after structural motifs within both the medicinal and synthetic organic 
chemistry communities. For example, 1,4-oxazines and 1,4-thiazines are found in a 
variety of pharmaceuticals that have been used as antibacterial, antioxidants, appetite 
suppressants, and antibiotics (Figure 4-1). They have also been used for other 
applications such as textile drying, bleaching, and fruit preservation agents. They have 
also been used by the organic synthetic communities as ligands as part of highly active 
metal based catalysts.5, 155-158  
N
S
O
NH2
Me
Me
(DPP-IV inhibitor)
N
O
acortatarin A
(antioxidant)
O
OHC
HO
HO
N
O
levofloxacin
(antibacterial)
N
N
Me
O
CO2H
F
Me
N
O
N
Me
H
9-oxabispidine
(ligand)  
Figure 4-1 Examples of biologically active compounds featuring 1,4-oxazine and 1,4-
thiazine derivatives 
The popularity of finding new ways to construct unsaturated azaheterocycles 
containing an oxygen or sulfur has become more and more relevant as they are found in 
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structurally complex pharmaceutical compounds such as levofloxacin  (antibacterial) 159 
and acortatarin A (antioxidant).5 This has driven the industry to find new cost-effective, 
efficient, and highly modular methodologies to construct these highly functionalized 
biologically-active motifs. These methodologies can then be used to create large diverse 
libraries of compounds that can be further functionalized or used in structure-activity 
relationship studies (SAR).5 
In recent times, several synthetic methodologies aimed at creating 1,4-oxazines 
and 1,4-thiazines, many of which use a metal catalyst, have emerged such as those 
popularized by Katukojvala160 (using diazoenals), Saa161, 162 (using catalytic ruthenium 
carbenes derived from alkynals and alkynones), Bode137, 163-167 (using SnAP and SLAP 
reagents), Tiecco168 (using vinyl selenones), and Carreira169, 170 (using spirocyclic 3-
oxetanones) (Figure 4-2 A-C). 
From our vantage point, a diversity oriented approach to the synthesis of 1,4-
oxazines and 1,4-thiazines that addresses elements such as cost-effectiveness, bench 
stability, and high modularity is imperative. However, it is recognized that developing 
such a protocol would be quite challenging as morpholines and thiomorpholines are 
prone to ring opening and have conformational limitations.  
  Our group previously reported that through the use of 1,3-azadienes of type 
2 and cyclic anhydrides such as 1, construction of highly-functionalized cyclic 
compounds with vicinal stereocenters with a high degree of modularity is possible 
through a Castagnoli-Cushman reaction (Figure 4-2D). The combination of 1,3-
azadienes with cyclic anhydrides with reduced α-C-H acidity provides a unique 
balance of reactivity and selectivity to form highly functionalized morpholine and 
 107 
thiomorpholine bearing compounds. With these products in hand, we theorized 
that their amenability to chemoselective Vilsmeier-Haack functionalizations would 
pave the way for a DOS approach to vinylated dihydro-1,4-oxazines and thiazines 
such as 4. 
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Figure 4-2  Proposed plan for accessing vinylated dihydro-1,4-oxazines and 1,4-thiazines 
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  We were highly interested in generating these vinylated dihydro-1,4-
oxazines and 1,4-thiazines because they are functionalized in all five possible 
positions around the ring. The Castagnoli-Cushman product 3 is already highly 
functionalized and the α-alkenyl motif can be used in a large variety of reactions 
such as hydroarylation,98 oxoamination,100 dioxygenation171 trifluoro-
methylation,101 aziridination,172 dihydropyranation 5,111 pentannulation 6,112 and 
boration.97 Additionally the β-ester motif can be utilized in a wide variety of 
reactions such as Grignard additions, reductions, and fragment coupling protocols. 
The vinylated dihydro-1,4-oxazines and 1,4-thiazines 5 could also be used in a 
similar manner to our α-halo eneformamide as it is an α-halo enamine. Thus, the 
functional halogen handle can be utilized in cross-coupling strategies.  
  We fully recognize that there are many challenges associated with the 
proposed plan of studies given that morpholines and thiomorpholines are highly 
prone to ring opening under strong acidic and basic conditions.  Thus, in order for 
our strategy to work, it would be absolutely imperative to find suitable conditions 
that negate/minimize ring-opening events. Additionally, the Vilsmeier-Haack 
reaction has been shown to react with esters, alkenes, electron-rich arenes, 
carboxylic acids, and lactams. Thus, achieving site-selective functionalization with 
the Vilsmeier-Haack reaction could prove to be a herculean task as our 
intermediate contains all of these functional groups. In this chapter, we present our 
thorough effort toward the assembly of a diverse library of structurally complex 
and fully substituted vinylated and arylated dihydro-1,4-oxazines and 1,4-
thiazines. This methodology stands alone over other methodologies as these 
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dihydro-1,4-oxazines and 1,4-thiazines can be achieved in a highly modular, cost 
effective, scalable manner and under mild conditions. Additionally, these highly 
functionalized dihydro-1,4-oxazines and 1,4-thiazines can be further functionalized 
by engaging them in some C-C and C-N bond forming processes, leading to the 
rapid assembly of molecular complexity.  
4.2 Results and Discussion 
4.2.1 Optimization of the Vilsmeier-Haack functionalization of allylic 
morpholinonate 
As previously discussed, we needed to find optimum conditions for the  
Vilsmeier-Haack reaction to prepare vicinally functionalized alkenylated or arylated 
dihydro-1,4-oxazines and thiazines from lactamoyl esters of type 3. The optimization 
conditions are shown in Figure 4-3. In a similar manner to the way we generated cyclic-
α-chloro eneformamides, preparation of the Vilsmeier-Haack reagent (by refluxing a 
solution of DMF and POCl3 in dichloromethane for one hour) was first achieved 
followed by addition of lactamoyl ester 3a. We allowed the reaction mixture to stir for 30 
minutes at 40 °C (Figure 4-3 entry 1) and after hydrolytic workup we isolated the 
iminium salt 4a1 in pretty low yield. The low yield was due to the starting material 3a not 
being fully consumed and the Vilsmeier-Haack reaction reacting with the alkene creating 
a mixture of E/Z isomers (see 7). We then allowed the reaction to go for 2 h (Figure 4-3 
entry 3) and got better yield and complete consumption of starting material (monitored by 
GC-MS), but the product was more of the E/Z isomers and less of the desired product. 
This led us to try the reaction at room temperature, and after 12 h (Figure 4-3, entry 4) we 
saw complete conversion to product and no signs of the formylation of the alkene with 
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75% yield. Allowing the reaction to go for an extended period of time (22 h) increased 
the yield to 89% (Figure 4-3, entry 5), but after allowing the reaction to go to 36 h 
(Figure 4-3, entry 6), we began to see formylation of the alkene again. To further 
optimize the reaction, we tried to use different solvents such as 1,2-dichloroethane and 
chloroform at different temperatures but the reaction was quite recalcitrant (Figure 4-3, 
entries 7-9) and the process was less efficient than under the dichloromethane conditions. 
In order to afford the chloro enamine 8 we tried the reaction without the use of 
dimethylformamide (DMF) and no reaction occurred. Lastly, we tried to add the POCl3 
and DMF to substrate 3a directly instead of using inverse addition and we saw no 
conversion to product, indicating that inverse addition (adding lactam to Vilsmeier-Haack 
reagent) is necessary for the reaction to proceed as intended.  
 
Figure 4-3  Optimization of the Vilsmeier-Haack functionalization of allylic 
morpholinonate 1a 
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4.2.2 Synthesis of vinylated dihydro-1,4-oxazines 
With optimized conditions for the Vilsmeier-Haack functionalization protocol in 
hand (Figure 4-3 entry 5), we began to apply these conditions to a large library of 
functionalized lactams 3. We wanted to test the limitations of the Vilsmeier-Haack 
reaction on a library of compounds featuring different N-substituents and alkenyl 
substituents. With this in mind, we chose our N-substituents carefully as we knew that the 
N-substituent on morpholines can have a huge effect on biological activity. Thus, we 
chose a wide range of N-substituents, including electron-rich-, electron neutral-, and 
electron-poor aryl groups. We also explored the use of benzyl and alkyl N-substituents to 
further diversify the library of compounds constructed. In each case, moderate to good 
yields were obtained (see 4a1-4a6). 
 One of the advantages of this synthetic pathway (Figure 4-4) is our ability to 
isolate the iminium diene salt intermediates (4a1 – 4a6).  This is beneficial as the salts 
are more stable than their haloenal counterparts. This allows us to hold onto the 
compounds for longer periods of time and allow us to use them in SAR studies or for 
future transformations. However, we still wanted to convert the iminium salt to the 
haloenal as this would provide a great substrate for further functionalization.  With this in 
mind, we ran the iminium salt compounds through flash chromatography on silica 
pretreated with triethylamine (4b1-4b4). To our satisfaction, this provided great recovery 
of the enal over the iminium salt. We also attempted to hydrolyze the iminium salt using 
a variety of conventional bases such as NaOH, KOH, NaOAc, or NH4OAc. However, this 
led to low yields, loss of the starting materials (i.e., 3), and high diastereomer ratio, 
presumably due to epimerization.  
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 Another benefit to this methodology is that it is highly scalable to a multi-gram 
scale (4b1 and 4b4). This transition metal-free, cost-effective, highly modular, scalable, 
and step-economical approach to vicinally functionalized alkenylated dihydro-1,4-
oxazines and thiazines stands alone over existing methodologies. 
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Figure 4-4  Synthesis of vinylated dihydro-1,4-oxazines 
4.2.3 Synthesis of α-amino-benzylic dihydro-1,4-oxazines 
 
We also wanted to explore this methodology on morpholinonates bearing α-amino  
benzylic stereocenters to construct dihydro-1,4-oxazines with similar efficiency to the 
vinylated products shown earlier (Figure 4-5). We have found that in these cases, it takes 
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longer reaction times. Nevertheless, the reaction still proceeds with high efficacy. In the 
specific cases where the N-substituent is a tert-butyl group or isopropyl group the 
reaction is more reluctant and much higher temperatures are required (10b1/10b2). 
Thinking ahead, we knew we wanted to use these haloenaminals for challenging cross-
coupling reactions. Thus, bromoenaminal variant 10a5 was synthesized in satisfactory 
and synthetically attractive yield. Although creating the bromoenaminal variant was not 
cost effective (1 g of POCl3 costs ~$0.045 while 1 g of POBr3 costs ~$4.6), we know that 
some cross-couplings, especially those featuring electron-deficient substituents, can be 
extremely challenging and would benefit from having a better leaving group. 
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Figure 4-5  Synthesis of α-amino-benzylic dihydro-1,4-oxazines 
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4.2.4 Synthesis of allylic and benzylic dihydro-1,4-thiazines 
 
As highlighted on several occasions, going from one ring system to another can 
be a very uphill task. In this case, we wanted to extend the synthetic methodology 
developed herein from morpholinates to thiomorpholinates, which are well known to ring 
open even under friendly reaction conditions. We were therefore very pleased to see that 
chemoselective vicinal difuntionalization of both allylic and benzylic thiomorpholinates 
(4c1 and 12) work with our newly found conditions (Figure 4-6). In the case of these 
thiomopholinates, the reactions are much faster than with the morpholinonate 
counterparts.  This is expected as typically sulfur-bearing heterocycles tend to be more 
reactive than oxygen-bearing heterocycles due to the size and electronegativity of sulfur 
over oxygen. Additionally, the thiomorpholinates are far more unstable than the 
morpholinates as they begin to decompose during the time it takes to run full NMR data 
analysis at room temperature. Due to the fragile nature of these compounds, yields were 
lower as some of the compound would decompose during the isolation and analysis steps.  
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Figure 4-6  Synthesis of allylic and benzylic dihydro-1,4-thiazines 
4.2.5 Sonogashira cross-coupling of iodoarylated chloro enamines or 
iodoarylated lactams with terminal alkynes and subsequent manipulation 
Having demonstrated how we could construct a large library of vinylated and 
benzylic dihydro-1,4-oxazines and dihydro-1,3-thiazines, we wanted to show what we 
could do with them (Figure 4-7). We wanted to illustrate their importance and to illustrate 
how synthetically useful these compounds are and how they can act as synthetic 
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precursors to even more structurally complex compounds. For example, if the N-
substituent on these dihydro-1,4-oxazines is an iodoaryl group (4b1) then the iodo group 
and the chloro group can be used in one-pot Pd- and Cu-catalyzed Sonogashira cross-
coupling reactions (Figure 4-7). In our case, we took the iodoarylated chloro enaminal 
(4b1) and reacted it with excess 4-ethynyltoluene to couple at both the iodo and chloro 
positions (13). To our excitement, the mild coupling conditions showed no signs of 
epimerization, hence, the diastereomer ratio was preserved. It is relevant that 4b1 couples 
efficiently at the chloro position since vinyl chlorides are rarely used in cross-couplings 
at room temperature. This is likely due to the slow oxidative addition step in the catalytic 
cycle.173 We have also found that we can take our N-aryliodo lactomyl esters (3d1 and 
3d2) and do Sonogashira type cross couplings before performing the Vilsmeier-Haack 
reaction (14a-c).  Pleasingly, we find that compounds such as 14a-c successfully undergo 
the Vilsmeier-Haack reaction (15a-b).  This is exciting as this allows us to cross-couple 
different reagents onto the aryl-iodo position and the α-amino position.  Once we couple 
the iodo-position on the lactamoyl ester, we performed the Vilsmeier-Haack reaction to 
generate the vinyl chloride and now the substrate is set up for additional cross-coupling 
strategies.  
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Figure 4-7  Sonogashira cross-coupling of iodoarylated chloro enamines or iodoarylated 
lactams with terminal alkynes and subsequent manipulation 
 
4.2.6 Condensation of β-chloroenals with primary amines 
After successfully functionalizing the vinyl chloride and iodoaryl motifs, we 
turned our attention to the aldehyde subunit (Figure 4-8). Treatment of enals with primary 
amines is a simple way to introduce C-N bonds. Thus, we took compounds 4b2 and 15a-
b and treated them with primary amines to furnish 1,3-aziadienes such as 16a-c.  
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When α-thioalkoxy-β-chloroenal 12b4 is subjected to the same reaction conditions, 
partial conversion to iminodiene 16d is observed even after two weeks at room 
temperature. Although these are simple transformations, they are noteworthy since the 
azadienes may be employed as dienes or dienophiles in hexannulative-type strategies. 
Additionally, it is quite remarkable that we are able to isolate and store such azadienes 
since the fragility of imines is a common problem that plagues the synthesis community. 
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Figure 4-8  Condensation of β-chloroenals with primary amines 
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4.2.7 Stereoselective Wittig olefination of β-chloro enal 18 and subsequent 
preparation of bis-homoallylic alkenol 19 
Wittig olefination of the aldehyde motif resident in 4b4 has been explored. 
Intrinsic to this design was the prospect of utilizing the diene product in Diels-Alder type 
reactions. Fortuitously, two undergraduate students in our lab have found that treatment 
of 4b4 with an instant ylide furnishes E-configured styrene derivative 17, in excellent 
stereospecificity. Our group has also had resounding success with Grignard additions to 
lactamoyl esters of type 3. We next attempted an addition of allylmagnesium bromide to 
highly functionalized dehydromorpholine 17 and were elated to obtain tertiary alkenol 18 
in good yield. Additionally, no complications arising from Grignard fragment exchange 
or enolization were observed.  
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Figure 4-9  Stereoselective Wittig olefination of β-chloro enal 17 and subsequent 
preparation of bis-homoallylic alkenol 18 
 
4.3 Conclusion 
In this chapter, we presented a cost-effective, highly modular, scalable, and DOS 
approach to functionalized 1,4-oxazines and 1,4-thiazines. We were able to generate 
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these highly functionalized 1,4-oxazines and 1,4-thiazines without the use of a transition 
metal-based catalyst. Since extending reactivity trends from one N-heterocycle to another 
can be a very challenging, partly due to conformational constraints and proneness to ring 
opening, we were quite pleased to demonstrate after rigorous optimization that these 
methodologies are applicable to both the morpholine and thiomorpholine heterocycles. 
We were also able to demonstrate the synthetic utility of these functionalized 1,4-
oxazines and 1,4-thiazines by taking advantage of the chlorine leaving group, the enal 
motif, and the ester functional group through the use of Sonagashira cross-couplings, 1,3-
azadiene formations, Wittig olefination, and Grignard additions, respectively.  
4.4 Methods 
All experiments involving palladium precatalysts were carried out under an inert 
atmosphere of argon or nitrogen. Et3N, MeOH, THF, benzene, toluene, Et2O, and 
acetonitrile were distilled using the Grubbs solvent system. Anhydrous DMF and 1,4-
dioxane were used as purchased. Dichloromethane was distilled from MgSO4. K2CO3, 
CuI, and the alkynes were used as purchased. Column chromatography was performed on 
silica gel (230-400 mesh). Thin-layer chromatography (TLC) was performed on silica 
plates. Visualization of the TLC plates was aided by UV irradiation at 254 nm or by 
staining with CAM, p-anisaldehyde, or KMnO4. Unless otherwise indicated, 
1H, 13C, 
DEPT-135 NMR spectra were acquired using C6D6 or CDCl3 as solvent at room 
temperature. Chemical shifts are quoted in parts per million (ppm).34, 38, 59, 109-112 
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4.4.1 General procedure A: Formation of 1,2-dihydrothiazines and –oxines 
To a solution of DMF (4 mmol, 4 equiv) in CH2Cl2 (5 mL) at 0 
oC was added 
dropwise, the corresponding phosphorus oxyhalide (2 mmol, 2 equiv) dissolved in 
CH2Cl2 (2 mL). The resulting mixture (pale yellow in the case of the chloride or milky 
white in the case of the bromide) was refluxed for 20 min. A solution of lactamoyl ester 
(1 mmol, 1 equiv) in CH2Cl2 (50 mL) was added slowly under reflux. After complete 
addition of the lactam, the mixture was stirred under reflux for the indicated time period 
(TLC and LC-MS monitoring was used to followed the extent of the reaction). Upon 
completion, the mixture was allowed to warm to room temperature and then poured into a 
large flask containing crushed ice. After stirring at rt for 30 min, the layers were 
separated. The aqueous layer was extracted once with CH2Cl2. The combined organic 
layer was concentrated to ~100 mL and was dried over Na2SO4 for 30 min. The mixture 
was filtered and concentrated under reduced pressure to give the desired product as salt. 
Flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAC 
afforded the corresponding enals. Caution: The haloenals are not very bench stable and 
should be stored in the refrigerator either neat or as a solution in benzene. 34, 38, 59, 109-112 
4.4.2 General procedure B: Sonogashira coupling of dihydro-1,4-oxazines 
To an oven-dried, septum-capped 2-neck-round bottom flask equipped with a stir 
bar, was added the 2-halo enamide (1 mmol, 1.0 equiv) in DMF (5 mL) under an argon or 
nitrogen atmosphere. The desired alkyne (1.2 equiv) was added followed by addition of 
Et3N (0.7 mL, 5 mmol, 5 equiv). After completely degassing the flask, PdCl2(PPh3)2 (35 
mg, 5 mol%) and CuI (2 mg, 1 mol%) were added rapidly and concurrently. The mixture 
was then stirred at the desired temperature for the desired length of time (as indicated by 
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TLC and LC-MS). Upon completion, the mixture was quenched with water and extracted 
with CH2Cl2. The combined organic layers were concentrated to ~20 mL and dried with 
for ~30 min with Na2SO4. It was filtered and evaporated to give the crude product. 
Purification: Flash chromatography on silica eluting with hexane/EtOAc. 34, 38, 59, 109-112 
4.4.3 General procedure C: Formation of 1,3-azadienes from 1,2-
dihydrothiazines and –oxines 
A roundbottom flask was equipped with a stir bar, followed by the addition of the 
enal (1 mmol), the amine (1.5 equiv), benzene (5 mL), and anhydrous MgSO4 (200 mg). 
The cloudy mixture was allowed to stir at room temperature with regular monitoring via 
Thin Layer Chromatography (TLC). After complete depletion of the amine, the mixture 
was filtered and concentrated under reduced pressure to attain the crude enamine, which 
was carried forward into the next step without further purification. Any amount of 
enamine not immediately used required storage in a freezer. 34, 38, 59, 109-112 
4.5 Peak Assignments 
4.5.1 Peak assignment of 4a1 
O
NCl
CO2Me
OMe
Ph
N
Me Me
 
Compound 4a1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 392 mg, 89%. 1H NMR (400 MHz, Chloroform-d) δ 7.89 - 6.69 (m, 10H), 6.32 
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(d, J = 15.8 Hz, 1H), 6.14 (dd, J = 15.8, 8.2 Hz, 1H), 4.94 (s, 1H), 4.82 (d, J = 8.1 Hz, 
1H), 3.69 - 3.28 (sm 12H).
 13C NMR (101 MHz, CDCl3) δ 162.7, 159.9, 151.3, 144.7, 
137.5, 136.1, 134.9, 129.3, 128.8, 127.7, 127.1, 124.7, 122.8, 114.8, 114.6, 74.1, 66.5, 
55.6, 53.7, 50.5, 41.7. 
4.5.2 Peak assignment of 4a2 
O
NCl
CO2Me
N
Me Me
OMe
OMe
 
Compound 4a2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 396 mg, 84%. 1H NMR (400 MHz, Chloroform-d) δ 8.14 (s, 1H), 7.29 (s, 2H), 
6.98 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.3 Hz, 1H), 6.80 (dd, J = 14.8, 7.7 Hz, 2H), 6.35 
(d, J = 14.6 Hz, 2H), 5.11 (s, 1H), 4.95 - 3.60 (m, 15H). 13C NMR (101 MHz, CDCl3) δ 
166.6, 160.3, 151.9, 136.6, 128.8, 134.8, 129.2, 128.0, 127.5, 123.6, 118.0, 116.0, 115.8, 
74.7, 66.1, 56.3, 55.9, 53.2, 51.5, 32.2, 41.4.  
Peak assignment of 4a3 
O
NCl
CO2Me
Ph
OMe
Me
N
Me Me
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Compound 4a3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 423 mg, 93%. 1H NMR (400 MHz, Chloroform-d) δ 8.23 (s, 1H), 7.75 – 6.98 (m, 
9H), 6.94 – 6.71 (d, 2H), 6.3 (s, 1H), 4.95 (s, 1H), 4.83 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H), 
3.73 (s, 3H), 3.72 (s, 6H), 2.04 – 1.89 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.7, 
162.6, 151.6, 146.1, 135.5, 133.8, 131.4, 130.0, 129.0, 128.8, 122.5, 115.3, 73.4, 71.6, 
55.7, 55.5, 53.9, 50.5, 50.2, 41.8, 15.1.  
Peak assignment of 4a4 
 
Compound 4a4: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 461 mg, 86%. 1H NMR (400 MHz, Chloroform-d) δ 8.26 (s, 1H), 7.67 (d, J = 7.4 
Hz, 2H), 7.36 (d, J = 7.3 Hz, 2H), 7.30 – 7.16 (m, 3H), 6.88 (d, J = 7.8 Hz, 2H), 6.45 (d, 
J = 15.0 Hz, 1H), 6.30 (dd, J = 15.5, 7.8 Hz, 1H), 5.05 (s, 1H), 4.93 (d, J = 6.6 Hz, 1H), 
3.83 (s, 3H), 3.63 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 168.9, 152.3, 143.3, 140.6, 
139.0, 138.5, 136.4, 134.6, 130.3, 129.1, 128.9, 126.7, 123.1, 120.7, 95.3, 75.2, 66.0, 
53.9, 50.9, 42.2. 
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4.5.3 Peak assignment of 4a5 
 
Compound 4a5: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 336 mg, 79%. 1H NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 7.33 - 6.48 (m, 
10H), 6.94 (dd, J = 15.8, 8.8 Hz, 1H), 5.22 (d, J = 15.5 Hz, 1H), 4.85 (s, 1H), 4.68 (d, J = 
15.7 Hz, 1H), 4.59 (d, J = 9.0 Hz, 1H), 3.76 – 3.57 (m, 9H). 13C NMR (101 MHz, CDCl3) 
δ 165.5, 150.6, 146.6, 138.0, 134.6, 133.0, 130.2, 129.5, 129.2, 128.8, 123.1, 118.2, 74.1. 
63.2, 55.9, 52.9, 50.4, 41.7. 
4.5.4 Peak assignment of 4a6 
 
Compound 4a6: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 373 mg, 85%. 1H NMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 7.50 – 7.02 (m, 
12H), 6.33 (s, 1H), 5.32 (d, J = 15.3 Hz, 1H), 4.87 (d, J = 5.8 Hz, 1H), 4.75 – 4.61 (m, 
1H), 4.35 – 4.26 (m, 1H), 4.16 -3.27 (s, 3H).
 13C NMR (101 MHz, CDCl3) δ 166.8, 151.4, 
147.4, 135.9, 134.4, 132.8, 131.1, 130.1, 129.0, 128.2, 127.3, 122.8, 73.4, 65.1, 63.2, 
60.2, 41.8, 14.2. 
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4.5.5 Peak assignment of 4b1 
O
NCl
CO2Me
I
Ph
O
 
Compound 4b1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 376 mg, 74%. 1H NMR (400 MHz, Chloroform-d) δ 9.70 
(s, 1H), 7.67 (d, J = 8.1 Hz, 2H), 7.40 – 7.22 (m, 2H), 6.88 (d, J = 8.2 Hz, 2H), 6.63 (d, J 
= 15.8 Hz, 1H), 6.21 (dd, J = 15.9, 6.5 Hz, 1H), 5.01 (s, 1H), 4.89 (d, J = 6.5 Hz, 1H), 
3.62 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 180.4, 167.7, 142.2, 138.5, 135.2, 134.1, 
132.8, 131.5, 130.3, 128.8, 127.2, 122.4, 119.6, 91.8, 74.6, 62.6, 52.7. 
4.5.6 Peak assignment of 4b2 
O
NCl
CO2Me
Ph
Ph
O
 
Compound 4b2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 280 mg, 73%. 1H NMR (400 MHz, Chloroform-d) δ 9.70 
(s, 1H), 7.41 - 7.11 (m, 10H), 6.65 (d, J = 15.8 Hz, 1H), 6.27 (dd, J = 15.8 Hz, 1H), 5.11 
(d, J = 12.6 Hz, 1H), 4.74 (d, J = 12.8 Hz, 1H), 3.66 (s, 3H). 13C NMR (101 MHz, 
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CDCl3) δ 180.5, 167.9, 142.4, 135.9, 134.2, 129.7, 128.8, 127.3, 126.8, 125.7, 124.8, 
122.6, 74.4, 64.2, 52.2. 
4.5.7 Peak assignment of 4b3 
O
NCl
CO2Me
Ph
CF3
O
 
Compound 4b3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 352 mg, 78%. 1H NMR (400 MHz, Chloroform-d) δ 9.75 
(s, 1H), 7.52 (d, J = 4.6 Hz, 2H), 7.42 – 7.23 (m, 7H), 6.69 (d, J = 15.9 Hz, 1H), 6.24 (dd, 
J = 15.9, 6.3 Hz, 1H), 5.06 (s, 1H), 4.96 (d, J = 6.3 Hz, 1H), 3.59 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 180.6, 167.6, 143.1, 135.2, 134.1, 133.4, 132.0, 131.7, 130.8, 128.8, 
126.9, 124.8, 123.5, 122.1, 121.9, 119.6, 74.6, 63.8, 52.6. 
4.5.8 Peak assignment of 4b4 
O
NCl
CO2Me
O
Me
OMe
 
Compound 4b4: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
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hexane/EtOAc (80:20). Yield = 342 mg, 80%. 1H NMR (400 MHz, Chloroform-d) δ 9.64 
(s, 1H), 7.29 (d, 2H), 6.98 (d, J = 8.7 Hz, 2H), 6.88 (d, 2H), 6.80 (dd, 2H), 6.5 (d, J = 
14.6 Hz, 1H), 6.11 (m, 1H), 4.95 - 4.60 (m, 2H), (3.84 – 3.52 (m, 6H), 2.41 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 180.6, 168.3, 140.9, 138.6, 134.8, 132.8, 129.2, 128.0, 127.5, 
120.6, 114.0, 74.7, 64.1, 54.3, 52.9, 21.4. 
4.5.9 Peak assignment of 10a1 
O
NCl
CO2Me
Ph
N
Me Me
 
Compound 10a1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h.  
Yield = 240 mg, 80%. 1H NMR (400 MHz, Chloroform-d) δ 8.35 (s, 1H), 7.87 - 6.96 (m, 
10H), 5.25 (d, J = 15.4 Hz, 1H), 4.90 (d, J = 12.6 Hz, 1H), 4.66 (d, J = 15.4 Hz, 1H), 4.02 
(d, J = 15.4 Hz, 1H), 3.56 - 3.38 (m, 9H).
 13C NMR (101 MHz, CDCl3) δ 166.4, 151.3, 
145.8, 134.9, 132.5, 129.7, 128.8, 128.0, 127.8, 122.2, 74.6, 63.9, 55.9, 53.1, 50.3, 41.6. 
4.5.10 Peak assignment of 10a2 
O
NCl
CO2Me
Ph
N
Me Me
OMe  
Compound 10a2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 360 mg, 84%. 1H NMR (400 MHz, Chloroform-d) δ 8.34 (s, 1H), 7.60 - 6.66 (m, 
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9H), 5.14 (d, J = 15.4 Hz, 1H), 4.67 (s, 1H), 4.57 (s, 1H), 4.17 (s, 1H), 3.67 (d, J = 15.4 
Hz, 1H), 3.63 – 3.28 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 166.4, 160.4, 151.2, 
147.2, 132.7, 129.7, 128.7, 127.7. 126.8, 124.8, 114.9, 74.7, 63.4, 55.3, 54.9, 52.9, 50.1, 
41.6. 
4.5.11 Peak assignment of 10a3 
O
NCl
OMe
O
Ph MeO
N
 
Compound 10a3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 335 mg 78%. 1H NMR (400 MHz, Chloroform-d) δ 8.51 (s, 1H), 7.68 - 6.54 (m, 
9H), 5.50 (d, J = 15.4 Hz, 1H), 4.67 (d, 1H), 4.21 -– 3.42 (m, 12H). 13C NMR (101 MHz, 
CDCl3) δ 165.4, 159.8, 150.8, 147.4, 132.7, 129.3, 128.2, 127.6. 126.5, 124.7, 112.9, 
74.7, 58.4, 6.3, 55.9, 51.9, 50.1, 41.4. 
4.5.12 Peak assignment of 10a4 
 
Compound 10a4: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 318 mg, 74%. 1H NMR (400 MHz, Chloroform-d) δ 8.51 (s, 1H), 7.44 - 6.49 (m, 
9H), 5.29 (d, J = 15.4 Hz, 1H), 4.91 (s, 1H), 4.73 (s, 1H), 4.27 (d, J = 15.4 Hz, 1H), 3.84 
 131 
(s, 1H), 3.73 - 3.40 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 166.4, 160.4, 151.4, 146.0, 
138.5, 132.5, 130.9, 129.2, 128.2, 126.7, 122.2, 118.6, 114.3, 112.7, 74.7, 62.1, 55.6, 
55.2, 53.1, 50.3, 41.7. 
4.5.13 Peak assignment of 10a5 
O
NBr
O
OMe
OMeMeMe
NMe2
 
Compound 10a5: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 341 mg, 80%.
 1H NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 7.02 (d, J = 8.5 
Hz, 2H), 6.78 (d, J = 8.4 Hz, 2H), 5.20 (s, 1H), 4.64 (d, J = 12.1 Hz, 2H), 3.72 (s, 3H), 
3.64 (d, J = 13.1 Hz, 6H), 3.40 (s, 3H), 1.11 (s, 3H), 0.88 (d, 3H). 13C NMR (101 MHz, 
CDCl3) δ 167.0, 159.9, 152.5, 146.0, 128.5, 126.4, 123.9, 114.7, 75.1, 58.7, 58.7, 56.1, 
53.5, 50.5, 46.0, 41.6, 22.5, 21.0. 
4.5.14 Peak assignment of 10b1 
O
NCl Ph
CO2Me
CMe3
O
 
Compound 10b1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 290 mg, 86%. 1H NMR (400 MHz, Chloroform-d) δ 9.65 
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(s, 1H), 7.33 - 7.12 (m, 5H), 5.52 (d, J = 18.2 Hz, 1H), 4.99 (d, J = 18.2 Hz, 1H), 3.77 (s, 
3H), 1.55 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 179.9, 169.3, 137.3, 132.7, 129.4, 
128.5, 128.1, 127.7, 126.0, 76.9, 61.2, 58.9, 52.8, 31.0. 
4.5.15 Peak assignment of 10b2 
O
NCl
O
OMe
OMeMeMe
O
 
Compound 10b2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 318 mg, 90%. 1H NMR (400 MHz, Chloroform-d) δ 9.61 
(s, 1H), 7.21 (d, 2H), 6.84 (d, 2H), 5.12 (d, J = 18.2 Hz, 1H), 4.89 (d, J = 18.2 Hz, 1H), 
3.58 (m, 1H), 3.85 (s, 6H), 1.04 (d, 6H). 13C NMR (101 MHz, CDCl3) δ 179.7, 169.6, 
160.3, 138.7, 131.4, 128.5, 114.1, 75.9, 58.2, 56.9, 53.8, 51.0, 21.3, 21.1. 
4.5.16 Peak assignment of 4c1 
S
NCl
CO2Me
Ph
OMe
Me
O
 
Compound 4c1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
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hexane/EtOAc (80:20). Yield = 314 mg, 71%.
 1H NMR (400 MHz, Chloroform-d) δ 9.99 
(s, 1H), 7.34 (m, 7H), 7.25 (d, J = 7.2 Hz, 2H), 6.46 (s, 1H), 4.88 (d, 1H), 3.96 (d, J = 2.5 
Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 1.91 (s, 3H).
 13C NMR (101 MHz, CDCl3) δ 185.4, 
170.4, 159.2, 142.6, 137.3, 136.5, 133.3, 131.5, 129.5, 129.1, 129.1, 114.9, 102.5, 72.6, 
55.5, 53.1, 40.1, 17.6. 
4.5.17 Peak assignment of 12a1 
S
NCl
CO2Me
N
Me Me
 
Compound 12a1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 278 mg, 67%. 1H NMR (400 MHz, Chloroform-d) δ 8.83 (s, 1H), 7.95 (s, 1H), 
7.39 – 7.28 (m, 10 H), 5.49 – 5.30 (m, 2H), 4.44 – 4.19 (m, 1H), 3.71 – 3.32 (m, 10H). 
13C NMR (101 MHz, CDCl3) δ 167.5, 162.7, 155.0, 138.9, 136.9, 136.7, 88.7, 67.5, 58.2, 
53.5, 50.1, 45.8, 42.6, 30.4. 
4.5.18 Peak assignment of 12a2 
S
NCl
CO2Me
Ph OMe
N
Me Me
 
Compound 12a2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
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Yield = 311 mg, 70%. 1H NMR (400 MHz, Chloroform-d) δ 8.71 (s, 1H), 7.34 –6.77 (m, 
10H), 5.34 (d, J = 15.8 Hz, 1H), 5.26, 4.32 (d, J = 22.8 Hz, 1H), 4.25 (s, 1H), 3.73 - 3.31 
(m, 12H). 13C NMR (400 MHz, CDCl3) δ 167.5, 162.3, 160.6, 155.0, 134.1, 130.6, 130.2, 
129.9, 114.7, 67.1, 57.9, 55.5, 53.4, 51.2, 44.3, 42.5. 
4.5.19 Peak assignment of 12a3 
S
NCl
CO2Me
N
Me Me
OMe  
Compound 12a3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 293 mg, 68%. 1H NMR (400 MHz, Chloroform-d) δ 8.69 (s, 1H), 7.34 (m, 9H), 
6.98 – 6.76 (m, 1H), 5.56 (s, 1H), 3.87 - 3.72 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
170.4, 162.4, 160.2, 154.6, 137.3, 130.5, 129.3, 129.5, 128.5, 88.6, 72.5, 53.1, 52.3, 51.4, 
42.1, 41.6. 
4.5.20 Peak assignment of 12a4 
S
NCl
CO2Me
OMe
N
Me Me
OMe  
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Compound 12a4: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 337 mg, 73%. 1H NMR (400 MHz, Chloroform-d) δ 8.71 (s, 1H), 7.44 - 6.71 (m, 
8H), 5.57 (d, J = 2.5 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.76 (s, 6H), 3.59 (d, J = 2.5 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 168.6, 162.0, 160.3, 159.9, 154.1, 136.8, 128.9, 
114.3, 88.0, 70.4, 55.6, 55.4, 53.7, 51.4, 44.1, 42.5. 
4.5.21 Peak assignment of 12a5 
S
NCl
CO2Me
Me Me OMe
N
MeMe
 
Compound 12a5: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h. 
Yield = 302 mg, 76%. 1H NMR (400 MHz, Chloroform-d) δ 8.39 (s, 1H), 6.98 (d, J = 8.2 
Hz, 2H), 6.68 (d, J = 8.3 Hz, 2H), 5.47 (s, 1H), 4.72 (dq, J = 13.6, 7.7, 6.9 Hz, 1H), 3.56 - 
3.38 (m, 12H), 1.19 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H). 13C NMR (400 MHz, 
CDCl3) δ 167.8, 162.4, 162.1, 160.0, 152.9, 131.1, 128.8, 127.4, 114.0, 87.9, 62.0, 59.7, 
55.3, 53.7, 50.8, 43.9, 42.2, 21.6, 20.5. 
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4.5.22 Peak assignment of 12b1 
S
NCl
CO2Me
OMe
O
OMe  
Compound 12b1: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 281 mg, 65%. 1H NMR (400 MHz, Chloroform-d) δ 9.90 
(s, 1H), 7.24 (d, J = 14.3 Hz, 1H), 7.13 (dd, J = 16.8, 8.4 Hz, 2H), 7.01 – 6.90 (m, 2H), 
6.92 – 6.73 (m, 3H), 5.34 (d, J = 2.1 Hz, 1H), 3.90 –3.08 (m, 10H). 13C NMR (101 MHz, 
CDCl3) δ 184.9, 170.0, 159.9, 159.8, 137.0, 131.2, 130.0, 129.5, 129.2, 128.9, 128.2, 
127.5, 127.2, 114.8, 100.8, 67.7, 55.5, 55.5, 53.0, 43.1. 
4.5.23 Peak assignment of 12b2 
S
NCl
CO2Me
CMe3
O
OMe
 
Compound 12b2: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 249 mg, 65%. 1H NMR (400 MHz, Chloroform-d) δ 9.84 
(s, 1H), 7.26 – 7.07 (m, 2H), 6.86 – 6.71 (h, J = 7.5, 6.6 Hz, 2H)), 5.66 (d, J = 4.3 Hz, 
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1H), 3.95 – 3.85 (d, 1H), 3.79 –3.11 (d, 6H), 1.31 (d, 9H), 1.24 – 1.14 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 183.8, 170.8, 159.9, 159.7, 144.6, 140.8, 130.0, 124.8, 118.7, 112.9, 
112.0, 63.5, 61.9, 55.4, 53.1, 48.3, 32.9. 
4.5.24 Peak assignment of 12b3 
S
NCl
CO2Me
Me Me OMe
O
 
Compound 12b3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 243 mg, 66%. 1H NMR (400 MHz, Chloroform-d) δ 9.85 
(d, J = 15.4 Hz, 1H), 7.06 (d, J = 8.2 Hz, 2H), 6.86 – 6.73 (m, 2H), 5.29 (d, J = 2.7 Hz, 
1H), 4.92 (p, J = 6.9 Hz, 1H), 3.74 (d, J = 8.3 Hz, 3H), 3.68 (s, 3H), 3.66 – 3.61 (m, 1H), 
1.27 (d, J = 6.8 Hz, 3H), 1.03 (dd, J = 20.2, 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
185.2, 169.8, 159.6, 144.0, 133.0, 128.5, 127.4, 114.0, 100.7, 59.3, 55.3, 53.7, 53.4, 52.7, 
42.1, 21.6, 20.6. 
4.5.25 Peak assignment of 12b4 
S
NCl
CO2Me
O
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Compound 12b3: Prepared using General Procedure A. 3 (1 mmol), POCl3 (0.31 
g, 0.2 mL, 2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 317 mg, 82%.
 1H NMR (400 MHz, Chloroform-d) δ 9.84 
(s, 1H), 7.31 – 7.02 (m, 10H), 5.25 (d, J = 16.0 Hz, 1H), 4.95 (s, 1H), 4.12 (d, J = 15.9 
Hz, 1H), 3.44 (s, 3H), 2.23 (dd, J = 16.2, 5.6 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ 
187.2, 171.7, 150.4, 139.1, 135.7, 129.2, 128.2, 127.5, 126.9, 106.2, 63.6, 53.8, 51.8, 
42.6. 
4.5.26 Peak assignment of 13 
O
N
CO2Me
Ph
O
Me
Me
 
Compound 13: Prepared using General Procedure B. 4b1 (1.0 mmol) and p-
methylphenyl-acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 514 mg, 89%. 
1H 
NMR (400 MHz, Chloroform-d) δ 9.73 (s, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.53 - 7.12 (m, 
10H), 6.89 (d, J = 8.1 Hz, 2H), 6.64 (d, J = 15.8 Hz, 1H), 6.22 (dd, J = 15.7, 6.8 Hz, 1H), 
5.02 (m, 2H), 3.65 (s, 3H), 2.36 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 180.5, 167.8, 
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143.7, 142.2, 139.5, 138.5, 135.2, 134.1, 132.8, 129.2, 128.8, 127.2, 126.9, 125.0, 122.3, 
118.8, 91.8, 81.6, 74.6, 73.5, 63.9, 52.7, 21.7. 
4.5.27 Peak assignment of 14a 
O
NO
CO2Me
Ph
 
Compound 14a: Prepared using General Procedure B. 3d1 (1.0 mmol) and p-
methylphenyl-acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 301 mg, 75%. 
1H 
NMR (400 MHz, Chloroform-d) δ 7.74 – 7.02 (m, 9H), 6.70 – 6.21 (m, 2H), 4.84 (m, 
1H), 4.68 (m, 1H), 4.62 (m, 1H), 4.51 (m, 1H), 3.95 – 3.72 (m, 3H), 1.52 (t, 1H), 0.92- 
0.81 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 172.5, 168.3, 139.5, 142.2, 139.5, 136.4, 
136.2, 134.1, 129.8, 128.2, 127.8, 124.2, 123.9, 94.8, 74.2, 73.8, 64.9, 62.7, 53.7, 9.8, 0.1. 
4.5.28 Peak assignment of 14b 
O
NO
CO2Me
Ph
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Compound 14b: Prepared using General Procedure B. 3d1 (1.0 mmol) and p-
methylphenyl-acetylene (2 mmol, 2 equiv) Purification: Flash chromatography on silica 
(pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 344 mg, 78%. 
1H 
NMR (400 MHz, Chloroform-d) δ 8.68 – 7.01 (m, 9H), 6.50 – 6.12 (m, 3H), 4.98 – 4.68  
(m, 4H), 4.01 – 4.2 (s, 3H), 2.30 – 1.98 (m, 4H), 1.78 – 1.52 (m, 4H). 13C NMR (101 
MHz, CDCl3) δ 170.3, 165.2, 140.2, 136.2, 136.0, 134.4, 130.2, 128.1, 127.8, 126.2, 
125.8, 120.2, 92.4, 85.2, 74.6, 64.5, 64.2, 52.4, 28.4, 24.3, 23.4, 22.8. 
4.5.29 Peak assignment of 15a 
O
NCl
CO2Me
Ph
O
 
Compound 15a: Prepared using General Procedure A. 14 (1 mmol), POCl3 (0.46 
g, 0.3 mL, 3 mmol), DMF (0.5 mL, 6 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20).Yield = 358 mg, 80%. 1H NMR (400 MHz, Chloroform-d) δ 9.72 
(s, 1H), 7.70 – 7.21 (m, 7H), 7.22 – 7.04 (m, 2H), 6.78 – 6.52 (d, 1H), 6.41 – 6.03 (d, 
1H), 5.02 – 4.88 (m, 2H), 3.87 – 3.51 (s, 3H), 1.62 – 1.42 (t, 1H), 0.98 – 0.72 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 180.5, 168.8, 141.2, 138.2, 136.5, 135.4, 134.2, 133.1, 
129.8, 127.2, 126.8, 125.2, 122.7, 96.1, 74.2, 63.8, 52.9, 9.7, 0.1. 
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4.5.30 Peak assignment of 15b 
O
NCl
CO2Me
Ph
O
 
Compound 15b: Prepared using General Procedure A. 14 (1 mmol), POCl3 (0.46 
g, 0.3 mL, 3 mmol), DMF (0.5 mL, 6 mmol), Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20).Yield = 419 mg, 86%. 1H NMR (400 MHz, Chloroform-d) δ 9.72 
(s, 1H), 7.69 – 7.41 (m, 8H), 7.20 – 7.02 (m, 2H), 6.98 – 6.48  (m, 1H), 6.41 – 6.02 (m, 
2H), 5.08 – 4.75 (m, 2H), 3.76 – 3.51 (s, 3H), 2.32 – 2.01 (m, 2H), 1.89 – 1.52 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 180.3, 168.2, 142.1, 136.0, 130.2, 128.1, 127.8, 126.2, 
120.2, 92.2, 85.2, 74.2, 62.5, 52.4, 28.2, 24.3, 23.8, 22.8, 22.4. 
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4.5.31 Peak assignment of 16a 
O
NCl
CO2Me
Ph
CF3
N
 
Compound 16a: Prepared using General Procedure C. 4b3 (1 mmol), amine (1.5 
mmol), benzene (5 mL, 5 equiv), Temp = room temperature, time = 22 h, Purification: 
Flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc 
(80:20).Yield = 455 mg, 93%. 1H NMR (400 MHz, Chloroform-d) δ 8.28 (s, 1H), 7.55 – 
7.22 (m, 9H), 6.78 (d, J = 15.8 Hz, 1H), 6.23 (dd, J = 15.8, 5.1 Hz, 2H), 5.24 – 5.09 (m, 
4H), 4.23 (d, J = 5.5 Hz, 2H), 3.83 – 3.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.8, 
152.9, 144.7, 135.6, 133.3, 132.0, 131.7, 131.0, 129.7, 128.7, 127.8, 126.9, 125.9, 123.6, 
122.3, 121.1, 119.7, 116.8, 75.0, 63.9, 62.7, 52.2. 
4.5.32 Peak assignment of 16b 
O
NCl
CO2Me
Ph
N
Me
Me
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Compound 16b: Prepared using General Procedure C. 15 (1 mmol), amine (1.5 
mmol), benzene (5 mL, 5 equiv), Temp = room temperature, time = 22 h, Purification: 
Flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc 
(80:20).Yield = 465 mg, 95%. 1H NMR (400 MHz, Chloroform-d) δ 8.32 (s, 1H), 7.90 – 
6.50 (m, 9H), 6.42 – 6.04 (d, 2H), 5.10 – 4.92 (m, 2H), 4.20 – 4.98 (m, 2H), 3.98 – 3.24 
(m, 4H), 2.04 – 0.92 (m, 11H). 13C NMR (101 MHz, CDCl3) δ 178.3, 150.2, 142.2, 
136.2, 136.0, 130.4, 130.2, 133.1, 129.8, 128.2, 124.8, 122.2, 96.3, 74.24 63.8, 63.5, 53.2, 
23.1, 9.8, 0.1. 
4.5.33 Peak assignment of 16c 
O
NCl
CO2Me
Ph
N
 
Compound 16c: Prepared using General Procedure C. 15 (1 mmol), amine (1.5 
mmol), benzene (5 mL, 5 equiv), Temp = room temperature, time = 22 h, Purification: 
Flash chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc 
(80:20).Yield = 485 mg, 92%. 1H NMR (400 MHz, Chloroform-d) δ 8.71 (s, 1H), 7.55 – 
7.24 (m, 9H), 7.10 – 6.92 (d, 2H), 6.98 – 6.48  (m, 1H), 6.47 – 6.06 (m, 2H), 5.12 – 4.68 
(m, 2H), 3.88 – 3.32 (s, 3H), 3.08 – 2.94 (m, 1H), 2.32 – 2.01 (d, 2H), 1.89 – 1.52 (m, 
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4H), 0.98-0.10 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 178.1, 151.2, 142.1, 136.0, 
132.4, 131.6, 130.8, 128.1, 127.8, 126.2, 120.8, 120.2, 92.4, 86.8, 74.4, 62.7, 52.4, 42.4, 
28.4, 26.8,  23.8, 22.6, 22.5, 8.4, 8.3. 
4.5.34 Peak assignment of 17 
O
NCl
CO2Me
Me
OMe
Ph
 
Prepared using 4b4 (1 mmol), ylide (1.2 mmol),THF (5 mL, 5 equiv), Temp = 
room temperature, time = 12 h, Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with hexane/EtOAc (80:20).Yield = 426 mg, 85%. 
1H NMR (400 
MHz, Chloroform-d) δ 7.64 -6.88 (m, 10H), 6.80 (dd, 2H), 6.21 (m, 2H), 5.11 (m, 1H), 
4.05 - 3.60 (m, 3H), (3.44 – 3.22 (m, 3H), 2.41-2.23 (m, 3H). 13C NMR (101 MHz, 
CDCl3) δ 180.6, 160.3, 142.9, 137.6, 136.8, 133.8, 132.2, 128.0, 127.5, 127.2, 127.1.0, 
122.7, 115.1, 75.3, 55.9, 51.1, 21.3. 
4.5.35 Peak assignment of 18 
O
NCl
Me
OMe
Ph
HO
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To the crude α-alkynyl imine (1.0 mmol) dissolved in freshly distilled THF (5 
mL), was slowly added allyl magnesium bromide (4.0 mL, 1.0 M solution in THF, 4 
equiv) under nitrogen at ‒78 °C. The mixture was warmed slowly to room temperature. 
After complete consumption of the ester (as indicated by TLC and GC-MS), the mixture 
was cooled to 0 °C, diluted with Et2O and quenched by slow addition of sat. aq NH4Cl. 
The layers were separated and the aqueous layer was extracted twice with EtOAc. The 
combined organic layers were dried over Na2SO4 for 30 min, filtered, and concentrated 
under reduced pressure to give the desired product. Purification: Flash chromatography 
on silica (pretreated with 1% Et3N) eluting with Hexane/EtOAc (1:2). Yield = 476 mg, 
86%. 1H NMR (400 MHz, Chloroform-d) δ 7.64 -6.88 (m, 10H), 6.80 (dd, 2H), 6.21 (m, 
2H), 5.11 (m, 4H), 4.35 - 4.10 (m, 1H), (3.94 – 3.72 (m, 3H), 2.41-2.23 (m, 3H), 1.95 – 
1.83 (s, 1H).
 13C NMR (101 MHz, CDCl3) δ 160.1, 142.9, 138.5, 137.6, 133.8, 132.2, 
128.0, 127.5, 127.2, 127.1.0, 122.7, 120.1, 119.6, 115.1, 84.3, 75.9, 61.1, 56.3, 41.2, 40.1, 
21.3. 
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Appendix A: Chapter 2 Spectroscopic Data 
 
 
 
Spectra 1-1  Proton NMR spectrum of 2c. 
 154 
 
Spectra 1-2  Carbon NMR spectrum of 2c. 
 
Spectra 1-3  DEPT-135 NMR spectrum of 2c. 
 
 155 
 
Spectra 1-4  Proton NMR spectrum of 2e. 
 
Spectra 1-5  Carbon NMR spectrum of 2e. 
 156 
 
Spectra 1-6  DEPT-135 NMR spectrum of 2e. 
 
 
Spectra 1-7  GC spectrum of 3a1. 
 157 
 
Spectra 1-8  MS spectrum of 3a1. 
 
Spectra 1-9  Proton NMR spectrum of 3a1. 
 158 
 
Spectra 1-10  Carbon NMR spectrum of 3a1. 
 
Spectra 1-11  DEPT-135 NMR spectrum of 3a1. 
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Spectra 1-12  GC spectrum of 3a2. 
 
Spectra 1-13  MS spectrum of 3a2. 
 160 
 
Spectra 1-14  Proton NMR spectrum of 3a2. 
 
Spectra 1-15  Carbon NMR spectrum of 3a2. 
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Spectra 1-16  GC spectrum of 3a3. 
 
Spectra 1-17  MS spectrum of 3a3. 
 162 
 
Spectra 1-18  Proton NMR spectrum of 3a3. 
 
Spectra 1-19  Carbon NMR spectrum of  3a3. 
 163 
 
Spectra 1-20  DEPT-135 NMR spectrum of 3a3. 
 
 
Spectra 1-21  GC spectrum of 3a4. 
 164 
 
Spectra 1-22  MS spectrum of 3a4. 
 
Spectra 1-23  Proton NMR spectrum of 3a4. 
 165 
 
Spectra 1-24  Carbon NMR spectrum of 3a4. 
 
Spectra 1-25  DEPT-135 NMR spectrum of 3a4. 
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Spectra 1-26  GC spectrum of 3a5. 
 
Spectra 1-27  MS spectrum of 3a5. 
 167 
 
Spectra 1-28  Proton NMR spectrum of 3a5. 
 
Spectra 1-29  Carbon NMR spectrum of 3a5. 
 168 
 
Spectra 1-30  DEPT-135 NMR spectrum of 3a5. 
 
 
Spectra 1-31  GC spectrum of 3a6. 
 169 
 
Spectra 1-32  MS spectrum of 3a6. 
 
Spectra 1-33  Proton NMR spectrum of 3a6. 
 170 
 
Spectra 1-34  Carbon NMR spectrum of 3a6. 
 
Spectra 1-35  DEPT-135 NMR spectrum of 3a6. 
 171 
 
Spectra 1-36  GC spectrum of 3a7. 
 
Spectra 1-37  MS spectrum of 3a7. 
 172 
 
Spectra 1-38  Proton NMR spectrum of 3a7. 
 
Spectra 1-39  Carbon NMR spectrum of 3a7. 
 173 
 
Spectra 1-40  DEPT-135 NMR spectrum of 3a7. 
 
Spectra 1-41  GC spectrum of 3a10/3a10b. 
 174 
 
Spectra 1-42  MS spectrum of 3a10b. 
 
Spectra 1-43  MS spectrum of 3a10. 
 175 
 
Spectra 1-44  Proton NMR spectrum of 3a10/3a10b. 
 
Spectra 1-45  Carbon NMR spectrum of 3a10/3a10b. 
 176 
 
Spectra 1-46  DEPT-135 NMR spectrum of 3a10/3a10b. 
 
 
Spectra l-47  GC spectrum of 3b1. 
 177 
 
Spectra 1-48  MS spectrum of 3b1. 
 
Spectra 1-49  Proton NMR spectrum of 3b1. 
 178 
 
Spectra 1-50  Carbon NMR spectrum of 3b1. 
 
Spectra 1-51  DEPT-135 NMR spectrum of 3b1. 
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Spectra 1-52  GC spectrum of 3b2. 
 
Spectra 1-53  MS spectrum of 3b2. 
 180 
 
Spectra 1-54  Proton NMR spectrum of 3b2. 
 
Spectra 1-55  Carbon NMR spectrum of 3b2. 
 181 
 
Spectra 1-56  DEPT-135 NMR spectrum of 3b2. 
 
 
Spectra 1-57  GC spectrum of 3b3. 
 182 
 
Spectra 1-58  MS spectrum of 3b3. 
 
Spectra 1-59  Proton NMR spectrum of 3b3. 
 183 
 
Spectra 1-60  Carbon NMR spectrum of 3b3. 
 
Spectra 1-61  DEPT-135 NMR spectrum of 3b3. 
 
 184 
 
Spectra 1-62  GC spectrum of 3b4. 
 
Spectra 1-63  MS spectrum of 3b4. 
 185 
 
Spectra 1-64  Proton NMR spectrum of 3b4. 
 
Spectra 1-65  Carbon NMR spectrum of 3b4. 
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Spectra 1-66  DEPT-135 NMR spectrum of 3b4. 
 
Spectra 1-67  GC spectrum of 3b5. 
 187 
 
Spectra 1-68  MS spectrum of 3b5. 
 
Spectra 1-69  Proton NMR spectrum of 3b5. 
 188 
 
Spectra 1-70  Carbon NMR spectrum of 3b5. 
 
Spectra 1-71  DEPT-135 NMR spectrum of 3b5. 
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Spectra 1-72  Proton NMR spectrum of 3c1. 
 
Spectra 1-73  Carbon NMR spectrum of 3c1. 
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Spectra 1-74  DEPT-135 NMR spectrum of 3c1. 
 
 
Spectra 1-75  Proton NMR spectrum of 3c2. 
 191 
 
Spectra 1-76  Carbon NMR spectrum of 3c2. 
 
Spectra 1-77  DEPT-135 NMR spectrum of 3c2. 
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Spectra 1-78  Proton NMR spectrum of 3c3. 
 
Spectra 1-79  Carbon NMR spectrum of 3c3. 
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Spectra 1-80  DEPT-135 NMR spectrum of 3c3. 
 
 
Spectra 1-81  Proton NMR spectrum of 3c4. 
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Spectra 1-82  Carbon NMR spectrum of 3c4. 
 
Spectra 1-83  DEPT-135 NMR spectrum of 3c4. 
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Spectra 1-84  MS spectrum of 3c6. 
 
Spectra 1-85  Proton NMR spectrum of 3c6. 
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Spectra 1-86  Carbon NMR spectrum of 3c6. 
 
Spectra 1-87  DEPT-135 NMR spectrum of 3c6. 
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Spectra 1-88  GC-MS spectrum of 3c7. 
 
Spectra 1-89  Proton NMR spectrum of 3c7. 
 198 
 
Spectra 1-90  Carbon NMR spectrum of 3c7. 
 
Spectra 1-91  DEPT-135 NMR spectrum of 3c7. 
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Spectra 1-92  MS spectrum of 3c9. 
 
Spectra 1-93  Proton NMR spectrum of 3c9. 
 200 
 
Spectra 1-94  Carbon NMR spectrum of 3c9. 
 
Spectra 1-95  DEPT-135 NMR spectrum of 3c9. 
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Spectra 1-96  Proton NMR spectrum of 3c10. 
 
Spectra 1-97  Carbon NMR spectrum of 3c10. 
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Spectra 1-98  DEPT-135 NMR spectrum of 3c10. 
 
 
Spectra 1-99  MS spectrum of 3c11. 
 203 
 
Spectra 1-100  Proton NMR spectrum of 3c11. 
 
Spectra 1-101  Carbon NMR spectrum of 3c11. 
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Spectra 1-102  DEPT-135 NMR spectrum of 3c11. 
 
 
Spectra 1-103  MS spectrum of 3c12. 
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Spectra 1-104  Proton NMR spectrum of 3c12. 
 
Spectra 1-105  Carbon NMR spectrum of 3c12. 
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Spectra 1-106  DEPT-135 NMR spectrum of 3c12. 
 
 
Spectra 1-107  Proton NMR spectrum of 3c13. 
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Spectra 1-108  Carbon NMR spectrum of 3c13. 
 
Spectra 1-109  DEPT-135 NMR spectrum of 3c13. 
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Spectra 1-110  MS spectrum of 3c14. 
 
Spectra 1-111  Proton NMR spectrum of 3c14. 
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Spectra 1-112  Carbon NMR spectrum of 3c14. 
 
Spectra 1-113  DEPT-135 NMR spectrum of 3c14. 
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Spectra 1-114  MS spectrum of 3c15. 
 
Spectra 1-115  Proton NMR spectrum of 3c15. 
 211 
 
Spectra 1-116  Carbon NMR spectrum of 3c15. 
 
Spectra 1-117  DEPT-135 NMR spectrum of 3c15. 
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Spectra 1-118  Proton NMR spectrum of 3c16. 
 
Spectra 1-119  Carbon NMR spectrum 3c16. 
 213 
 
Spectra 1-120  DEPT-135 NMR spectrum 3c16. 
 
Spectra 1-121  Proton NMR spectrum of 3c18. 
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Spectra 1-122  Carbon NMR spectrum of 3c18. 
 
Spectra 1-123  DEPT-135 NMR spectrum of 3c18. 
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Spectra 1-124  Proton NMR spectrum of 3c19. 
 
Spectra 1-125  Carbon NMR spectrum of 3c19. 
 216 
 
Spectra 1-126  DEPT-135 NMR spectrum of 3c19. 
 
 
Spectra 1-127  MS spectrum of 3c20. 
 217 
 
Spectra 1-128  Proton NMR spectrum of 3c20. 
 
Spectra 1-129  Carbon NMR spectrum of 3c20. 
 218 
 
Spectra 1-130  DEPT-135 NMR spectrum of 3c20. 
 
Spectra 1-131  Proton NMR spectrum of 3c21. 
 219 
 
Spectra 1-132  Carbon NMR spectrum of 3c21. 
 
Spectra 1-133  DEPT-135 NMR spectrum of 3c21. 
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Spectra 1-134  MS spectrum of 3c23. 
 
Spectra 1-135  Proton NMR spectrum of 3c23. 
 221 
 
Spectra 1-136  Carbon NMR spectrum of 3c23. 
 
Spectra 1-137  DEPT-135 NMR spectrum of 3c23. 
 222 
 
Spectra 1-138  Proton NMR spectrum of 3c24. 
 
Spectra 1-139  Carbon NMR spectrum of 3c24. 
 223 
 
Spectra 1-140  DEPT-135 NMR spectrum of 3c24. 
 
Spectra 1-141  MS spectrum of 3c25. 
 224 
 
Spectra 1-142  Proton NMR spectrum of 3c25. 
 
Spectra 1-143  Carbon NMR spectrum of 3c25. 
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Spectra 1-144  DEPT-135 NMR spectrum of 3c25. 
 
Spectra 1-145  Proton NMR spectrum of 3c26. 
 226 
 
Spectra 1-146  Carbon NMR spectrum of 3c26. 
 
Spectra 1-147  DEPT-135 NMR spectrum of 3c26. 
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Spectra 1-148  GC spectrum of 3d1. 
 
Spectra 1-149  MS spectrum of 3d1. 
 228 
 
Spectra 1-150  Proton NMR spectrum of 3d1. 
 
Spectra 1-151  Carbon NMR spectrum of 3d1. 
 229 
 
Spectra 1-152  DEPT-135 NMR spectrum of 3d1. 
 
Spectra 1-153  Proton NMR spectrum of 3d2. 
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Spectra 1-154  Carbon NMRspectrum of 3d2. 
 
Spectra 1-155  DEPT-135 NMR spectrum of 3d2. 
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Spectra 1-156  GC spectrum of 3d3. 
 
Spectra 1-157  MS spectrum of 3d3. 
 232 
 
Spectra 1-158  Proton NMR spectrum of 3d3. 
 
Spectra 1-159  Carbon NMR spectrum of 3d3. 
 233 
 
Spectra 1-160  DEPT-135 NMR spectrum of 3d3. 
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Appendix B: Chapter 3 Spectroscopic Data 
 
Spectra 1-1  Proton NMR spectrum of 1a. 
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Spectra 1-2  Carbon NMR spectrum of 1a. 
 
 
Spectra 1-3  DEPT-135 NMR spectrum of 1a. 
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Spectra 1-4  MS spectrum of 1b. 
 
Spectra 1-5 Proton NMR spectrum of 1b. 
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Spectra 1-6  Carbon NMR spectrum of 1b. 
 
Spectra 1-7  DEPT-135 NMR spectrum of 1b. 
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Spectra 1-8  MS spectrum of 1c. 
 
Spectra 1-9  Proton NMR spectrum of 1c. 
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Spectra 1-10  Carbon NMR spectrum of 1c. 
 
Spectra 1-11  DEPT-135 NMR spectrum of 1c. 
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Spectra 1-12  Proton NMR spectrum of 1d. 
 
Spectra 1-13  Carbon NMR spectrum of 1d. 
 
 241 
 
Spectra 1-14  DEPT-135 NMR spectrum of 1d. 
 
Spectra 1-15  Proton NMR spectrum of 1e. 
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Spectra 1-16  Carbon NMR spectrum of 1e. 
 
Spectra 1-17  DEPT-135 NMR spectrum of 1e. 
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Spectra 1-18  MS spectrum of 1f. 
 
Spectra 1-19  Proton NMR spectrum of 1f. 
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Spectra 1-20  Carbon NMR spectrum of 1f. 
 
Spectra 1-21  DEPT-135 NMR spectrum of 1f. 
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Spectra 1-22  Proton NMR spectrum of 1g. 
 
Spectra 1-23  Carbon NMR spectrum of 1g. 
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Spectra 1-24  DEPT-135 NMR spectrum of 1g. 
 
 
Spectra 1-25  MS spectrum of 1h. 
 
 247 
 
Spectra 1-26  Proton NMR spectrum of 1h. 
 
Spectra 1-27  Carbon NMR spectrum of 1h. 
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Spectra 1-28  DEPT-135 NMR spectrum of 1h. 
 
Spectra 1-29  Proton NMR spectrum of 1i. 
 249 
 
Spectra 1-30  Carbon NMR spectrum of 1i. 
 
Spectra 1-31  DEPT-135 NMR spectrum of 1i. 
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Spectra 1-32  MS spectrum of 1j. 
 
Spectra 1-33  Proton NMR spectrum of 1j. 
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Spectra 1-34  Carbon NMR spectrum of 1j. 
 
Spectra 1-35  DEPT-135 NMR spectrum of 1j. 
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Spectra 1-36  Proton NMR spectrum of 1k. 
 
Spectra 1-37  Carbon NMR spectrum of 1k. 
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Spectra 1-38  DEPT-135 NMR spectrum of 1k. 
 
Spectra 1-39  MS spectrum of 1l. 
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Spectra 1-40  Proton NMR spectrum of 1l. 
 
Spectra 1-41  Carbon NMR spectrum of 1l. 
 255 
 
Spectra 1-42  DEPT-135 NMR spectrum of 1l. 
 
Spectra 1-43  Proton NMR spectrum of 1m. 
 256 
 
Spectra 1-44  Carbon NMR spectrum of 1m. 
 
Spectra 1-45  DEPT-135 NMR spectrum of 1m. 
 257 
 
Spectra 1-46  MS spectrum of 1n. 
 
Spectra 1-47  Proton NMR spectrum of 1n. 
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Spectra 1-48  Carbon NMR spectrum of 1n. 
 
Spectra 1-49  DEPT-135 NMR spectrum of 1n. 
 
 259 
 
Spectra 1-50  GC spectrum of 10b. 
 
Spectra 1-51  MS spectrum of 10b. 
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Spectra 1-52  Proton NMR spectrum of 10b. 
 
Spectra 1-53  Carbon NMR spectrum of 10b. 
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Spectra 1-54  DEPT-135 NMR spectrum of 10b. 
 
Spectra 1-55  Proton NMR spectrum of 18. 
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Spectra 1-56  Carbon NMR spectrum of 18. 
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Spectra 1-57  DEPT-135 NMR spectrum of 18. 
 
Spectra 1-58  GC-MS spectrum of 20. 
 
Spectra 1-59  Proton NMR spectrum of 20. 
 264 
 
Spectra 1-60  Carbon NMR spectrum of 20. 
 
Spectra 1-61  Carbon NMR spectrum of 20. 
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Appendix C: Chapter 4 Spectroscopic Data 
 
Spectra 1-1  Proton NMR spectrum of 4a1. 
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Spectra 1-2  Carbon NMR spectrum of 4a1. 
 
Spectra 1-3  DEPT-135 NMR spectrum of 4a1. 
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Spectra 1-4  Proton NMR spectrum of 4a2. 
 
Spectra 1-5  Carbon NMR spectrum of 4a2. 
 268 
 
Spectra 1-6  DEPT-135 NMR spectrum of 4a2. 
 
Spectra 1-7  Proton NMR spectrum of 4a3. 
 269 
 
Spectra 1-8  Carbon NMR spectrum of 4a3. 
 
Spectra 1-9  DEPT-135 NMR spectrum of 4a3. 
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Spectra 1-10  Proton NMR spectrum of 4a4. 
 
Spectra 1-11  Carbon NMR spectrum of 4a4. 
 271 
 
Spectra 1-12  DEPT-135 NMR spectrum of 4a4. 
 
Spectra 1-13  Proton NMR spectrum of 4a5. 
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Spectra 1-14  Carbon NMR spectrum of 4a5. 
 
Spectra 1-15  DEPT-135 NMR spectrum of 4a5. 
 273 
 
Spectra 1-16  Proton NMR spectrum of 4a6. 
 
Spectra 1-17  Carbon NMR spectrum of 4a6. 
 274 
 
Spectra 1-18  DEPT-135 NMR spectrum of 4a6. 
 
Spectra 1-19  Proton NMR spectrum of 4b1. 
 275 
 
Spectra 1-20  Carbon NMR spectrum of 4b1. 
 
Spectra 1-21  DEPT-135 NMR spectrum of 4b1. 
 276 
 
Spectra 1-22  Proton NMR spectrum of 4b2. 
 
Spectra 1-23  Carbon NMR spectrum of 4b2. 
 277 
 
Spectra 1-24  DEPT-135 NMR spectrum of 4b2. 
 
Spectra 1-25  Proton NMR spectrum of 4b3. 
 278 
 
Spectra 1-26  Carbon NMR spectrum of 4b3. 
 
Spectra 1-27  DEPT-135 NMR spectrum of 4b3. 
 279 
 
Spectra 1-28  Proton NMR spectrum of 4b4. 
 
Spectra 1-29  Carbon NMR spectrum of 4b4. 
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Spectra 1-30  DEPT-135 NMR spectrum of 4b4. 
 
Spectra 1-31  Proton NMR spectrum of 10a1. 
 281 
 
Spectra 1-32  Carbon NMR spectrum of 10a1. 
 
Spectra 1-33  DEPT-135 NMR spectrum of 10a1. 
 282 
 
Spectra 1-34  Proton NMR spectrum of 10a2. 
 
Spectra 1-35  Carbon NMR spectrum of 10a2. 
 283 
 
Spectra 1-36  DEPT-135 NMR spectrum of 10a2. 
 
Spectra 1-37  Proton NMR spectrum of 10a3. 
 284 
 
Spectra 1-38  Carbon NMR spectrum of 10a3. 
 
Spectra  1-39  DEPT-135 NMR spectrum of 10a3. 
 285 
 
Spectra 1-40  Proton NMR spectrum of 10a4. 
 
Spectra 1-41  Carbon NMR spectrum of 10a4. 
 286 
 
Spectra 1-42  DEPT-135 NMR spectrum of 10a4. 
 
Spectra 1-43  Proton NMR spectrum of 10a5. 
 287 
 
Spectra 1-44  Carbon NMR spectrum of 10a5. 
 
Spectra 1-45  DEPT-135 NMR spectrum of 10a5. 
 288 
 
Spectra 1-46  Proton NMR spectrum of 10b1. 
 
Spectra 1-47  Carbon NMR spectrum of 10b1. 
 289 
 
Spectra 1-48  DEPT-135 NMR spectrum of 10b1. 
 
Spectra 1-49  Proton NMR spectrum of 10b2. 
 290 
 
Spectra 1-50  Carbon NMR spectrum of 10b2. 
 
Spectra 1-51  DEPT-135 NMR spectrum of 10b2. 
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Spectra 1-52  Proton NMR spectrum of 4c1. 
 
Spectra 1-53  Carbon NMR spectrum of 4c1. 
 292 
 
Spectra 1-54  DEPT-135 NMR spectrum of 4c1. 
 
Spectra 1-55  Proton NMR spectrum of 12a1. 
 293 
 
Spectra 1-56  Carbon NMR spectrum of 12a1. 
 
Spectra 1-57  DEPT-135 NMR spectrum of 12a1. 
 294 
 
Spectra 1-58  Proton NMR spectrum of 12a2. 
 
Spectra 1-59  Carbon NMR spectrum of 12a2. 
 295 
 
Spectra 1-60  DEPT-135 NMR spectrum of 12a2. 
 
Spectra 1-61  Proton NMR spectrum of 12a3. 
 296 
 
Spectra 1-62  Carbon NMR spectrum of 12a3. 
 
Spectra 1-63  DEPT-135 NMR spectrum of 12a3. 
 297 
 
Spectra 1-64  Proton NMR spectrum of 12a4. 
 
Spectra 1-65  Carbon NMR spectrum of 12a4. 
 298 
 
Spectra 1-66  DEPT-135 NMR spectrum of 12a4. 
 
Spectra 1-67  Proton NMR spectrum of 12a5. 
 299 
 
Spectra 1-68  Carbon NMR spectrum of 12a5. 
 
Spectra 1-69  DEPT-135 NMR spectrum of 12a5. 
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Spectra 1-70  Proton NMR spectrum of 12b1. 
 
Spectra 1-71  Carbon NMR spectrum of 12b1. 
 301 
 
Spectra 1-72  DEPT-135 NMR spectrum of 12b1. 
 
Spectra 1-73  Proton NMR spectrum of 12b2. 
 302 
 
Spectra 1-74  Carbon NMR spectrum of 12b2. 
 
Spectra 1-75  DEPT-135 NMR spectrum of 12b2. 
 303 
 
Spectra 1-76  Proton NMR spectrum of 12b3. 
 
Spectra 1-77  Carbon NMR spectrum of 12b3. 
 304 
 
Spectra 1-78  DEPT-135 NMR spectrum of 12b3. 
 
Spectra 1-79  Proton NMR spectrum of 12b4. 
 305 
 
Spectra 1-80  Carbon NMR spectrum of 12b4. 
 
Spectra 1-81  DEPT-135 NMR spectrum of 12b4. 
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Spectra 1-82  Proton NMR spectrum of 13. 
 
Spectra 1-83  Carbon NMR spectrum of 13. 
 307 
 
Spectra 1-84  DEPT-135 NMR spectrum of 13. 
 
Spectra 1-85  Proton NMR spectrum of 14a. 
 308 
 
Spectra 1-86  Carbon NMR spectrum of 14a. 
 
Spectra 1-87  DEPT-135 NMR spectrum of 14a. 
 309 
 
Spectra 1-88  Proton NMR spectrum of 14b. 
 
Spectra 1-89  Carbon NMR spectrum of 14b. 
 310 
 
Spectra 1-90  DEPT-135 NMR spectrum of 14b. 
 
Spectra 1-91  Proton NMR spectrum of 15a. 
 311 
 
Spectra 1-92  Carbon NMR spectrum of 15a. 
 
Spectra 1-93  DEPT-135 NMR spectrum of 15a. 
 312 
 
Spectra 1-94  Proton NMR spectrum of 15b. 
 
Spectra 1-95  Carbon NMR spectrum of 15b. 
 313 
 
Spectra 1-96  DEPT-135 NMR spectrum of 15b. 
 
Spectra 1-97  Proton NMR spectrum of 16a. 
 314 
 
Spectra 1-98  Carbon NMR spectrum of 16a. 
 
Spectra 1-99  DEPT-135 NMR spectrum of 16a. 
 315 
 
Spectra 1-100  Proton NMR spectrum of 16b. 
 
Spectra 1-101  Carbon NMR spectrum of 16b. 
 316 
 
Spectra 1-102  DEPT-135 NMR spectrum of 16b. 
 
Spectra 1-103  Proton NMR spectrum of 16c. 
 317 
 
Spectra 1-104  Carbon NMR spectrum of 16c. 
 
Spectra 1-105  DEPT-135 NMR spectrum of 16c. 
 318 
 
Spectra 1-106  Proton NMR spectrum of 18. 
 
Spectra 1-107  Carbon NMR spectrum of 18. 
 319 
 
Spectra 1-108  DEPT-135 NMR spectrum of 18. 
 
